TJU Dept of Medicine 2025 Annual Report

2025 ANNUAL REPORT DEPARTMENT OF MEDICINE

Department of Medicine College Building, Room 822 1025 Walnut Street Philadelphia, PA 19107

ACKNOWLEDGEMENTS Department of Medicine 200: Through the Lens Capturing Art, Medicine, & Humanity

TABLE OF CONTENTS

ATTENDINGS Jonathan Foster, MD Gregory Kane, MD

0 3 Division of Cardiology 15

Division of Endocrinology, Diabetes and Metabolic Diseases

19

Division of Gastroenterology and Hepatology

Alyssa Yeager, MD

RESIDENTS Sara Badenhausen, MD Susanna Betti, MD Jessica Cobb, MD Joseph DeSimone, MD

25

Division of Hematology and Cardeza Foundation for Hematologic Research

29

Division of Hospital Medicine

Abdulmojeed Ekiyoyo, MD Umma Fatema, MD Ilana Goldberg, MD Natasha Reddy, MD Brian Schonewald, MD

33

Division of Infectious Diseases and Environmental Medicine STUDENTS

37

Division of Internal Medicine

41

Division of Nephrology

Anna Hamtic Junthe Jonth Emilio Mansilla Rachel Menane Kathleen Spritzer

47

Division of Pulmonary, Allergy and Critical Care Medicine

55

Division of Rheumatology

59

Center for Translational Medicine

63

Graduate Medical Educational Programs in Internal Medicine

Mary Wilkinson

Photographs ©Thomas Jefferson University Photography Services

Department of Medicine 2025 Annual Report

1

CHAIRMAN'S LETTER OF INTRODUCTION Dear Friends and Colleagues: Progress in Medicine and its subspecialties is often measured not only in landmark discoveries, but also in the steady, incremental advances that build upon the work of those who came before us. Our department remains deeply committed to honoring that legacy—advancing the state of the art across each of our specialties through thoughtful innovation, rigorous inquiry, and collaborative care. This year reflects the power of these cumulative gains. Through focused effort and interdisciplinary collaboration, we have translated scientific insight into meaningful improvements in patient care. Our achievements span the full spectrum of medicine: enhancing patient safety, advancing the development of new therapies and cures, strengthening preventive strategies, and refining treatments for chronic disease. Importantly, these advances are not merely academic, they are tangible. Patients are experiencing shorter recovery times, more effective and personalized treatment options, and greater autonomy in managing their health. Each improvement, no matter how incremental, contributes to a broader transformation in how care is delivered and experienced. It continues to be obvious that diverse leadership teams provide access to new ideas and new ways of succeeding that may have previously escaped us.

275,609 Total outpatient visits

47,054

New patient visits in FY25

29,088

Highlights from this past year include:

Telehealth visits

•

2

A focus on primary care of the whole patient and the recognition that the best care for complex patients is centered around a skilled primary practice physician and the office system that supports patient health.

•

The expectation for new therapies including a renewal of the use of bone marrow transplant and the prospect of gene therapy to serve our population of patients with sickle cell disease.

•

This success of an Addiction Medicine Consult service that works so well, one might wonder why every American hospital does not have such a service. Already we see greater comfort among our nurses and house staff as they help patients avoid withdrawal and move toward hope and recovery.

•

Growth and success in each of our current solid organ transplant programs – kidney, liver and heart. New for FY25 was launching of our lung transplantation program which completed its first 11 transplants without any perioperative or early mortality.

Divisions Ranked in USNWR Top 50

93

Best of Philadelphia Doctors

91

Liver Transplants

109

•

The impact of our transition away from a race-based adjustment of the eGFR, bringing more underserved populations to the top of our transplantation list.

•

New successes in lung cancer screening which focus on enrollment of Asian Americans and the LGBTQ community.

•

The opening of a satellite Cystic Fibrosis Clinic in the Lehigh Valley to serve a population that previously had to travel further for greater expertise in cystic fibrosis care.

16

The clinical expertise in our conjoint clinics such as our Interstitial Lung Disease Clinic which features faculty from Rheumatology and Pulmonary working shoulder to shoulder and side by side in the same clinic space fostering efficiency for some of the most complex patients, we see at Jefferson.

3

•

The success of these programs is catalyzed by Jefferson Health’s market penetration in key subspecialties of medicine necessitating that we think seriously about offering the most complex therapies to the market we serve which now comprises more than one quarter (or > 25%) of the 5,000,000 plus population in the Philadelphia and South Jersey region!

Kidney Transplants

Heart Transplants

Kidney/Pancreas Transplants

6

Lung Transplants

Department of Medicine 2025 Annual Report

2 I invite you to read about our strength and excellence across a broad array of programs. The impact of the year can be appreciated based upon our continued growth in outpatient practices; our total outpatient visits topped 275,000, with more than 47,000 of those being new patient visits. Additionally, our telehealth services expanded dramatically from 9,000 visits in FY20, to over 58,000 in FY21 and settled at 29,000 in FY25. Telehealth has become a mainstay of our core business providing flexibility for both patients and providers. This tool continues to be an integral part of how we served our patients in FY25. We also continued to increase our volume in the Bala Cynwyd multispecialty practice and opened 6 more exam rooms in fiscal year 25 to allow for expansion of Gastroenterology, Cardiology, and Primary Care. In this location, faculty and providers see outpatients in a multidisciplinary setting. Our ability to care for over 21,000 patients in FY25 at this multispecialty site has further enhanced the health of the enterprise. The numbers referenced on the previous page are impressive, but I am reminded that we see each individual patient one at a time. We are not defined by visits and volume, or revenues and profits. We are so much more as an academic department. It is by delivering on the promise of exceptional care, with learners and without, in every single encounter that we demonstrate who we truly are as a department. It is through the growth of our clinical research and basic science enterprise that we bring new insights into understanding the core mechanisms of health and disease. And it is the character of our relationships, through which we leave our legacy. Thanks for your interest, and we look forward to continuing to serve our patients, our trainees, and our students. Sincerely,

Gregory C. Kane, MD, MACP The Jane and Leonard Korman Professor of Pulmonary Medicine Chair of the Department of Medicine

Department of Medicine 2025 Annual Report

DIVISION OF CARDIOLOGY

3

The Division of Cardiology is a core component of the Bruce & Robbi Toll Heart and Vascular Institute, combining cardiology, cardiac surgery and vascular surgery to focus on the care of patients with heart and vascular disease. The Bruce & Robbi Toll Heart and Vascular Institute housed at the Honickman Center at 1101 Chestnut Street is the hub of outpatient cardiology teaching and clinical activity. It is the primary site of the clinical practice for the 50 Jefferson University Physicians (JUP) and Jefferson Community Physicians (JCP) cardiologists. On-site echocardiography, stress testing, nuclear cardiology, vascular imaging, and electrophysiologic device testing and management are available for patient convenience. The Bruce & Robbi Toll Heart and Vascular Institute is committed to excellence in patient care, education, research, and graduate medical education. We continue to strive to meet the needs of our patients, community, and institution. Our reach extends from Center City to Northeast Philadelphia, its western suburbs and South Jersey. We are actively recruiting the best and the brightest physicians to help the Bruce & Robbi Toll Heart and Vascular Institute grow and deliver the best healthcare to our patients and lead in innovation, education, clinical care, and research.

PAT I E N T C A R E

OUTPATIENT Outpatient care and consultation are provided in Center City at Jefferson’s new multidisciplinary practice site at the Honickman Center (general cardiology, electrophysiology, advanced heart failure and transplantation, cardio-oncology, interventional cardiology and structural heart disease). We expanded multidisciplinary programs in cardiac amyloidosis and cardioobstretrics strong demand to see cardiologists continue at Center City and across all our practice sites. In Center City, the number of patients seen grew by 8.4% from the previous fiscal year. 33,799 outpatients were seen, 18% of whom were new patients. 22,176 patient visits in our many satellite

offices comprised a 6% increase, yielding a total of 55,975 visits across all our sites. The Jefferson Outpatient Cardiac Imaging Center at the Honickman Center is the principal cardiac imaging site for Bruce & Robbi Toll Heart and Vascular Institute and for TJUH. A satellite imaging site at the Korman Respiratory Institute supports our joint programs in cardiopulmonary medicine. In FY25, 15,336 imaging studies were performed at the Center City locations. A total of 23,661 cardiac imaging studies were done across all our sites. The section of Nuclear Cardiology continues to expand its offerings with pyrophosphate scans to assist the advanced heart failure program with the diagnosis of TTR amyloidosis. We are now performing MUGA scans as well. Over the last 4 years, we have been doing PET/CT using rubidium. This

procedure has a greater diagnostic accuracy than conventional SPECT imaging. It also allows for the absolute quantitation of coronary blood flow, which improves the diagnosis of transplant arteriopathy and microvascular disease. Cardiology has multiple outpatient satellite locations; the largest is in Northeast Philadelphia, with others in the Art Museum area, South Philadelphia, Bala Cynwyd, PA, Voorhees, NJ and Turnersville, NJ. Convenient access to clinical cardiologists, subspecialty physicians in electrophysiology and heart failure, Jefferson vascular surgeons, as well as advanced cardiac imaging, are provided at our satellite locations. In FY25, the cardiology faculty expanded to support growth in our clinical cardiology programs. We added two clinical and imaging cardiologists, one electrophysiologist and two

FACU LT Y Juan Carlos Plana, MD, FACC, FASE Robert Capizzi Professor of Medicine Division Director

Rene J. Alvarez, Jr., MD, FACC, FAHA, FACP Lubert Family Professor of Cardiology Janet Cai, MD Assistant Professor of Medicine Sung-Hae Cho, MD Clinical Assistant Professor of Medicine Glenn S. Cooper, MD Clinical Assistant Professor of Medicine Indranil Dasgupta, MD, MPh, MBA Clinical Assistant Professor of Medicine Mark DeCaro, MD Clinical Assistant Professor of Medicine Matthew Delfiner, MD Assistant Professor of Medicine Danielle Duffy, MD Associate Professor of Medicine Howard J. Eisen, MD Professor of Medicine Darius Farzad, MD Clinical Assistant Professor of Medicine Brian D. Fedgchin, MD Clinical Instructor of Medicine Lori Frank, MD Clinical Assistant Professor of Medicine Daniel R. Frisch, MD Associate Professor of Medicine Jack L. Garden, MD Clinical Instructor of Medicine Gregory Gibson, MD Clinical Assistant Professor of Medicine Paulina Gorodin-Kiliddar, MD Clinical Associate Professor of Medicine Christopher L. Hansen, MD Professor of Medicine and Radiology Reginald T. Ho, MD Professor of Medicine

Department of Medicine 2025 Annual Report

4 advanced heart failure and transplant physicians. Cardiology provides expert consultation and cardiac assessment with a special focus on perioperative cardiac assessment and management with a rapid access program with the Patient Testing Center to facilitate patient care and partnering with the Farber inpatient neurohospitalists. We offer a one-call continuum of high value, patient-oriented outpatient and inpatient cardiac assessment and management, and access to our specialized cardiology programs, across the Jefferson Center City Campus.

INPATIENT The Cardiovascular Intensive Care Unit (CVICU) remains a 25 bed, shared Medical & Surgical subspecialty ICU on both the 3rd (8 beds) and 4th (17 beds) floors of the Gibbon building, with highly trained, certified Critical Care Registered Nurse (CCRN) staff. The medical patients are managed exclusively by three Cardiac Intensivists (Gregary D. Marhefka, MD (Director, Medical CVICU), Mark J. DeCaro, MD and Darius Farzad, MD) in three repeating 7-day continuous shifts ensuring the highest level of expertise, quality and continuity of care. In addition to rounding on some of the sickest patients admitted from within the hospital and transferred from the surrounding tristate area, the attending faculty provide critical care cardiology consultative services to the other intensive care units and are an integral part of the multi-disciplinary Cardiogenic Shock Team. Dedicated Advanced Heart Failure & Transplant cardiologists provide highly specialized consultative services to both the Medical and Surgical CVICU critically ill patients, some of whom are being evaluated for and listed for orthotopic heart transplantation (OHT). Cardiovascular conditions

treated by our devoted staff include: complicated ST-segment Elevation Myocardial Infarction (STEMI) and high-risk non-STEMI; out-of-hospital and in-hospital cardiac arrest and anoxic brain injury; hypertensive emergencies including acute aortic syndromes (active site for the International Registry of Acute Aortic Dissection (IRAD)); lethal arrhythmias including ventricular tachycardia storm; heart block requiring temporary transvenous pacing; pericardial diseases including cardiac tamponade requiring pericardiocentesis; cardiogenic shock in acute and chronic advanced heart failure patients, some of whom go on to require mechanical circulatory support such as intra-aortic balloon pump counterpulsation, temporary left ventricular assist devices (such as Impella CP, or surgically placed Impella 5.5), temporary right ventricular assist devices, VenousArterial Extra Corporal Membrane Oxygenation (VA-ECMO), VenousVenous ECMO, and ultimately some patients going on to require permanent left ventricular assist devices (LVAD) or OHT; high-risk Maternal Fetal Medicine patients with complex cardiovascular conditions through delivery; acute endocarditis with severe valvular heart failure; critically ill adult congenital heart disease; and before and after structural heart disease interventions like higher risk Transcatheter Aortic Valve Replacement and MitraClip percutaneous mitral valve repair. As patient volume and acuity continue to grow on both the Medical and Surgical CVICU teams, we await a new, state-of-the-art CVICU planned for the 6th floor of Gibbon building in the next couple of years.

ECHOCARDIOGRAPHY The Echocardiography laboratory provides a wide array of cardiac ultrasound services at Thomas Jefferson University Hospital

(TJUH), Jefferson Hospital for Neuroscience (JHN), and several outpatient facilities across the greater Philadelphia area managed by the Jefferson Heart Institute. The lab is comprised of 25 sonographers, 19 full-time faculty members in the Division of Cardiology, and three nurses. The lab provides several fundamental cardiac ultrasound services, including transthoracic echocardiography (TTE), transesophageal echocardiography (TEE), and stress (treadmill and pharmacologic) echocardiography, as well as several advanced services including contrast, threedimensional, myocardial strain, and interventional echocardiography. In FY25, the echocardiography lab performed 30,951 transthoracic echocardiograms, 1,728 stress echocardiograms, and 1,213 transesophageal echocardiograms including 160 transesophageal studies to guide interventional structural heart disease procedures. In FY25, the echocardiography lab added two full-time faculty members – Dr. Janet Cai who completed her fellowship at Rutgers Health and Robert Wood Johnson Medical School in 2024 and Dr. Matthew Delfiner who completed his fellowship at Temple University Hospital in 2023 and an advanced heart failure fellowship at the Hospital of the University of Pennsylvania Hospital in 2024. Members of the echocardiography laboratory continue to be active at the national and local level. Dr. David Wiener serves as Presidentelect of the American Society of Echocardiography (ASE) and in the following year will serve as President of the American Society of Echocardiography, an 18,000member global organization for cardiovascular ultrasound imaging. Dr. Peters serves on the Nominating Committee and is a participant in the Leadership

FACU LT Y Drew Johnson, MD Assistant Professor of Medicine Andria Jones, DO Clinical Assistant Professor of Medicine Susan Joseph, MD Professor of Medicine Yair Lev, MD Clinical Associate Professor of Medicine Gregary D. Marhefka, MD Howard H. Weitz, MD, MACP, FRCP (London), FACC Professor in Cardiology Sofia Carolina Masri, MD Associate Professor of Medicine Praveen Mehrotra, MD Associate Professor of Medicine Meghan Nahass, MD Clinical Assistant Professor of Medicine Steven J. Nierenberg, MD Clinical Assistant Professor of Medicine David O’Neil, MD, FACC Clinical Assistant Professor of Medicine Alyson Owen, MD Clinical Assistant Professor of Medicine Behzad Pavri, MD, FACC Professor of Medicine Ashley Pender, MD Clinical Assistant Professor of Medicine Andrew Peters, MD Assistant Professor of Medicine Ileana Pina, MD, MPH Robert M. Stein, MD 68', FACC, FAHA Professor in Cardiovascular Quality & Safety J. Eduardo Rame, MD, M.Phil, FAHA, FESC Louis R. Dinon, MD, Teaching Chair of Clinical Cardiology Professor Steven Roberts, MD Clinical Assistant Professor of Medicine Nicholas Ruggiero, MD, FACP, FACC, FSCAI, FSVM Professor of Medicine Michael Savage, MD Ralph J. Roberts Professor of Cardiology Mital P. Sheth, MD Clinical Instructor of Medicine David M. Shipon, MD Clinical Assistant Professor of Medicine Alexis Sokil, MD Associate Professor of Medicine Tayla Spivack, MD Clinical Assistant Professor of Medicine

Department of Medicine 2025 Annual Report

5 Academy of the ASE. Drs. Praveen Mehrotra and Andrew Peters also sit on the Board of Directors for the Delaware Valley Echocardiography Society. The echocardiography laboratory continues to be active in clinical program development, education and research. The echocardiography laboratory has begun to use new technology to assess left atrial and right ventricular strain in addition to left ventricular strain by speckle tracking echocardiography. Dr. Matthew Delfiner recently initiated the lab’s echo CPET program. Dr. Mehrotra continues his partnership with AISAP and Ultrasight, Ltd. – companies focusing on AI solutions for cardiac ultrasound with scans performed at Jefferson helping these companies achieve FDA approval for their respective software. Dr. Ashley Pender published a comprehensive review on the use of echocardiography for the diagnosis and management of cardiomyopathies in Current Cardiology Reports. In collaboration with the cardiac catheterization laboratory, Drs. Mehrotra and Peters continue their work on sizing strategies for TAVR and PFO closure and the effects of PFO closure on let atrial strain.

ELECTROPHYSIOLOGY The section of clinical cardiac electrophysiology has been committed to delivering compassionate and innovative care to patients with a variety of heart rhythm disorders for over 45 years while training the next generation of electrophysiologists. Our section consists of four full-time faculty members (two of whom hold the rank of full Professor), two outpatient nurse practitioners, three outpatient clinical nurses, and a fourth nurse dedicated to remote monitoring of cardiac implanted electronic devices (CIEDs). We have two state-ofthe-art EP laboratories located

at Thomas Jefferson University Hospital with three computerized mapping systems to assist in catheter ablation procedures. In FY25 we performed more than 1,300 procedures, which is a 20% increase from 4 years prior. The procedures include ablation for atrial fibrillation using pulsed field ablation technology, ablation of supraventricular and ventricular arrhythmias (including epicardial ventricular tachycardia ablation), implantation of CIEDs including pacemakers, ICDs, subcutaneous ICDs, extra-vascular ICDs, cardiac resynchronization devices (CRT), and implantable loop recorders (ILRs). We also implant leadless pacemakers, conduction system pacing leads, and left atrial occlusion devices for non-pharmacologic stroke risk mitigation. Additionally, we implant cardiac contractility modulation (CCM) therapy systems and implantable systems for central sleep apnea. We are a center for complex lead extraction procedures utilizing laser sheaths and mechanical sheaths. We have been at the forefront of delivering the latest technology to the care of our patients. We follow most of our CIED patients using remote monitoring. Currently, we are following more than 3,400 patients. We have developed a program with stroke neurologists and neurosurgeons for evaluating patients with unexplained stroke who may have occult atrial fibrillation. Patients have ILRs implanted at the bedside at time of their hospitalization at JHN. The EP team follows them remotely and if atrial fibrillation is detected, the stroke neurologist and primary care physicians receive an immediate message via the EPIC EMR, which significantly shortens the time to anticoagulation. All core EP faculty are actively engaged in clinical research, including home-grown projects,

industry-sponsored studies, and federally approved trials. The collective publication output of the EP core continues to grow. The faculty are also active participants in education efforts/conferencing in the cardiovascular diseases and CCEP fellowship programs, and the ECG core curriculum is taught entirely by the EP faculty. Faculty members are invited every year to lecture at local, national and international conferences.

INTERVENTIONAL CARDIOLOGY Jefferson’s Interventional Cardiology Section has a long tradition of clinical excellence and innovation. Over 25 years ago, Drs. David Fischman and Michael Savage were the lead authors of the landmark STRESS and SAVED trials published in the New England Journal of Medicine. These studies revolutionized the management of coronary artery disease. Their coronary brachytherapy program for in-stent restenosis of drug eluting stents, an interdisciplinary collaboration involving Interventional Cardiology and Radiation Oncology has been a regional referral center for this specialized procedure for many years. This program will be expanded to include the utilization of drug coated balloons to further treat this complex patient population. Their contributions to interventional cardiology with investigator-initiated studies, ongoing clinical trials (including novel drug coated balloons) and multicenter meta-analyses have answered many important questions for the practicing clinician. In the next few months, their novel ANOCA (Angina with non-obstructive coronary arteries) program will be starting to treat patients with coronary microvascular dysfunction, endothelial dysfunction, microvascular and epicardial spasm, and myocardial bridging.

FACU LT Y Hans Stabenau, MD Assistant Professor of Medicine Eugene Storozynsky, MD, PhD, FACC Professor of Medicine and Oncology Marc Tecce, MD Clinical Assistant Professor of Medicine Alec Vishnevsky, MD, FACC Assistant Professor of Medicine Howard Weitz, MD, FACP, FACC Vice Chair, Department of Medicine Bernard L. Segal Endowed Professor of Medicine David Whellan, MD, MHS, FACC, FAHA Deputy Provost for Research Executive Director, Jefferson Clinical Research Institute James C. Wilson Professor of Medicine David Wiener, MD, FACC, FAHA, FASE Clinical Professor of Medicine Mark Jay Zucker, MD, JD, FACC, FACP, FCCP Clinical Professor of Medicine

Department of Medicine 2025 Annual Report

6 The Structural Heart Program, led by Dr. Nicholas Ruggiero, in conjunction with Dr. Alec Vishnevsky, has become a national leader in trans-catheter valve therapies. Structural heart procedures including aortic and mitral balloon valvuloplasty, TAVR, TMVR, TTVR, MitraClip, Pascal, Watchman LAA closure, ASD closure, VSD closure, PFO closure, PDA closure and paravalvular leak closure are performed routinely. Management of tricuspid valve disease including Triclip and Evoque are beginning. Research studies such as the Empower trial for left ventricular remodeling in patients with cardiomyopathies and Corvia interatrial shunts are ongoing. Upcoming trials looking at new PFO closure devices (ENCORE PerFOrm Trial) and a novel interatrial shunt (Alleviant) will be starting in the next few months. The Cardiogenic Shock and Temporary Mechanical Circulatory Support program, led by Dr. Alec Vishnevsky, is a multidisciplinary effort involving Structural Cardiology, Heart Failure/ Transplant, Cardiac Surgery, and Cardiac Intensivists that enables a nuanced and tailored approach for each patient presenting with Cardiogenic Shock. Since its inception, the program has been very successful, achieving a survival rate above the national average in patients with shock who require temporary mechanical circulatory support, including ECMO, Impella, TandemHeart, and ProtekDuo. Under Dr. Vishnevsky’s leadership, the Jefferson Enterprise has joined the Cardiogenic Shock Working Group, a multicenter, multinational registry consortium of over 40 health systems, and is one of the highest enrollers each year. This collaborative initiative has led to numerous publications and continues to be at the forefront of cutting-edge care for patients with Cardiogenic Shock. The continued growth of the program has also led to the initiation of numerous

device trials, including the AortixDrain HF trial investigating the use of novel therapies for these patients. With these efforts, the Jefferson Enterprise has quickly become amongst the national leaders in care of patients with Cardiogenic Shock. In FY25, under the direction of Dr. Nicholas Ruggiero, the Jefferson catheterization laboratory performed over 3,500 diagnostic and interventional procedures. Complex percutaneous coronary interventions are performed with the utilization of state-of-the-art devices, including excimer laser, orbital atherectomy, rotational atherectomy, Shockwave lithotripsy, fractional flow reserve, instantaneous flow reserve and intravascular imaging (both intravascular ultrasound and optical coherence tomography). The tradition of exemplary patient outcomes continues, in the most recent NCDR PCI registry report, where Jefferson’s outcomes were once again above the 90% percentile. The section is also launching renal denervation for the management of patients with uncontrolled hypertension. The Jefferson Angioplasty Center provides a unique regional resource as a secondopinion center for thousands of high-risk patients with complex cardiovascular disease each year looking to bypass open heart surgery. The section is also very academically productive as seen by over 50 peer reviewed manuscripts, numerous abstracts and complex case presentations. The section members have been honored to be selected to edit multiple prestigious journals including JACC Case Reports and JSCAI. They have served as faculty at SCAI, TCT, ACC and the AHA scientific meetings. The Center’s Philadelphia Cardiovascular Congress Meeting has become a national entity with international faculty and attendees. Drs. Savage,

Fischman and Ruggiero have been annually named as “Philly Top Docs” in Interventional Cardiology.

STRUCTURAL HEART PROGRAM The Jefferson Structural Heart Program, under the leadership of Dr. Nicholas Ruggiero, in conjunction with Dr. Alec Vishnevsky and stewardship of Rebecca Marcantuono CRNP and Emily Alliss CRNP has grown exponentially into a preeminent program with national recognition. The program has expanded to include AngioVac management of bacterial endocarditis and tricuspid valve interventions including TriClip and soon Evoque. The “Heart-Brain-Blood” model of collaboration between Neurology, Hematology and Cardiology to evaluate patients with PFO and cryptogenic stroke has become the national gold standard for managing patients with this diagnosis. Drs. Ruggiero, Vishnevsky, Tzeng, Dharia and Rhoades have published and spoken extensively on this topic, awarding Jefferson the designation of a National PFO Center of Excellence. Our Jefferson Structural Heart Program prides itself on not only the ability to scientifically provide improved quality of life with trans-catheter therapies, but also the ability to make our patients feel comfortable and safe. We believe that collaboration is the key to success, and we have created relationships with multiple cardiology groups throughout the tri-state area, as well as unique relationships with our cardiothoracic surgery, electrophysiology, and imaging colleagues. Drs. John Entwistle and Vakhtang Tchantchaleishvili have been integral in providing surgical support to the TAVR and MitraClip programs. Dr. Daniel Frisch of Electrophysiology has been instrumental in the growth of

the left atrial appendage occlusion program. Drs. Konstadinos Plestis of Cardiothoracic Surgery and Paul Dimuzio of Vascular Surgery are instrumental in the management of patients with complex aortic disease. Drs. Mehrotra, Peters and Pender, our interventional echocardiographers, have been paramount to our program’s success and have taken the lead on multiple groundbreaking investigator-initiated trials including upcoming presentation at the ACC 2024 looking at a novel TAVR valve sizing approach for patients with borderline aortic annular sizes. The structural heart disease fellowship under the direction of Dr. Nicholas Ruggiero is producing highly skilled structural interventionalists who are providing top notch care to patients all over the United States. Our team continues to look forward to representing Jefferson as a leader in the delivery of transcatheter therapies and further evolution of our Structural Heart Program for many years to come with an emphasis on providing cutting-edge treatment with patient focused care.

ADVANCED CARDIAC AND PULMONARY VASCULAR DISEASE The field of heart failure is dynamic with multi-faceted acute and chronic syndromes that require timely targeted interventions delivered by an integrated medical and surgical team. Since the first successful application of cardiopulmonary bypass (heart-lung machine) in May of 1953 by Dr. John Gibbon to surgically correct a young woman suffering from an atrial septal defect at Thomas Jefferson University Hospital, Jefferson has been committed to innovation and clinical excellence in the management of complex cardiovascular

Department of Medicine 2025 Annual Report

7 disease. Over 70 years later, the current teams at Jefferson are applying a broad spectrum of medical and device innovation for patients with inherited and acquired cardiomyopathies from novel therapeutics and remote monitoring systems to short-term and durable mechanical cardiopulmonary support and transplantation. To meet the current challenge of delivering targeted and timely multi-disciplinary care across the Enterprise for patients with acute and chronic heart failure, the section of Advanced Cardiac and Pulmonary Vascular Disease was created in 2020 under the helm of Dr. Eduardo Rame and Dr. Rene Alvarez. Their vision—to have a group of physician faculty, nursing clinical providers, and clinical staff working together at the nexus of advanced heart failure and pulmonary hypertension - has led to growth from three faculty members in the Spring of 2020 to over ten faculty members staffing two independent inpatient services. This year, there has been significant growth in the Section, with several “firsts” achieved. A total of 21 orthotopic heart transplants were performed in the calendar year, the most in the history of the program. Included in this cohort were the first combined heart-liver and heartlung transplants to be performed at Jefferson. A critical component of the Section’s success is the Cardiogenic Shock and Durable Mechanical Circulatory Support Program, which is led by Dr. Susan Joseph. This program continued its practice of providing both temporary and durable device support for patients with complex critical illness. As the Enterprise has grown in scope, steps have been taken to integrate with our partners at the Lehigh Valley Health Network to better serve the patients in this region, as Dr. Mark Zucker has continued to

lead Jefferson’s New Jersey heart failure program. In the ambulatory setting, Dr. Matthew Delfiner has developed a comprehensive cardiopulmonary exercise testing (CPET) program which incorporates real-time hemodynamic data to aid in diagnosis and treatment of undifferentiated exercise intolerance. For patients with infiltrative diseases such as sarcoidosis, Dr. Carolina Masri works alongside colleagues in the Pulmonology and Rheumatology Sections and utilizes advanced imaging techniques to care for these patients. Dr. Eugene Storozysnky has continued to lead the Enterprise-wide CardioOncology Program. Dr. Ileana Pina has continued to serve as Jefferson’s Chief Quality Officer for the Cardiovascular Service Line, while Dr. Howard Eisen oversees the Division’s research efforts.

Q UA L I T Y I N I T I AT I V E S Over the past year, under the leadership of Dr. Yair Lev and in close collaboration with divisional and enterprise partners, the Division of Cardiology has continued to expand its quality improvement efforts with a strong emphasis on high impact, data driven, and patient centered initiatives. Building on prior work, current efforts focus on optimizing evidence based care delivery, improving procedural and surgical outcomes, and leveraging advanced analytics, including artificial intelligence, to identify gaps in care and intervene earlier across the cardiovascular disease spectrum. A major area of focus has been the identification and management of cardiac amyloidosis, particularly in patients undergoing transcatheter aortic valve replacement. Recognizing the clinical overlap between aortic stenosis and infiltrative cardiomyopathies,

the Division has initiated efforts to improve detection of cardiac amyloidosis within this population. In collaboration with Dr. Nahass, ongoing work is exploring the use of artificial intelligence applied to existing clinical and imaging datasets to enhance identification of patients at higher risk for amyloidosis who may otherwise go unrecognized. These efforts aim to facilitate earlier diagnosis, improve risk stratification, and ensure appropriate referral for disease specific therapies. In the realm of cardiac surgery and electrophysiology, a key quality initiative centers on evaluating and improving the utilization of surgical ablation in patients with preexisting atrial fibrillation undergoing cardiac surgery. Despite established guideline recommendations supporting concomitant ablation, variability in practice patterns remains. Current efforts are directed at systematically assessing utilization rates, identifying barriers to implementation, and aligning surgical practice with evidencebased standards to improve rhythm outcomes and long-term morbidity. Advancements in cardiovascular imaging also represent a significant priority. The development and expansion of a cardiac stress MRI program is underway, with the goal of enhancing diagnostic precision in ischemic heart disease and cardiomyopathies. This initiative is expected to improve noninvasive risk stratification, reduce reliance on less sensitive modalities in selected populations, and further integrate advanced imaging into clinical decision-making pathways. Several initiatives are focused on strengthening adherence to guideline directed medical therapy. Efforts to improve anticoagulation in patients with atrial fibrillation are targeting appropriate initiation and persistence of therapy, with attention to both inpatient and outpatient transitions of care. In parallel, the Division has prioritized

optimization of lipid management with a focus on intensifying therapy in high risk populations, improving adherence to statin and non statin therapies, and closing gaps in secondary prevention. Interventional cardiology quality initiatives remain central to divisional efforts. Preventing early stent thrombosis has been identified as a critical priority, with workstreams focused on procedural optimization, medication adherence, and post discharge follow up. Closely aligned with this is the initiative to improve access to dual antiplatelet therapy, recognizing that barriers related to cost, education, and care coordination can directly impact outcomes. These efforts aim to ensure that all eligible patients receive timely and sustained therapy following percutaneous coronary intervention. In cardiac surgery, the Division is also emphasizing the increased use of multiarterial grafting in coronary artery bypass procedures. Given the well-established long-term benefits of arterial conduits, this initiative seeks to promote broader adoption through surgeon engagement, outcomes tracking, and alignment with best practice guidelines. A major cross cutting initiative involves collaboration with enterprise data scientists and physician leaders to develop advanced analytic tools capable of identifying previously unaddressed cardiovascular risk. One such effort focuses on patients with documented coronary artery calcifications on prior CT imaging who have not received appropriate clinical follow up. By systematically extracting this information and integrating it into actionable dashboards, the Division aims to identify high risk individuals, including those who are not receiving statin therapy or not yet evaluated by cardiology, and proactively direct them toward evidence-based care pathways.

Department of Medicine 2025 Annual Report

8 Collectively, these initiatives reflect a comprehensive and forwardlooking approach to quality improvement within the Division of Cardiology. By combining rigorous adherence to established guidelines with innovative applications of data science and artificial intelligence, the Division continues to advance patient care, improve clinical outcomes, and strengthen its role as a leader in cardiovascular quality and innovation.

E D U C AT I O N The Division of Cardiology has been providing comprehensive training of cardiovascular disease fellows since 1959, later introducing sub-specialty training in Interventional Cardiology in 1982 (with Structural Heart Disease added in 2017), Clinical Cardiac Electrophysiology in 1984, and Advanced Heart Failure & Transplant in 2004. Our 4 fellowship programs are accredited by the ACGME (American College of Graduate Medical Education). The Interventional Cardiology program has an optional nonaccredited second year for selected fellows who wish to focus on advanced structural heart and peripheral vascular disease. The Division of Pulmonary and Critical Care, in conjunction with the Division of Cardiology, provides a one-year ACGME accredited training program in critical care cardiology for fellows who have completed a Cardiovascular Disease Fellowship. Sung-Hae Cho, MD, is the Program Director of the General Cardiovascular Disease Fellowship supervising 24 general fellows during a 3-year program. Of these fellows, there are 6 (2 per class) in the community track with Abington Jefferson Health in partnership with Associate Program Director, Adam Cohen, MD, from Abington, and 3 (1 per class) in the recently formed

community track with Jefferson Torresdale Hospital with Associate Program Director, Mohammed Murtaza, MD, from Torresdale. 15 fellows (5 per class) are in the main TJUH track. David L. Fischman, MD was the Program Director for the Interventional Cardiology Fellowship, supervising 1 fellow. After David Fischman’s departure from the division, the interim program director is now Saif Anwaruddin, MD. Behzad Pavri, MD, is the Program Director for the Clinical Cardiac Electrophysiology Fellowship, overseeing 2 fellows. Greg Gibson, MD, is the Program Director for the Advanced Heart Failure & Transplant Fellowship, supervising 1 fellow. David Oxman, MD, is the Program Director for the Critical Care Medicine Fellowship. The faculty provides direct teaching and supervision of fellows, with fellows playing an active role in patient care, including diagnosis and management of a wide range of cardiac conditions. The inpatient care includes general cardiology, heart failure, electrophysiology, critical care, and postoperative care of the cardiac surgery patients. The fellows receive comprehensive hands-on training in both inpatient and outpatient procedures which include cardiac catheterization, percutaneous intervention, structural interventions, electrophysiology studies, ablations, device placements, transthoracic and transesophageal echocardiography, stress echocardiography, interventional echocardiography, and nuclear cardiology. The program also provides training in cardioobstetrics, women’s health, cardio-oncology, cardiac MRI, and congenital heart disease. Core faculty update and deliver a daily, rigorous 45-minute morning lecture curriculum in a repeating weekly format: ECG and Electrophysiology (coordinated by Behzad Pavri,

MD), Interventional Cardiology (coordinated by David L. Fischman, MD), Echocardiography (coordinated by Sung-Hae Cho, MD), and Clinical Cardiology Conference, also known as Cardiology Grand Rounds, for all faculty and fellows (coordinated by Gregary D. Marhefka, MD). Both Echocardiography and Clinical Cardiology conference series are ACCME (Accreditation Council for Continuing Medical Education) accredited. Friday morning conferences also include monthly Morbidity & Mortality Conference, combined RadiologyCardiology Advanced Imaging Conferences, and multiple funded Louis R. Dinon, MD, Memorial Lectureship, attracting highly renowned, external speakers from all over the world. This past year’s speakers from the Louis R. Dinon, MD Memorial Lectureship were: Nader Moazami, MD, from NYU, who spoke about innovations in heart transplantation; Uri Elkayam, MD, who leads the cardio-OB program in USC in LA; Philip Greenland, MD, preventive cardiologist from Northwestern and senior editor for JAMA; Göran Dellgren, MD, PhD, the Director Heart & Lung Transplantation & Mechanical Circulatory Support from Sahlgrenska University Hospital in Sweden and former ISHLT Annual Meeting Chair; Mourad Senussi, MD, from Baylor College of Medicine, who spoke about Visceral Organ Doppler; Theodore Abraham, MD, from UCSF, who presented on emerging therapies in hypertrophic cardiomyopathy. We also had the first Edmund L. Housel, MD Memorial Hypertension Lecture, and this year’s speaker was Eric A. Secemsky, MD, from Harvard, who discussed re-emergence of renal denervation in managing uncontrolled hypertension. On a repeating monthly basis, core faculty provide lectures to our fellows in Nuclear Cardiology (coordinated by

Christopher L. Hansen, MD), Advanced Heart Failure & Transplant (coordinated by Greg Gibson, DO), Adult Congenital Heart Disease (coordinated by Gregary D. Marhefka, MD, also ACCME accredited), Journal Club (coordinated by Susan Joseph, MD). Additionally, there are lectures/didactics in Cardiac MRI (coordinated by Andrew Peters, MD), General Cardiovascular Disease Board Review (coordinated by Alec Vishnevsky, MD), and Echocardiography Board Review (coordinated by Sung-Hae Cho, MD). Furthermore, the Interventional and Structural Heart Disease and the Advanced Electrophysiology programs provide weekly educational conferences for their own subspecialty fellows. Finally, the Cardiology Division provides ongoing formal lectures and bedside teaching during rounds for Internal Medicine and Family Medicine residents, for trainees in other departments and divisions, as well as for medical students, both from Sidney Kimmel Medical College (coordinated by Lori Frank, MD) and visiting from abroad.

RESE ARCH Research activity within the Cardiology Division remained robust throughout the fiscal year. The portfolio encompassed a wide range of initiatives, including fellow-driven independent projects, sponsored clinical trials, investigator-initiated studies, and faculty-led grant efforts. Collectively, the Jefferson Cardiology group continues to strengthen its academic impact and maintain a leading role in advancing cardiovascular research and innovation. During this period, 16 cardiology research trials were open to enrollment with 90 participants across all studies. Faculty leading these efforts included Drs. Eisen,

Department of Medicine 2025 Annual Report

9 Gibson, Frisch, Joseph, Mehrotra, Nahass, Pavri, Pina, Savage, Ruggiero, Vishnevsky, and Whellan.

contributing meaningfully to the evolving field of cardiology.

Our research portfolio reflects a broad and diverse spectrum of cardiovascular investigations. This includes studies focused on heart failure, with particular emphasis on heart failure with preserved ejection fraction. In addition, ongoing work addresses key topics in electrophysiology, including atrial fibrillation, as well as research targeting historically underdiagnosed populations, such as patients with cardiac amyloidosis. The program is also engaged in initiatives aimed at advancing point-ofcare ultrasound acquisition and utilization, improving the management of cardiogenic shock, and evaluating standards of care in heart transplantation.

PUBLICATIONS (2024-2025)

Over the past year, the team has benefited from the support of a dedicated full-time Senior Research Project Manager, Jordan Price coordinating efforts across Abington, Thomas Jefferson University Hospital, and Einstein. In this role, she has been instrumental in developing standardized processes for Single Site Multi-Location (SSML) studies, positioning the Jefferson enterprise to better engage with sponsors and external partners. In addition, she has played a key role in coordinating the cardiology group’s participation in multiple prospective registries and fostering connections between students, fellows, and faculty-led research initiatives. She has also provided ongoing support to cardiologists in preparing grant applications, advancing investigator-initiated trials, and overseeing research projects across all phases. Together, these efforts represent a comprehensive, multidisciplinary approach to cardiovascular research, with the goals of improving patient outcomes, expanding treatment options, and

Improvement in Biomarkers and Freedom From Hospitalization in Bariatric Surgery Patients With Heart Failure. Foster M, Al Soueidy A, Riley JM, Badenhausen S, Naidu S, Williams N, Brailovsky Y, Alvarez RJ, Dumon K, Rame JE. JACC Heart Fail. 2025 Nov;13(11):102674. doi: 10.1016/j.jchf.2025.102674. Epub 2025 Sep 22.PMID: 40987144 No abstract available. Veno-pulmonary extracorporeal membrane oxygenation for concomitant right ventricular and respiratory support: A systematic review of utilization patterns and outcomes. Nasher N, Mounzer M, Mallur K, Fayek FB, Rahimov D, Rame JE, Alvarez RJ, Entwistle JW, Rajagopal K, Hoopes CW, Tchantchaleishvili V. Perfusion. 2025 Oct 15:2676591251389383. doi: 10.1177/02676591251389383. Online ahead of print. PMID: 41195481 Review. Ideal Body Weight Ratio for Donorto-Recipient Size Matching in Heart Transplantation. Pritting CD, Nasher N, Rahimov D, Sanders V, Rame JE, Alvarez RJ, Bavaria JE, Entwistle JW, Rajagopal K, Hoopes CW, Tchantchaleishvili V. Clin Transplant. 2025 Nov;39(11):e70369. doi: 10.1111/ctr.70369. PMID: 41137649 Incidence, risk factors and clinical outcomes of pericardial effusion in left ventricular assist device patients. Khan MZ, Brailovsky Y, Bhuiyan MAN, Marhefka G, Faisal ASM, Sircar A, O'Neill P, Rame JE, Franklin S, Waqas M, Shah H, Rajapreyar I, Alvarez RJ. World J Cardiol. 2025 Jun 26;17(6):105330. doi: 10.4330/wjc.v17.i6.105330. PMID: 40575433 Impact of waitlist weight change on outcomes in heart transplant recipients: a UNOS database analysis.Austin MA, Ahmad D, Rosen JL, Weber MP, Rajapreyar I,

Rame JE, Alvarez RJ, Entwistle JW, Massey HT, Tchantchaleishvili V. Gen Thorac Cardiovasc Surg. 2025 May;73(5):336-342. doi: 10.1007/ s11748-024-02078-y. Epub 2024 Oct 3. PMID: 39361224

Alvarez RJ, Rame E, Massey HT, Tchantchaleishvili V, Thoma B, Rajapreyar IN. Artif Organs. 2024 Oct;48(10):1162-1167. doi: 10.1111/ aor.14803. Epub 2024 Jun 18. PMID: 38887186

Trends in Left Ventricular Assist Device Utilization and Survival Outcomes Following the Donor Allocation Policy Change. Pritting CD, Rahimov D, Weber MP, Storozynsky E, Eisen HJ, Rame JE, Alvarez RJ, Rajagopal K, Entwistle JW, Tchantchaleishvili V. Artif Organs. 2025 Nov 17. doi: 10.1111/ aor.70046. Online ahead of print. PMID: 41243743

Swiss Cheese Heart: A Tale of Multiple Valve Perforations. Al Hennawi H, Khan SI, Khan A, Sadiq U, Cho SH. Methodist Debakey Cardiovasc J. 2024 Apr 5;20(1):1822. doi: 10.14797/mdcvj.1341. eCollection 2024. PMID: 38618611

Impact of 2018 Donor Heart Allocation Policy Change on Patients on Biventricular Support: A UNOS Database Analysis. Rahimov D, Nasher N, Sakata T, Macmillan TR, Pritting CD, Rame JE, Alvarez RJ, Rajagopal K, Entwistle JW, Tchantchaleishvili V. Artif Organs. 2025 Nov 27. doi: 10.1111/ aor.70047. Online ahead of print. PMID: 41309503 Leadership Practices, Organization Structure, and Other Factors Associated with Higher 2022-2023 US News and World Report Ranking. Sankisa D, Tatum R, Saxena A, Whellan DJ, Alvarez RJ, Morris RJ, Tchantchaleishvili V. J Gen Intern Med. 2025 Dec;40(16):3909-3915. doi: 10.1007/s11606-024-09028-7. Epub 2024 Oct 2. PMID: 39358498 Heart Allograft Utilization Rates Following Donation After Circulatory Death Compared to Donation After Brain Death in the Ideal Heart Donor. Nasher N, Rahimov D, Macmillan TR, Siddique F, Rame JE, Eisen HJ, Alvarez RJ, Rajagopal K, Entwistle JW, Tchantchaleishvili V. Clin Transplant. 2025 Aug;39(8):e70266. doi: 10.1111/ctr.70266. PMID: 40844484 Peri-operative fever and LVAD: SIRS or impaired right ventricular strain? Marek-Iannucci S, Wildemann R, Brailovsky Y, Dyer S, Gamero MT,

Clinical Variability in Presentation and Management of Quadricuspid Aortic Valve: A Case Series.Corsi DR, Kelly B, Nair N, Luo M, Osler B, Cho SH, Mehrotra P, Wiener D, Johnson D. CASE (Phila). 2025 Feb 22;9(4):130-134. doi: 10.1016/j. case.2024.12.008. eCollection 2025 Apr. PMID: 40309471 Chylopericardium and Superior Vena Cava Syndrome Caused by Central Venous Occlusion From Indwelling Hemodialysis Catheters. Underberg DL, DeMario NJ, Rodriguez S, Mirzozoda K, DeCaro MJ, Marhefka GD. JACC Case Rep. 2024 Sep 4;29(17):102483. doi: 10.1016/j.jaccas.2024.102483. eCollection 2024 Sep 4. PMID: 39359502 Embolic Stroke in a Patient With Left Atrial Myxoma. Sabri M, Qamar S, Ijaz N, DeCaro M. JACC Case Rep. 2024 Dec 18;29(24):102852. doi: 10.1016/j.jaccas.2024.102852. eCollection 2024 Dec 18. PMID: 39822630 Purulent Pericarditis: Treating a Medically-Complex Patient With Intrapericardial Antibiotics. Guler M, Vemula S, Hart M, Wiener J, Farzad D, DeCaro M, Marhefka GD, Weber D, Entwistle J, Urtecho J. JACC Case Rep. 2025 Sep 24;30(29):105152. doi: 10.1016/j. jaccas.2025.105152.PMID: 41005839 Hemodynamic Support With the Impella 5.5 Acute Mechanical Circulatory Support Device. Schurr JW, Pearson A, Delfiner MS, Brown A, Quinn MF, Karpenshif Y, Ortega-

Department of Medicine 2025 Annual Report

10 Legaspi J, Parikh A, Cevasco M, Wald JW. ASAIO J. 2025 Apr 1;71(4):300-307. doi: 10.1097/ MAT.0000000000002331. Epub 2024 Oct 14. PMID: 39401450 Rare variants in cardiomyopathy genes predispose to cardiac injury in severe COVID-19 patients of African or Hispanic ancestry. Qu HQ, Delfiner MS, Gangireddy C, Vaidya A, Nguyen K, Whitman IR, Wang J, Song J, Bristow MR, McTiernan CF, Gerhard GS, Hakonarson H, Feldman AM. J Mol Med (Berl). 2025 Feb;103(2):175185. doi: 10.1007/s00109-02402510-z. Epub 2024 Dec 27. PMID: 39730912 Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by NeutrophilLymphocyte Ratio and LDLCholesterol Levels. Rikken SAOF, Gibson CM, Bahit MC, Duffy D, Chi G, Korjian S, Mohammadnia N, White H, Anschuetz G, Kingwell BA, Ophuis TO, Nicolau JC, Lopes RD, Lewis BS, El Messaoudi S, Vinereanu D, Ten Berg JM, Goodman SG, Bode C, Steg PG, Libby P, Bainey KR, van 't Hof AWJ, Ridker PM, Mahaffey KW, Nicholls SJ, Mehran R, Harrington RA, Cornel JH; AEGIS-II Committees and Investigators. JACC Adv. 2025 May;4(5):101727. doi: 10.1016/j. jacadv.2025.101727. Epub 2025 Mar 29. PMID: 40288083 Apolipoprotein A1 (CSL112) Increases Lecithin-Cholesterol Acyltransferase Levels in HDL Particles and Promotes Reverse Cholesterol Transport.Mathias RA, Velkoska E, Didichenko SA, Greene BH, Tan X, Navdaev AV, Collins HL, Adelman SJ, Young K, Gille A, Duffy D, Gibson CM, Pelzing M, Kingwell BA. JACC Basic Transl Sci. 2025 Apr;10(4):405-418. doi: 10.1016/j. jacbts.2024.11.001. Epub 2024 Nov 15. PMID: 40306849 Navigating Advanced Heart Failure in the Shadow of Primary Graft Dysfunction: A Shared Dilemma for Patient and Physician. Yuzefpolskaya M, Eisen HJ. JACC

Heart Fail. 2025 Nov;13(11):102678. doi: 10.1016/j.jchf.2025.102678. Epub 2025 Oct 8. PMID: 41193110 No abstract available Is There Hope With Hypothermic Oxygenated Perfusion? Eisen HJ, Bent A. Transplantation. 2025 Dec 1;109(12):1816-1817. doi: 10.1097/ TP.0000000000005524. Epub 2025 Sep 17. PMID: 40958145 No abstract available Early outcomes in patients undergoing heart re-transplantation in the era of HCV-viremic donors. Mazur M, Pisani B, Carmona Rubio A, Eisen HJ, Bhat G, Núñez M. J Cardiol. 2025 Sep 16:S09145087(25)00235-7. doi: 10.1016/j. jjcc.2025.09.005. Online ahead of print. PMID: 40967272 Heart Transplantation Outcomes in Patients With Hypertrophic Cardiomyopathy in the Era of Mechanical Circulatory Support. Mazur M, Dowling R, Bhat G, Carmona Rubio A, Eisen HJ. ASAIO J. 2025 May 1;71(5):409-417. doi: 10.1097/MAT.0000000000002347. Epub 2024 Nov 12. PMID: 39531589 Trends in Left Ventricular Assist Device Utilization and Survival Outcomes Following the Donor Allocation Policy Change. Pritting CD, Rahimov D, Weber MP, Storozynsky E, Eisen HJ, Rame JE, Alvarez RJ, Rajagopal K, Entwistle JW, Tchantchaleishvili V. Artif Organs. 2025 Nov 17. doi: 10.1111/ aor.70046. Online ahead of print. PMID: 41243743 Heart Allograft Utilization Rates Following Donation After Circulatory Death Compared to Donation After Brain Death in the Ideal Heart Donor. Nasher N, Rahimov D, Macmillan TR, Siddique F, Rame JE, Eisen HJ, Alvarez RJ, Rajagopal K, Entwistle JW, Tchantchaleishvili V. Clin Transplant. 2025 Aug;39(8):e70266. doi: 10.1111/ctr.70266. PMID: 40844484 Sex differences in the association of vascular risk and APOE Genotype with cognitive decline and dementia: evidence from a U.S.

longitudinal study. Liu L, Hou J, Cui S, Zhao X, Liu Z, Longenecker JC, May NS, Luo JJ, DiMaria-Ghalili RA, Eisen HJ. Lancet Reg Health Am. 2025 Dec 26;54:101346. doi: 10.1016/j.lana.2025.101346. eCollection 2026 Feb. PMID: 41536502 Purulent Pericarditis: Treating a Medically-Complex Patient With Intrapericardial Antibiotics. Guler M, Vemula S, Hart M, Wiener J, Farzad D, DeCaro M, Marhefka GD, Weber D, Entwistle J, Urtecho J. JACC Case Rep. 2025 Sep 24;30(29):105152. doi: 10.1016/j.jaccas.2025.105152. PMID: 41005839 Investment in Alzheimer's disease research for the next generation of adults with Down syndrome will yield health benefits for future generations. Weden MM, Frank L, Dick AW, Wang Z, Peschin S, Bovenkamp DE, Rossi SL, Sciullo D, Hillerstrom H, Fisher RA. Alzheimers Dement. 2025 Sep;21(9):e70348. doi: 10.1002/ alz.70348. PMID: 40928009 Acute atrial infarction precipitating sinus node dysfunction with challenging pacemaker placement and subsequent pericarditis. Moylan DD, Majeed A, Foster MW, Marhefka GD, Frisch DR. Heart Rhythm Case Rep. 2025 Oct 29;12(1):32-37. doi: 10.1016/j. hrcr.2025.10.030. eCollection 2026 Jan. PMID: 41732462 Not in the Gym… But at Home. Gibson GT, Piña IL. JACC Heart Fail. 2025 May;13(5):707-709. doi: 10.1016/j.jchf.2025.03.011. PMID: 40335225 No abstract available. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction (HFpEF). Pecchia B, Samuel R, Shah V, Newman E, Gibson GT. Heart Fail Rev. 2025 Jul;30(4):777-789. doi: 10.1007/ s10741-025-10504-3. Epub 2025 Mar 13. PMID: 40080287 When Guidelines Meet Reality: Frailty's Role in Shaping Heart Failure Therapy. Sabri MS, Sharma

S, Ahmad Sadiq M, Sadiq U, Gibson GT, Haas D. JACC Adv. 2025 Jul 14;4(12):102000. doi: 10.1016/j. jacadv.2025.102000. Online ahead of print. PMID: 40704938 A novel thermochromic myocardial phantom for radiofrequency ablation and cryoablation. Saija C, Pradeep Kundur S, Leung L, Sabu S, Pinto M, Herridge M, Gabbeta A, Chavan R, Chowdry N, Gibson G, Byrne C, Pontiki A, Housden RJ, Berthet-Rayne P, Behar JM, Rhode K. Sci Rep. 2025 Oct 7;15(1):34931. doi: 10.1038/s41598-025-18732-1. PMID: 41057472 Hansen, CL, Nahass, M, Reist, K.The Jefferson Protocol Improves the Diagnostic Yield of Amyloid Imaging. Presented ASNC 2025. Yan, C, Moylan, D, Cai, J, Nahass, M, Hansen, C. Apical sparing of echocardiographic strain in transthyretin amyloidosis is not explained by reduced infiltration of amyloid as determined by technetium-99m pyrophosphate uptake. Accepted AHA 2025. Cardiovascular Effects of Antiseizure Medications for Epilepsy. Nei M, Ho J, Ho RT. CNS Drugs. 2025 Apr;39(4):383-401. doi: 10.1007/s40263-025-01163-x. Epub 2025 Feb 14. PMID: 39951223 Profound Asystole Following Pulsed Field Application to the Left Superior Pulmonary Vein. Ho RT. J ACC Clin Electrophysiol. 2025 Dec 16:S2405-500X(25)00989-2. doi: 10.1016/j.jacep.2025.11.007. Online ahead of print. PMID: 41400596 Clockwise "Mitral Isthmus Block" complicating ablation of left free wall accessory pathways - two cases and review of the literature. Kocovic N, Nagashima K, Ho RT. J Interv Card Electrophysiol. 2025 Dec;68(9):19131924. doi: 10.1007/s10840-02502119-3. Epub 2025 Aug 23. The Tale of 2 Tachycardias. Ho RT.JACC Clin Electrophysiol. 2026 Jan;12(1):236-241. doi: 10.1016/j. jacep.2025.09.019. Epub 2025 Oct 31. PMID: 41171235

Department of Medicine 2025 Annual Report

11 Cardiac screening findings and referral patterns in male AfricanAmerican basketball players: Analysis of the HeartBytes Registry. Corsi D, Saraiya A, Doyle M, Shah V, O'Malley B, Qiu G, Lanstaff R, Masood I, Osler B, Hajduczok AG, Johnson D, Shipon D. Am J Cardiol. 2025 May 15;243:73-80. doi: 10.1016/j.amjcard.2025.02.007. Epub 2025 Feb 18. PMID: 39978564 Fragile X and Fatal Rhythms: Electroconvulsive TherapyInduced Ventricular Tachycardia. Sabri MS, Klair N, Wiener J, Gamero MT, Johnson D. JACC Case Rep. 2025 Sep 10;30(27):105077. doi: 10.1016/j.jaccas.2025.105077. Epub 2025 Aug 14. PMID: 40810709 Clinical Variability in Presentation and Management of Quadricuspid Aortic Valve: A Case Series. Corsi DR, Kelly B, Nair N, Luo M, Osler B, Cho SH, Mehrotra P, Wiener D, Johnson D. CASE (Phila). 2025 Feb 22;9(4):130-134. doi: 10.1016/j. case.2024.12.008. eCollection 2025 Apr. PMID: 40309471 Erratum to “Cardiac screening findings and referral patterns in male African-American basketball players: Analysis of the HeartBytes Registry” [The American Journal of Cardiology 243 (2025) 73-80]. Corsi D, Saraiya A, Doyle M, Shah V, O'Malley B, Qiu G, Lanstaff R, Masood I, Osler B, Hajduczok AG, Johnson D, Shipon D. Am J Cardiol. 2025 Sep 12;255:109. doi: 10.1016/j. amjcard.2025.08.015. Online ahead of print. PMID: 40887037 Plasma proteomic biomarkers of physical frailty in heart failure: a propensity score matched discovery-based pilot study. Denfeld QE, Pavlovic NV, Lee CS, Jacobs JM, Roberts Davis M, Powell SM, Gritsenko M, Joseph SM, Habecker BA. BMC Cardiovasc Disord. 2025 Apr 15;25(1):284. doi: 10.1186/s12872-025-04725-5. PMID: 40234744 Purulent Pericarditis: Treating a Medically-Complex Patient With Intrapericardial Antibiotics. Guler

M, Vemula S, Hart M, Wiener J, Farzad D, DeCaro M, Marhefka GD, Weber D, Entwistle J, Urtecho J. JACC Case Rep. 2025 Sep 24;30(29):105152. doi: 10.1016/j. jaccas.2025.105152. PMID: 41005839 Incidence, risk factors and clinical outcomes of pericardial effusion in left ventricular assist device patients. Khan MZ, Brailovsky Y, Bhuiyan MAN, Marhefka G, Faisal ASM, Sircar A, O'Neill P, Rame JE, Franklin S, Waqas M, Shah H, Rajapreyar I, Alvarez RJ. World J Cardiol. 2025 Jun 26;17(6):105330. doi: 10.4330/wjc.v17.i6.105330. PMID: 40575433 Acute atrial infarction precipitating sinus node dysfunction with challenging pacemaker placement and subsequent pericarditis. Moylan DD, Majeed A, Foster MW, Marhefka GD, Frisch DR. HeartRhythm Case Rep. 2025 Oct 29;12(1):32-37. doi: 10.1016/j. hrcr.2025.10.030. eCollection 2026 Jan. PMID: 41732462 Clinical Variability in Presentation and Management of Quadricuspid Aortic Valve: A Case Series. Corsi DR, Kelly B, Nair N, Luo M, Osler B, Cho SH, Mehrotra P, Wiener D, Johnson D. CASE (Phila). 2025 Feb 22;9(4):130-134. doi: 10.1016/j. case.2024.12.008. eCollection 2025 Apr.PMID: 40309471 Device Embolization After Transcatheter Patent Foramen Ovale Closure: The Importance of Tunnel Width Assessment. Peters AC, Ruggiero N, Datta T, Pender A, Vishnevsky A, Mehrotra P. JACC Case Rep. 2025 Dec 10;30(40):105837. doi: 10.1016/j. jaccas.2025.105837. Epub 2025 Oct 24. PMID: 41134227

Pavri BB. JACC Clin Electrophysiol. 2025 Dec;11(12):2772. doi: 10.1016/j.jacep.2025.10.025. PMID: 41432323 Incidence and Predictors of Symptom-Arrhythmia Association During Outpatient Holter Monitoring. Saraiya A, Corsi DR, Farhan S, Hazlewood C, Qiu G, Pavri BB. Cureus. 2025 Nov 6;17(11):e96201. doi: 10.7759/ cureus.96201. eCollection 2025 Nov. PMID: 41356964 Differing impacts of cardiac implantable electronic device leads on tricuspid regurgitation. Leon SA, Austin M, Nasher N, Rahimov D, Siddique F, Parikh C, Ahmad D, Tchantchaleishvili V, Pavri BB. J Arrhythm. 2025 Jul 7;41(4):e70133. doi: 10.1002/ joa3.70133. eCollection 2025 Aug. PMID: 40630159 S/QRS ratio in lead I: A surface electrocardiographic finding associated with need for permanent pacemaker in patients with right bundle branch block. Pavri BB, Goodman J, Frankel E. Heart Rhythm. 2025 May 19:S15475271(25)02449-X. doi: 10.1016/j. hrthm.2025.05.025. Online ahead of print. PMID: 40398550 Jumps and concealed conduction: Interactions between a manifest anteroseptal accessory pathway and the fast and slow pathways of the atrioventricular node. Pavri BB. Indian Pacing Electrophysiol J. 2025 Sep-Oct;25(5):374-378. doi: 10.1016/j.ipej.2025.10.001. Epub 2025 Oct 17.PMID: 41110605

Serendipitous Supernormality. Pavri BB, Frankel E. Ann Noninvasive Electrocardiol. 2025 May;30(3):e70069. doi: 10.1111/ anec.70069. PMID: 40181525

Device Embolization After Transcatheter Patent Foramen Ovale Closure: The Importance of Tunnel Width Assessment. Peters AC, Ruggiero N, Datta T, Pender A, Vishnevsky A, Mehrotra P. JACC Case Rep. 2025 Dec 10;30(40):105837. doi: 10.1016/j. jaccas.2025.105837. Epub 2025 Oct 24. PMID: 41134227

There Is a Link Between Ventricular Pre-Excitation and Long QT Syndrome-Related Arrhythmias.

Device Embolization After Transcatheter Patent Foramen Ovale Closure: The Importance

of Tunnel Width Assessment. Peters AC, Ruggiero N, Datta T, Pender A, Vishnevsky A, Mehrotra P. JACC Case Rep. 2025 Dec 10;30(40):105837. doi: 10.1016/j. jaccas.2025.105837. Epub 2025 Oct 24. PMID: 41134227 iCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025. Chopra V, Khan MS, Abdelhamid M, Abraham WT, Amir O, Anker SD, Atherton JJ, Bacal F, von Bardeleben RS, Brito D, Burgos LM, Butler J, Costanzo MR, Damasceno A, Ezekowitz JA, Hameed I, Harikrishnan S, Jaarsma T, Lala A, Piña IL, Saldarriaga C, Sim D, Teerlink JR, Tsabedze N, Tsutsui H, Yu J, Zhang Y, Zubaid M, Balankhe N, Gomez-Mesa JE, Januzzi JL, Konstam M, Monroe R, Ogola E, Palaniappan V, Petrie MC, Pinto FJ, Rajadhyaksha GC, Rakisheva A, Ramos CE, Rossel V, Sato N, Schulze PC, Sindone A, Skouri HN, Van Spall HGC, Štaraitė A, Stevenson LW, Sulaiman K, Wang TD, Böhm M, Coats AJS, Zieroth S. Heart Lung Circ. 2025 Jul;34(7):e55-e82. doi: 10.1016/j. hlc.2025.05.094. Epub 2025 Jun 17. PMID: 40533340 Not in the Gym… But at Home. Gibson GT, Piña IL. JACC Heart Fail. 2025 May;13(5):707-709. doi: 10.1016/j.jchf.2025.03.011. PMID: 40335225 Social Drivers of Health in Heart Failure Trials: An Analysis From the Heart Failure Collaboratory. DeFilippis EM, Blumer V, Makuvire TT, Echols MR, Adamson PB, Solomon S, Piña IL, Stein KM, Vaduganathan M, Walsh MN, Vardeny O, Jessup M, Yancy CW, Lindenfeld J, O'Connor CM, Fiuzat M. JACC Heart Fail. 2025 Sep;13(9):102546. doi: 10.1016/j. jchf.2025.102546. Epub 2025 Jul 17. PMID: 40680703 Reassessing the need for primary prevention implantable cardioverter-defibrillators in contemporary patients with heart failure. Goldenberg I, Ezekowitz J, Albert C, Alexis JD, Anderson

Department of Medicine 2025 Annual Report

12 L, Behr ER, Daubert J, Di Palo KE, Ellenbogen KA, Dzikowicz DJ, Hsich E, Huang DT, Januzzi JL, Kutyifa V, Lala A, Onwuanyi A, Piña IL, Sandhu RK, Sears S, Sroubek J, Strawderman R, Zareba W, Butler J. Heart Rhythm. 2025 Apr;22(4):1040-1051. doi: 10.1016/j. hrthm.2024.10.078. Epub 2025 Feb 5. PMID: 39918486 Multiregional Implementation Initiative's Impact on GuidelineBased Performance Measures for Patients Hospitalized With Heart Failure: IMPLEMENT-HF. Sauer AJ, Beon C, Cherkur S, Mallas-Serdynski L, Thomas K, Spertus J, Chahoud G, Mody KP, Saltzberg MT, Goldberg LR, Lindenfeld J, Sweitzer N, Butler J, Kittleson MM, Piña I Paul S, Lewis EF, Wald J, Allen LA, Jessup M, Congdon M, Kiser R, Yancy C, Fonarow GC. Circ Heart Fail. 2025 May;18(5):e012547. doi: 10.1161/ CIRCHEARTFAILURE.124.012547. Epub 2025 Mar 21. PMID: 40115978 Rationale and design of the comparative effectiveness of ICD vs non-ICD therapy in contemporary heart failure patients at a low risk for arrhythmic death (CONTEMPICD) trial. Goldenberg I, Zareba W, Ezekowitz JA, Albert C, Alexis JD, Anderson L, Behr ER, Daubert J, Di Palo KE, Ellenbogen KA, Dzikowicz DJ, Harrington JM, Hsich E, Huang DT, Januzzi JL, Jawaid A, Kutyifa V, Lala-Trindade A, Nakonechnyi A, Onwuanyi A, Piña IL, Sandhu RK, Sears S, Sroubek J, Baykaner T, Strawderman R, Beck C, Butler J. Am Heart J. 2026 Jan;291:162174. doi: 10.1016/j.ahj.2025.08.020. Epub 2025 Sep 4. PMID: 40914445 Closing the Gap, A Commentary on Sex Differences in Efficacy of Multidomain Rehabilitation Among Older Adults With Acute Heart Failure: The REHAB-HF Trial. Piña IL, Gonzalez VL, Moylan DD. JACC Heart Fail. 2025 Nov;13(11):102669. doi: 10.1016/j.jchf.2025.102669. Epub 2025 Sep 29. PMID: 41027394 Reassessing the need for primary prevention implantable

cardioverter-defibrillators in contemporary patients with heart failure. Goldenberg I, Ezekowitz J, Albert C, Alexis JD, Anderson L, Behr ER, Daubert J, Di Palo KE, Ellenbogen KA, Dzikowicz DJ, Hsich E, Huang DT, Januzzi JL, Kutyifa V, Lala A, Onwuanyi A, Piña IL, Sandhu RK, Sears S, Sroubek J, Strawderman R, Zareba W, Butler J. J Card Fail. 2025 Aug;31(8):1326-1338. doi: 10.1016/j. cardfail.2024.12.001. Epub 2025 Feb 5. PMID: 39915204 Chronic kidney disease following left ventricular assist device implantation: contemporary insights and future perspectives. Alvarez-Echeverry I, Guven G, Jahangiri P, Hesselink DA, Soliman O, Rajapreyar I, Rame JE, Ince C, Caliskan K. Heart Fail Rev. 2025 Dec 10;31(1):12. doi: 10.1007/s10741025-10571-6. PMID: 41369803 Outcomes following isolated right ventricular assist device as durable support for primary right heart failure: An INTERMACS analysis. Birati EY, Grandin EW, Zhang RS, Cabezas F, Rajagopal K, Seigerman M, Padegimas A, Mazurek JA, Kiernan MS, Kapur NK, Atluri P, Oliveira GH, Pagani FD, Myers SL, Teuteberg J, Kormos RL, Kirklin JK, Acker MA, Eduardo Rame J. JHLT Open. 2025 Apr 1;8:100258. doi: 10.1016/j. jhlto.2025.100258. eCollection 2025 May. PMID: 40276318 Impact of functional status in patients with muscular dystrophyassociated cardiomyopathy on survival after heart transplantation. Patil S, Nasher N, Macmillan TR, Rahimov D, Storozynsky E, Rame JE, Rajagopal K, Entwistle JW, Hoopes CW, Tchantchaleishvili V. Expert Rev Cardiovasc Ther. 2025 Oct;23(10):625-633. doi: 10.1080/14779072.2025.2559679. Epub 2025 Sep 14. PMID: 40924049 Improvement in Biomarkers and Freedom From Hospitalization in Bariatric Surgery Patients With Heart Failure. Foster M, Al Soueidy

A, Riley JM, Badenhausen S, Naidu S, Williams N, Brailovsky Y, Alvarez RJ, Dumon K, Rame JE. JACC Heart Fail. 2025 Nov;13(11):102674. doi: 10.1016/j.jchf.2025.102674. Epub 2025 Sep 22. PMID: 40987144 Veno-pulmonary extracorporeal membrane oxygenation for concomitant right ventricular and respiratory support: A systematic review of utilization patterns and outcomes. Nasher N, Mounzer M, Mallur K, Fayek FB, Rahimov D, Rame JE, Alvarez RJ, Entwistle JW, Rajagopal K, Hoopes CW, Tchantchaleishvili V. Perfusion. 2025 Oct 15:2676591251389383. doi: 10.1177/02676591251389383. Online ahead of print. PMID: 41195481 Incidence, risk factors and clinical outcomes of pericardial effusion in left ventricular assist device patients. Khan MZ, Brailovsky Y, Bhuiyan MAN, Marhefka G, Faisal ASM, Sircar A, O'Neill P, Rame JE, Franklin S, Waqas M, Shah H, Rajapreyar I, Alvarez RJ. World J Cardiol. 2025 Jun 26;17(6):105330. doi: 10.4330/wjc.v17.i6.105330. PMID: 40575433 Precise monitoring of transpulmonic resistance in bridge-to-transplant patients supported by the Aeson total artificial heart. Pya Y, Bekbossynova M, Medressova A, Latremouille C, Jansen P, Tauyekelova A, Kaliyev R, Jetybayeva S, Ziegler LA, Rajapreyar I, Eduardo Rame J. J Heart Lung Transplant. 2025 Jul;44(7):1161-1164. doi: 10.1016/j. healun.2025.02.001. Epub 2025 Feb 6. PMID: 39922552 Trends in Left Ventricular Assist Device Utilization and Survival Outcomes Following the Donor Allocation Policy Change. Pritting CD, Rahimov D, Weber MP, Storozynsky E, Eisen HJ, Rame JE, Alvarez RJ, Rajagopal K, Entwistle JW, Tchantchaleishvili V. Artif Organs. 2025 Nov 17. doi: 10.1111/ aor.70046. Online ahead of print. PMID: 41243743

Impact of 2018 Donor Heart Allocation Policy Change on Patients on Biventricular Support: A UNOS Database Analysis. Rahimov D, Nasher N, Sakata T, Macmillan TR, Pritting CD, Rame JE, Alvarez RJ, Rajagopal K, Entwistle JW, Tchantchaleishvili V. Artif Organs. 2025 Nov 27. doi: 10.1111/ aor.70047. Online ahead of print. PMID: 41309503 HeartMate 3 left ventricular assist device infection-related left ventricular pseudoaneurysm: Extirpation in the setting of left ventricular recovery. Rajagopal HK, Zucker MJ, Rame JE, Samuels LE, Rajagopal K. JTCVS Tech. 2025 Jan 24;30:104-106. doi: 10.1016/j. xjtc.2025.01.013. eCollection 2025 Apr. PMID: 40242124 Heart Allograft Utilization Rates Following Donation After Circulatory Death Compared to Donation After Brain Death in the Ideal Heart Donor. Nasher N, Rahimov D, Macmillan TR, Siddique F, Rame JE, Eisen HJ, Alvarez RJ, Rajagopal K, Entwistle JW, Tchantchaleishvili V. Clin Transplant. 2025 Aug;39(8):e70266. doi: 10.1111/ctr.70266. PMID: 40844484 Management and Outcomes of Coronary Artery Aneurysms: A Patient-Level Systematic Review. Rahimov D, Nasher N, Ahmad D, Morris RJ, Upadhyaya A, Yost C, Wong D, Patel P, Vishnevsky A, Ruggiero NJ 2nd, Entwistle JW, Tchantchaleishvili V. Crit Pathw Cardiol. 2025 Jun 1;24(2):e0381. doi: 10.1097/ HPC.0000000000000381. Epub 2025 May 23. PMID: 39902814 Device Embolization After Transcatheter Patent Foramen Ovale Closure: The Importance of Tunnel Width Assessment. Peters AC, Ruggiero N, Datta T, Pender A, Vishnevsky A, Mehrotra P. JACC Case Rep. 2025 Dec 10;30(40):105837. doi: 10.1016/j. jaccas.2025.105837. Epub 2025 Oct 24. PMID: 41134227

Department of Medicine 2025 Annual Report

13 Current Evidence-Based Treatment of Angina With Nonobstructive Coronary Arteries (ANOCA). Toleva O, Smilowitz NR, Quesada O, Kesarwani M, Savage MP, Prasad M, Barseghian El-Farra A, Holoshitz N, Moses JW, Fearon WF, Tremmel JA, Samuels B, Henry TD; Microvascular Network. J Soc Cardiovasc Angiogr Interv. 2025 Apr 15;4(7):102633. doi: 10.1016/j. jscai.2025.102633. eCollection 2025 Jul. PMID: 40933110 Embolic Myocardial Infarction from Takayasu Arteritis. Lam JH, Challa A, Savage M, Murdoch D, Raffel OC. CASE (Phila). 2025 Nov 21;10(2):47-54. doi: 10.1016/j. case.2025.10.003. eCollection 2026 Feb. PMID: 41727867 Impact of Ceiling Suspended Shield Size on Primary Operator Radiation Dose During Coronary Angiography and Intervention. Crowhurst JA, Andersen E, Savage M, Tse J, Murdoch D, Walters D, Dautov R. J Med Radiat Sci. 2025 Dec 9. doi: 10.1002/jmrs.70042. Online ahead of print. PMID: 41362250 Comparison of Outcomes of Transcatheter Edge-to-Edge Repair With Early Versus Latest Generation MitraClip for Severe Mitral Regurgitation. Thaw KM, Scalia W, Petersen R, Hlaing SH, Savage M, Murdoch D, Poon K, Raffel OC, Lau K, Tomlinson S, Walters L, Scalia G, Walters DL. Heart Lung Circ. 2025 Nov;34(11):1228-1234. doi: 10.1016/j.hlc.2025.06.1033. Epub 2025 Sep 3. PMID: 40908251 Cardiac screening findings and referral patterns in male AfricanAmerican basketball players: Analysis of the HeartBytes Registry. Corsi D, Saraiya A, Doyle M, Shah V, O'Malley B, Qiu G, Lanstaff R, Masood I, Osler B, Hajduczok AG, Johnson D, Shipon D. Am J Cardiol. 2025 May 15;243:73-80. doi: 10.1016/j.amjcard.2025.02.007. Epub 2025 Feb 18. PMID: 39978564 Beyond Racial Categorization in Sports Cardiology: A Systematic Review of Cardiac Adaptations in

Athletes. Corsi D, Hernandez R, Bao JY, Garrova S, Shipon D. J Clin Med. 2025 Oct 9;14(19):7107. doi: 10.3390/jcm14197107. Erratum to “Cardiac screening findings and referral patterns in male African-American basketball players: Analysis of the HeartBytes Registry” [The American Journal of Cardiology 243 (2025) 73-80]. Corsi D, Saraiya A, Doyle M, Shah V, O'Malley B, Qiu G, Lanstaff R, Masood I, Osler B, Hajduczok AG, Johnson D, Shipon D. Am J Cardiol. 2025 Sep 12;255:109. doi: 10.1016/j.amjcard.2025.08.015. Online ahead of print. PMID: 40887037 Spatial ventricular gradient is associated with pacing-induced cardiomyopathy. Raad M, Kramer DB, Stabenau HF, Anyanwu E, Frankel DS, Waks JW. Heart Rhythm. 2025 Nov;22(11):2887-2894. doi: 10.1016/j.hrthm.2024.12.037. Epub 2024 Dec 28. PMID: 39736431 Larger spatial ventricular gradient magnitude is associated with higher rates of response to cardiac resynchronization therapy. Shepherd AJ, Stabenau HF, Sau A, Tung P, Maher TR, Yang S, Locke AH, Zimetbaum P, Michaud GF, d'Avila A, Peters NS, Buxton AE, Ng FS, Kramer DB, Waks JW. Heart Rhythm O2. 2025 Aug 13;6(11):1725-1734. doi: 10.1016/j. hroo.2025.08.024. eCollection 2025 Nov. PMID: 41357280 Cardiac Amyloid, The Great Imitator. Fox NR, Fox NJ, Newman E, Osler B, Storozynsky E. JACC Case Rep. 2025 May 28;30(12):103373. doi: 10.1016/j. jaccas.2025.103373. Epub 2025 Apr 23. PMID: 40447370 Characteristics and outcomes of cardiac amyloid disease after heart transplantation: A systematic review and meta-analysis. Rahimov D, Yan VZ, Ahmad D, Nasher N, Tatum R, Im M, Storozynsky E, Rame JE, Rajagopal K, Entwistle JW, Massey HT, Tchantchaleishvili V. Transplant Rev (Orlando). 2025

Apr;39(2):100908. doi: 10.1016/j. trre.2025.100908. Epub 2025 Jan 9. PMID: 39981794 Impact of functional status in patients with muscular dystrophyassociated cardiomyopathy on survival after heart transplantation. Patil S, Nasher N, Macmillan TR, Rahimov D, Storozynsky E, Rame JE, Rajagopal K, Entwistle JW, Hoopes CW, Tchantchaleishvili V. Expert Rev Cardiovasc Ther. 2025 Oct;23(10):625-633. doi: 10.1080/14779072.2025.2559679. Epub 2025 Sep 14.PMID: 40924049 Nonbacterial Thrombotic Endocarditis as a Presenting Paraneoplastic Manifestation of Acute Promyelocytic Leukemia. Fradin JJ, Riley JM, Storozynsky E, Tchantchaleishvili V, Wilde LR. JACC Case Rep. 2025 Jul 16;30(19):104043.10.1016/j. jaccas.2025.104043. PMID: 40681269 Trends in Left Ventricular Assist Device Utilization and Survival Outcomes Following the Donor Allocation Policy Change. Pritting CD, Rahimov D, Weber MP, Storozynsky E, Eisen HJ, Rame JE, Alvarez RJ, Rajagopal K, Entwistle JW, Tchantchaleishvili V. Artif Organs. 2025 Nov 17. doi: 10.1111/ aor.70046. Online ahead of print. PMID: 41243743 The Heart of the Matter: Cardiac Toxicity in Allogenic Stem Cell Transplant with Post-Transplant Cyclophosphamide. Gradone A, Bi X, Durugu S, Bao A, Gattas B, Nath AD, Filicko-O'Hara J, O'Hara W, Storozynsky E, Grosso D, Flomenberg N, Gergis U. Transplant Cell Ther. 2026 Jan;32(1):65-73. doi: 10.1016/j.jtct.2025.09.009. Epub 2025 Oct 27. PMID: 41161639 Predictors of venous thromboembolic events in hospitalized patients with COVID-19. Scimeca G, Krishnathasan D, Rashedi S, Lan Z, Sato A, Hamade N, Bejjani A, Khairani CD, Davies J, Porio N, Assi AA, Armero A, Tristani A, Ortiz-Rios

MD, Nauffal V, Almarzooq Z, Wei E, Zuluaga-Sánchez V, Zarghami M, Achanta A, Jesudasen SJ, Tiu B, Merli GJ, Leiva O, Fanikos J, Sharma A, Rizzo S, Pfeferman MB, Morrison RB, Vishnevsky A, Hsia J, Nehler MR, Welker J, Bonaca MP, Carroll B, Goldhaber SZ, Campia U, Bikdeli B, Piazza G. J Thromb Thrombolysis. 2025 Apr;58(4):485-496. doi: 10.1007/s11239-025-03078-2. Epub 2025 Mar 10.PMID: 40064840 Adjudicated Cardiovascular Events in Patients With COVID-19: Association With Vaccination Status and Changes over Time. Bikdeli B, Krishnathasan D, Bejjani A, Khairani CD, Hamade N, Campia U, Davies J, Porio N, Assi A, Armero A, Tristani A, Ortiz-Rios MD, Nauffal V, Almarzooq ZI, Wei EQ, McGonagle B, Pfeferman M, Rashedi S, Sato A, Scimeca G, Zuluaga-Sánchez V, Zarghami M, Achanta A, Jesudasen S, Tiu BC, Merli GJ, Leiva O, Fanikos J, Sharma AM, Rizzo SM, Morrison RB, Vishnevsky A, Rao SJ, Naveh S, El Rafei A, Welker J, Bonaca MP, Carroll BJ, Goldhaber SZ, Lan Z, Piazza G; CORONA-VTE Network Investigators. J Am Heart Assoc. 2025 Dec 16;14(24):e044011. doi: 10.1161/JAHA.125.044011. Epub 2025 Dec 11. PMID: 41378506 Management and Outcomes of Coronary Artery Aneurysms: A Patient-Level Systematic Review. Rahimov D, Nasher N, Ahmad D, Morris RJ, Upadhyaya A, Yost C, Wong D, Patel P, Vishnevsky A, Ruggiero NJ 2nd, Entwistle JW, Tchantchaleishvili V. Crit Pathw Cardiol. 2025 Jun 1;24(2):e0381. doi: 10.1097/ HPC.0000000000000381. Epub 2025 May 23. PMID: 39902814 Device Embolization After Transcatheter Patent Foramen Ovale Closure: The Importance of Tunnel Width Assessment. Peters AC, Ruggiero N, Datta T, Pender A, Vishnevsky A, Mehrotra P. JACC Case Rep. 2025 Dec 10;30(40):105837. doi: 10.1016/j. jaccas.2025.105837. Epub 2025 Oct 24. PMID: 41134227

Department of Medicine 2025 Annual Report

14 Association between Active Cancer and Risk of Thrombotic and Cardiovascular Outcomes in Outpatients with COVID-19: A CORONA-VTE Network Analysis. McGonagle B, Greason C, Krishnathasan D, Scimeca G, Bejjani A, Khairani CD, Hamade N, Sato A, Leyva H, Campia U, Davies J, Porio N, Assi AA, Armero A, Tristani A, Ortiz-Rios MD, Nauffal V, Almarzooq Z, Wei E, ZuluagaSánchez V, Zarghami M, Achanta A, Jesudasen SJ, Tiu BC, Merli GJ, Leiva O, Fanikos J, Sharma A, Rizzo S, Pfeferman MB, Morrison RB, Vishnevsky A, Hsia J, Nehler MR, Welker J, Bonaca MP, Carroll BJ, Goldhaber SZ, Lan Z, Bikdeli B, Piazza G. TH Open. 2025 Oct

17;9:a27132715. doi: 10.1055/a2713-2715. eCollection 2025. PMID: 41143106 Web Exclusive. Annals Consult Guys - Anticoagulation, Atrial Fibrillation, and Lower Gastrointestinal Bleeding. Weitz HH, Merli GJ, Lip G. Ann Intern Med. 2025 Aug;178(8):e2503595CG. doi: 10.7326/ANNALS-25-03595-CG. PMID: 4082521 Sex Differences in Efficacy of Multidomain Rehabilitation Among Older Adults With Acute HF: The REHAB-HF Trial. Pandey A, Gilbert ON, Kitzman DW, Bertoni AG, Duncan PW, Mentz RJ, Reeves GR, Whellan DJ, Nelson MB, Chen H, Subramanian V, Reed SD, Upadhya B, O'Connor

CM, Pastva AM. JACC Heart Fail. 2025 Nov;13(11):102547. doi: 10.1016/j.jchf.2025.102547. Epub 2025 Sep 24. PMID: 40990882 ASE Achieves Excellence in Advocacy. Wiener DH. J Am Soc Echocardiogr. 2025 Nov;38(11):A13. doi: 10.1016/j.echo.2025.09.007. PMID: 41193163 JASE - The Powerhouse Echocardiography Journal. Wiener DH, Pellikka PA. J Am Soc Echocardiogram. 2025 Sep;38(9):A11. doi: 10.1016/j. echo.2025.07.002. PMID: 40912867 Echoing Excellence: ASE Shapes the Future of Cardiovascular Imaging. Wiener DH. J Am Soc Echocardiogr. 2025 Jul;38(7):A25-A26. doi:

10.1016/j.echo.2025.05.003. PMID: 40617628 Echoes of Alignment: The American Society of Echocardiography Forges Intersociety Partnerships. Wiener DH. J Am Soc Echocardiogr. 2025 Oct;38(10):A9. doi: 10.1016/j. echo.2025.08.010. PMID: 41043878 HeartMate 3 left ventricular assist device infection-related left ventricular pseudoaneurysm: Extirpation in the setting of left ventricular recovery. Rajagopal HK, Zucker MJ, Rame JE, Samuels LE, Rajagopal K. JTCVS Tech. 2025 Jan 24;30:104-106. doi: 10.1016/j. xjtc.2025.01.013. eCollection 2025 Apr. PMID: 40242124

Department of Medicine

DIVISION OF ENDOCRINOLOGY, DIABETES AND METABOLIC DISEASES The Division of Endocrinology, Diabetes, and Metabolic Diseases has continued its high profile clinical, educational, and clinical research activities, with a primary focus on diabetes, obesity, and related disorders. Our clinical practice has accommodated the widespread activities of the Jefferson Health System, and we operate busy practice locations at Walnut Towers on 9th Street in Center City, Methodist Hospital (Bove) in South Philadelphia, and Jefferson locations in Turnersville, NJ, Navy Yard, Art Museum, Bala Cynwyd, Jefferson Internal Medicine Associates, and the Women’s Center. We have numerous programs within the Division. A comprehensive weight management program that focuses on serving patients with medical complications of obesity and rapid weight loss for patients anticipating organ transplantation or major surgery. The Jefferson Diabetes Center, where patients are seen by expert diabetologists and certified diabetes educators, offering the most advanced technology including insulin pumps and continuous glucose sensors. We also have a Jefferson Thyroid and Parathyroid Center in collaboration with other departments, including ENT, surgery, radiology, and pathology. Our Jefferson Neuroscience Center, in collaboration with neurosurgery, offers the most advanced treatments for patients with a variety of pituitary disorders.

PAT I E N T C A R E The Division provides comprehensive services for inpatient and ambulatory care at Thomas Jefferson University Hospital, Methodist Hospital, Turnersville, Navy Yard, Art Museum, Bala Cynwyd, Women’s Center, and Jefferson Internal Medicine Associates outpatient locations, covering all aspects of endocrinology and diabetes. We offer specialty care centers for diabetes, obesity, thyroid disease, parathyroid disease, pituitary diseases, adrenal disorders, calcium, and bone disorders as well as gonadal

disorders. We work with other experts in different departments at Jefferson. In FY25, the Division had 25,822 outpatient visits, which was a 3.25% increase over FY24. Of these, 3,623 were new patient visits and 8,642 were telehealth visits. In the outpatient setting, we also offer a variety of classes or individual sessions covering diabetes education as well as nutritional counseling in addition to a low-calorie diet combined with behavioral modification, which is an integral part of our weight management program.

In the inpatient setting, we see all of the endocrine consults. Our team was behind the creation and the cornerstone of all inpatient diabetes protocols and guidelines, including the intravenous insulin infusion protocols, DKA/HHNK guidelines, hypoglycemia protocols, etc.

Q UA L I T Y I N I T I AT I V E S Our quality committee representative is Eric Shiffrin, MD. He works closely with our faculty and fellows on various quality improvement projects. Quality Improvement (QI) activities within the Division of

2025 Annual Report

15

FACU LT Y Serge Jabbour, MD Professor of Medicine Division Director

Intekhab Ahmed, MD Professor of Medicine Raad Haddad, MD Assistant Professor of Clinical Medicine Jeffrey Miller, MD Professor of Medicine Eric Shiffrin, MD Associate Professor of Clinical Medicine Monika Shirodkar, MD Associate Professor of Clinical Medicine Barbara Simon, MD Associate Professor of Clinical Medicine Jessica Watari, DO Assistant Professor of Clinical Medicine Lubna Zuberi, MD Assistant Professor of Clinical Medicine Sanjay Jumani, MD Assistant Professor of Clinical Medicine

N U RS E PRACTITIONE RS Lisa Coco, CRNP, CDE Christine Clancy, CRNP, CDE

DIETICIANS/ DIABETES EDU CATORS Cheryl Marco, RD, CDE Erin Ormsby, RD, CDE

Department of Medicine 2025 Annual Report

16 Endocrinology, Diabetes, and Metabolic Diseases in the past year have focused on various clinical outcome measures associated with diabetes.

E D U C AT I O N Our division is involved in teaching at all levels of medical school and graduate school curriculum, residency, and fellowship programs: biochemistry and physiology clinical lectures, medical students’ lectures/casebased learning, pharmacology course and physical diagnosis, medical students’ clerkships, ambulatory interns’ rotations, residency electives, and all facets of the clinical fellowship program in endocrinology. We also provide education, lectures and grand rounds, to all departments across Jefferson. Our internal educational activities include: a weekly CMEactivity, Friday Forum, with case discussions/presentations (with other local endocrinologists); monthly thyroid conference in collaboration with ENT, surgery, radiology, and cytopathology; monthly pituitary conference in collaboration with neurosurgery; monthly Philadelphia Endocrine Society meetings (at Jefferson, in collaboration with local/regional endocrinologists); and the fellows weekly curriculum lectures.

R E S E A RC H We have experience in both federally funded, pharmaceutical industry-sponsored clinical trials and investigator-initiated research studies. We have 15-30 active studies at any point in time. In these research studies, our focus is mostly on diabetes and obesity. Occasional studies might focus on pituitary or adrenal disorders. We study new insulin analogs, new diabetes & obesity drugs, as well

as new delivery systems for the management of high glucose levels including insulin pumps, continuous glucose sensors, and novel medications for the prevention or management of the complications of diabetes, including hypertension, lipid disorders, nephropathy, etc., in patients with type 1 and type 2 diabetes. We also have experience and interest in trials looking at cardiovascular outcomes in type 2 diabetes. Each study enrolls between 5 and 40 patients and lasts between 24 and 104 weeks, some with extensions up to 5 years. The NIH-sponsored Diabetes Prevention Program Outcomes Study involves testing lifestyle and metformin in patients at high risk for diabetes to see if it can be prevented or its onset delayed. Cardiovascular endpoints are also evaluated in this study as an extension to the initial DPP study, called DPPOS. Jefferson is one of 27 centers in the United States to follow patients with impaired glucose tolerance to determine whether lifestyle modification or medications can prevent or delay the onset of type 2 diabetes or its vascular complications. Our Jefferson cohort includes 150 patients. We are also part of another NIHfunded trial in collaboration with the Emergency Medicine research team. It is a pragmatic randomized controlled trial assessing the impact of medically tailored meals and medical nutrition therapy via telehealth among patients with poorly controlled diabetes.

P U B L I C AT I O N S Stezzi M, Brose M, Gordon SW, Solomides C, Tuluc M, Miller J. Well-Differentiated Lung Neuroendocrine Tumor Masquerading as Metastatic Medullary Thyroid Cancer. JCEM Case Rep. 2025;3(9): luaf172. Published 2025 Jul 31. doi:10.1210/jcemcr/

Simonson DC, Testa MA, Ekholm E, Su M, Vilsbøll T, Jabbour SA, Lind M. Improved Continuous Glucose Monitoring Profiles and Health Outcomes after Randomization to Dapagliflozin plus Saxagliptin vs. Insulin Glargine in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 2024; 109(12): e2261-e2272 Nasser M, Nasr J, Jabbour S. Two-Bag vs. One-Bag Fluid Delivery in Pediatric Diabetic Ketoacidosis: A Systematic Review and Meta-analysis. Clinical and Experimental Pediatrics 2024; 67(10):486-497 Jabbour SA, Paik JS, Aleppo G, Sharma P, Valderas EG, Benneyworth BD. Switching to Tirzepatide 5 mg from GLP1-Ras: Clinical Expectations in the First 12 Weeks of Treatment. Endocrine Practice 2024; 30(8):701-709 Goldberg R, Umarji G, Jabbour SA. A Heterozygous Form of Hereditary Vitamin D-Dependent Rickets Type 2A (VDDR2A) in a Patient Presenting with Pseudoarthrosis After Surgery. Case Reports in Endocrinology 2025, April 9th: 1-4 Kelly, MS., Scopelliti EM., Goodson KE., Lo, CMA., Nguyen HX., Simon B. Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus. Journal of Diabetes Obesity and Metabolism. 2024 September; 26(12):56615668. doi: 10.1111/dom.15934. Thomas-Nembhard, C., EversHunt, H., Thelmo, F., Dimarco, R., Shiffrin, E., & Miles, A. (2025). Oncology Infusion Center Hyperglycemia Protocol: P174. Oncology Nursing Forum, 52(2), 107–108. Jumani, S., Maggee SN., Nokoff, N. Insulin Resistance and Cardiovascular Risk in Transgender and Gender-Diverse Adolescents Undergoing Puberty Suppression. (2025) Horm Res

N OTA B L E ACH I E V E M E N T S 2025 Philadelphia Magazine Top Doctors SERGE JABBOUR, MD INTEKHAB AHMED, MD MONIKA SHIRODKAR, MD Philadelphia Endocrine Society Board BARBARA SIMON, MD ERIC SHIFFRIN, MD

Department of Medicine 2025 Annual Report

17 Paediatr 2025; 72(suppl 3):4–348 DOI: 10.1159/000549079 Trick J., Jumani S, Merke DM. Paradoxical Drop of Testosterone Levels After Treatment of Familial Male-Limited Precocious Puberty. (2025) Horm Res Paediatr 2025;98(suppl 3):4–348 DOI: 10.1159/000549079 Bondarenko D, Thelmo FL, Shirodkar MK. Metastatic Insulinoma Managed with Continuous Glucose Monitoring in a Young Female Patient. JCEM Case Reports. 2025; 3(2): luaf005. DOI: 10.1210/jcemcr/luaf005.Feb 2025-JCEM Case Report

A B S T R AC T S/P O S T E R S Desai K, Umarji G, Harris R, Simon B, Diagnostic Uncertainty in Cushing's Screening and the Risks of Mifepristone Therapy. Poster presented at AACE Annual Meeting; May 2025; Orlando, FL. Jabbour SA, Paik JS, Aleppo G, Sharma P, Valderas EG, Benneyworth BD. Switching to Tirzepatide 5 mg from GLP1-Ras: Clinical Expectations in the First 12 Weeks of Treatment. 26th Scientific Meeting of the Chinese Diabetes Society, November 2024, Nanjing, China Paik JS, Jabbour SA, Benneyworth BD, Sharma P, Aleppo G. Changes in CGM Metrics for People with T2D Switching from Dulaglutide or Semaglutide to Tirzepatide 5 mg: A Sub-Analysis of the SURPASSSWITCH-2 Study. ATTD (Advanced Technologies & Treatments for Diabetes), March 2025, Amsterdam, The Netherlands Jabbour SA, Paik JS, Aleppo G, Sharma P, Valderas EG, Benneyworth BD. Switching to Tirzepatide 5 mg from GLP1-Ras: Clinical Expectations in the First 12 Weeks of Treatment. The 59th Diabetes Congress 2025 (DDG 2025), May 2025, Berlin, Germany

Jabbour SA, Paik JS, Aleppo G, Sharma P, Valderas EG, Benneyworth BD. Switching to Tirzepatide 5 mg from GLP1-Ras: Clinical Expectations in the First 12 Weeks of Treatment. Romanian Society of Diabetes, Nutrition and Metabolic Diseases - 51st National Congress, May 2025, Romania Jabbour SA, Arnaldi G, Auchus RJ, Badiu C, Cannavo S, GarciaCenteno R, Dobri GA, Donegan DM, Fassnacht M, Hannoush ZC, Pivonello R, Ranetti AE, Stigliano A, Wang C, Hand AL, Araque KA, Moraitis AG. Impact of Relacorilant on Blood Pressure and Antihypertensive Medication Burden in Patients with Hypercortisolism and Hypertension: Results from the GRACE Study. Heart in Diabetes (HiD) congress, June 2025, Philadelphia, Pennsylvania Hamidi O, Auchus RJ, Busch RS, East H, Feelders RA, GilisJanuszewska A, Giordano R, Hannoush ZC, Isidori A, Jabbour SA, Reincke M, Rovner S, Salvatori R, Silverstein J, Terzolo M, Wang C, Hand AL, Araque KA, Moraitis AG. Effects of Relacorilant on Glycemic Measures and Body Composition in Patients with Endogenous Hypercortisolism. American Diabetes Association annual meeting, June 2025, Chicago, Illinois Hamidi O, Auchus RJ, Busch RS, East H, Feelders RA, GilisJanuszewska A, Giordano R, Hannoush ZC, Isidori A, Jabbour SA, Reincke M, Rovner S, Salvatori R, Silverstein J, Terzolo M, Wang C, Hand AL, Araque KA, Moraitis AG. Effects of Relacorilant on Body Weight and Composition in Patients with Endogenous Hypercortisolism in the Phase 3 GRACE and GRADIENT Studies. Endocrine Society, July 2025, San Francisco, California

Stezzi MA, Desai K, Umarji G, Kagita NV, Jabbour SA. A Pheo False Alarm - Deception with Cyclobenzaprine. Endocrine Society, July 2025, San Francisco, California Umargi G, Desai K, Kagita NV, Stezzi MA, Jabbour SA. An Innocuous Adrenal Incidentaloma Proved to Be an Adrenal Ganglioneuroma. Endocrine Society, July 2025, San Francisco, California Glucagon-Like Peptide-1 Receptor Agonists and Their Effects on Gastric Emptying Scans: A Retrospective Review. Nick Noverati, Kevan Josloff, Barbara Simon. Abstract accepted & presented, Digestive Disease Week (DDW) May 3-6, 2025, San Diego CA Improving Patient Access to Diabetes Education and Medical Nutrition Therapy. Goldberg R., Papich Theresa, Jamshidian Yassamin., Simon B. Lau K., Marco C. Abstract presented at the Health Equity and Quality Improvement Summit, Thomas Jefferson University Hospital, May 15, 2025 Grover, A., Ferreira, C. R., Gafni, R. I., Jumani, S., Collins, M. T., Roszko, K. L., & Hartley, I. R. I. S. (2024, September). Diaphyseal Medullary Stenosis with Malignant Fibrous Histiocytoma: A Rare Skeletal Dysplasia/Sarcoma Syndrome. In ASBMR 2024 Annual Meeting, Toronto, Canada

Department of Medicine

DIVISION OF GASTROENTEROLOGY AND HEPATOLOGY

2025 Annual Report

19

FACU LT Y David Kastenberg, MD

The Division of Gastroenterology and Hepatology continues to be at the forefront and one of Jefferson’s flagship programs. This year the Division celebrates 30 years of growth and national prominence. Under Dr. Kastenberg’s leadership, fiscal year 2025 marked a year of continued growth, academic distinction, and enterprise-wide leadership for the Division of Gastroenterology & Hepatology.

PAT I E N T C A R E Across clinical care, research and education, our faculty, fellows, and staff advanced our mission to deliver innovative patientcentered care while shaping the future of digestive and liver disease medicine. The GI Division had seven new faculty members start this past year. The new providers allowed us to grow in the areas of Hepatology, IBD, Advanced Endoscopy and General GI services. Our new faculty expanded our services in Center City, South Philadelphia, Bala Cynwyd and New Jersey. The Division saw over 12,000 new patients in the office setting and completed over 13,000 procedures at our TJUH, Honickman and Bala surgery center locations. As Jefferson Health continues to expand, the Division has taken a leadership role in enterprise-wide GI integration across: •

Education

•

Quality Improvement

•

Advanced Endoscopy

•

Operations

•

Hepatology

A major milestone is the Jefferson GI Enterprise Scientific Symposium, organized by Drs. Choudhary and Halegoua. The symposium fosters collaboration, innovation, and system-wide academic alignment. From a thriving transplant hepatology program and nationally recognized advanced endoscopy services to expanding clinical trials and award-winning educators, the Division continues to set the standard regionally and nationally. The Division now includes 8 transplant hepatologists, reflecting strategic growth in response to increasing patient need. Under the leadership of Dr. Sass, the liver transplant program performed: •

81 liver transplants in FY2025

•

7 living donor transplants

The living donor program, led by Dr. Tholey, continues to gain national prominence, demonstrating our commitment to expanding access to life-saving transplantation. The IBD Center has expanded to include three fellowship-trained IBD specialists, strengthening comprehensive care delivery.

Highlights include: •

Planning for patient education symposium

•

Expansion of investigatorinitiated research

•

Multiple actively enrolling IBD clinical trials

Our 6-physician Advanced Endoscopy Section, led by Director of Endoscopy Dr. Pawa, continues to provide cuttingedge interventional procedures, including: •

ERCP

•

Interventional Endoscopic Ultrasound

•

Third-space endoscopy (ESD, POEM, G-POEM)

•

Endohepatology

•

Pancreatic cyst ablation

The section remains at the forefront of minimally invasive GI innovation. The GI Division expanded our direct access colonoscopy program to include Saturday services. Patients now have more access to screening services within their community. We performed over 300 weekend direct access colonoscopies this past year. We are planning

J. Edward Berk Professor in Medicine Division Director

Jeffrey Abrams, MD Clinical Assistant Professor Christopher Adkins, MD Assistant Professor Monjur Ahmed, MD Professor Curtis Alloy, DO Clinical Assistant Professor Charles Andrew Kistler, MD, PharmD Clinical Assistant Professor Diyva Ayyala, MD Assistant Professor Louis Broad, MD Clinical Assistant Professor Austin Chiang, MD Assistant Professor Cuckoo Choudhary, MD Clinical Professor Dorrance H. Hamilton Professor of Medicine Jesse Civan, MD Associate Professor Robert Coben, MD Anthony J. DiMarino, Jr., MD Professor Shaman Dalal, MD Assistant Professor Andrew Dargan, MD Clinical Assistant Professor Richard Denicola, MD Clinical Assistant Professor Michael DiMarino, MD Clinical Assistant Professor Jonathan Fenkel, MD Professor Dina Halegoua-DeMarzio, MD Professor Christopher Henry, MD Assistant Professor Steven Herrine, MD Professor Faisal Kamal, MD Assistant Professor Leo Katz, MD Clinical Associate Professor Cecilia Kelly, MD Clinical Assistant Professor

Department of Medicine 2025 Annual Report

20 to continue to build on the success and expand the program next year.

E D U C AT I O N Education remains the core of the Division’s identity. FELLOWSHIP PROGRAMS Subspecialty fellowships include: •

IBD Fellowship (1–2 fellows/year)

•

Advanced Endoscopy Fellowship (1–2 fellows/year)

•

Transplant Hepatology Fellowship (1–2 fellows/year)

The categorical GI fellowship remains highly competitive, with hundreds of applicants competing for four positions annually. Under the leadership of Dr. Coben and our education leadership team, we are: •

•

•

Reinventing endoscopy training Modernizing conference structure

case on-time starts (FCOTS), length of stay, session fulfillment, readmissions, colonoscopy metrics (cercal intubation rate, average withdrawal time, adenoma detection rates (ADR)), reduction of procedure cancellation, improving prep adequacy, and developing best practice advisories using the electronic medical record system. Several Fellow QI projects were undertaken, to improve teaching, documentation, and overall patient care. Two of these projects were selected for Plenary Session presentation at Digestive Disease Week.

I N T E R N AT I O N A L A F FA I R S Drs Kastenberg and HalegouaDeMarzio traveled to Rome and worked with Gamelli Hospital leadership about future research and clinical collaborations.

RESE ARCH Research productivity remains a defining strength of the Division.

FY 2025 RESEARCH METRICS

Enhancing experiential learning

•

60 peer-reviewed publications

The Division organizes three major annual postgraduate courses:

•

60+ national meeting abstracts

•

Annual Advances in GI

•

•

Advances in Liver Disease

24 residents serving as co-authors

•

Women and GI Health

In addition, we host visiting professorships and named lectureships.

Q UA L I T Y I N I T I AT I V E S The Division of Gastroenterology has an active Quality Improvement Program. Over the past year, our efforts have continued to focus on patient satisfaction, first

ACTIVE CLINICAL TRIAL PORTFOLIO Patients have access to cuttingedge therapies in: •

MASLD

•

Drug-Induced Liver Injury (DILI)

•

Portal Hypertension

•

Lysosomal Acid Lipase Deficiency

•

Inflammatory Bowel Disease (IBD)

•

Celiac Disease

•

Primary Sclerosing Cholangitis (PSC)

P U B L I C AT I O N S Gastrointestinal Tuberculosis Presenting as a Massive Lower Gastrointestinal Bleed in a Patient with Newly Diagnosed HIV/AIDS Kosloff K, Spritzer K, Chen A, Katz L. ACG Case Rep J. 2025 Aug 18;12(8): e01808. doi: 10.14309/ crj.0000000000001808. PMID: 40832129; PMCID: PMC12360450. An Unusual Complication of Diverticular Bleed: Dysphagia and Food Impaction from Black Esophagus. Noverati N, Torre B, Mostyka M, Choudhary C, Henry C, Kastenberg D, Moleski S. Case Rep Gastroenterol. 2025 Apr 28;19(1):298-302. doi: 10.1159/000545171. PMID: 40297387; PMCID: PMC12037161. Cattaneo EF, Shmidt E, Bar-Gil Shitrit A, Nara P, Shivashankar R, Kane S. Twin Pregnancies in Inflammatory Bowel Disease Are Associated with Increased Adverse Outcomes. Clin Gastroenterol Hepatol. 2025 Jul;23(8):1448-1449. doi: 10.1016/j.cgh.2024.12.005. Epub 2025 Jan 3. PMID: 39756771. Economic impact and utilization trends of peroral endoscopic myotomy and endoscopic submucosal dissection. Gervase J, Le J, Robles M, Persaud A, Ansari W, Carrelli D, Liao ZJ, Moore K, Curran H, Kastenberg D, Kamal F, Kowalski T, Kumar A, Xiao Y, Schlachterman A. Gastrointest Endosc. 2025 Nov 1: S00165107(25)02134-0. Doi: 10.1016/j. gie.2025.10.038. Epub ahead of print. PMID: 41183600. Twin Pregnancies in Inflammatory Bowel Disease Are Associated with Increased Adverse Outcomes.

FACU LT Y Charles Andrew Kistler, MD, PharmD Clinical Assistant Professor Thomas Kowalski, MD Professor Patricia Kozuch, MD Associate Professor Howard Kroop, MD Clinical Assistant Professor Anand Kumar, MD Clinical Associate Professor Rebecca Loh, MD Assistant Professor Aarati Malliah, MD Clinical Assistant Professor Aaron Martin, MD Clinical Assistant Professor Stephanie Moleski, MD Associate Professor Nicholas Orfanidis, MD Clinical Assistant Professor Rishi Pawa, MD Professor Tatiana Policarpo, MD Assistant Professor Jorge Prieto, MD Clinical Assistant Professor Leonard Salese, MD Clinical Instructor David Sass, MD Professor Rorer Professor of Medicine Debbie Schiller, MD Instructor Alexander Schlacterman, MD Associate Professor Priya Sehgal, MD Assistant Professor Raina Shivashankar, MD Associate Professor Kristen Singer, MD Clinical Assistant Professor Colin Smith, MD Assistant Professor Danielle Tholey, MD Assistant Professor Yasi Xiao, MD Assistant Professor

Department of Medicine 2025 Annual Report

21 Cattaneo EF, Shmidt E, Bar-Gil Shitrit A, Nara P, Shivashankar R, Kane S. Clin Gastroenterol Hepatol. 2025 Jul;23(8):1448-1449. doi: 10.1016/j.cgh.2024.12.005. Epub 2025 Jan 3. PMID: 39756771. B Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and metaanalysis. ayoumy AB, Clarke LM, Deepak P, Desai A, Sehgal P, Gorelik U, Bar-Yoseph H, Villumsen M, Mulder CJJ, Stenvers DJ, Tushuizen ME, de Boer NKH. J Crohns Colitis. 2025 Nov 8;19(10): jjaf181. doi: 10.1093/ecco-jcc/ jjaf181. PMID: 41071055; PMCID: PMC12668684. Safety and Clinical Effectiveness of GLP1 Receptor Agonists in Inflammatory Bowel Disease Patients. Sehgal P, Lewis JD, Pickett-Blakely O, Nandi N, Bewtra M, Lichtenstein GR. Clin Gastroenterol Hepatol. 2025 Jul;23(8):1453-1454.e3. doi: 10.1016/j.cgh.2024.12.017. Epub 2025 Jan 30. PMID: 39892632. Obesity Is Associated with Worsened Outcomes in Patients with Ulcerative Colitis on Advanced Therapies: A Propensity Matched Cohort Study from the U.S. Desai A, Sehgal P, Khataniar H, Lewis JD, Farraye FA, Lichtenstein GR, Kochhar GS. Aliment Pharmacol Ther. 2025 Apr;61(7):1197-1207. doi: 10.1111/apt.18513. Epub 2025 Jan 22. PMID: 39844347. Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis-The Fat of the Matter: Authors' Reply. Desai A, Sehgal P. Aliment Pharmacol Ther. 2025 May;61(10):1711-1712. doi: 10.1111/ apt.70125. Epub 2025 Apr 3. PMID: 40181634. Epidemiology of metabolic syndrome in patients with inflammatory bowel disease: a population-level cohort study from the United States. Desai A, Khataniar H, Hashash JG, Sehgal P, Farraye FA, Kochhar GS.

Ann Gastroenterol. 2025 NovDec;38(6):618-628. doi: 10.20524/ aog.2025.1011. Epub 2025 Oct 10. PMID: 41586396; PMCID: PMC12829534.

Alpdogan O, Civan JM, Sass DA. \ ACG Case Rep J. 2026 Jan 26;13(1): e01970. doi: 10.14309/ crj.0000000000001970. PMID: 41602510; PMCID: PMC12834432.

Real-World Outcomes of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Obese Patients with Ulcerative Colitis and IPAA With a History of Pouchitis Desai A, Habib H, Khataniar H, Farraye FA, Sehgal P, Barnes EL, Kochhar GS, Hashash JG. Inflamm Bowel Dis. 2025 Dec 9: izaf301. doi: 10.1093/ ibd/izaf301. Epub ahead of print. PMID: 41365321.

Microbubble-based Radiosensitization of Hepatocellular Carcinoma: Evaluation of Safety and Efficacy in a Phase II Randomized Trial. Wessner CE, Forsberg F, Lyshchik A, O'Kane P, Bradigan K, Liu JB, Delaney LJ, Anton K, Topper SR, Civan J, Maley W, Keith SW, Shaw CM, Eisenbrey JR. Radiology. 2025 Sep;316(3): e250083. doi: 10.1148/ radiol.250083. PMID: 41025990; PMCID: PMC12501628.

Modulate Obesity and related metabolic complications For Yielding improvements in IBD outcomes (MODIFY-IBD): Consensus on Obesity and Cardiometabolic Comorbidities in Inflammatory Bowel Disease using Evidence Synthesis and the RAND/UCLA Appropriateness Method Devin J, Samaan S, Sehgal P, Mohamed M, Vincent M, Coombs S, Doering M, Barnes EL, Johnson AM, Yarur AJ, Deepak P. medRxiv [Preprint]. 2025 Dec 22:2025.12.20.25342738. doi: 10.64898/2025.12.20.25342738. PMID: 41480017; PMCID: PMC12755269. Expanding Nutrition Training in Gastroenterology: A Call to Action. Lin JC, Lin JC, Zhao J, Holt EG, Mcdonald EK, Moleski SM. Gastroenterology. 2025 Sep;169(4):753-754. doi: 10.1053/j. gastro.2025.04.035. Epub 2025 May 30. PMID: 40449757. The Effect of HCV on Methadone Dose During Pregnancy. Boudova S, Iyer NS, Tholey DM, Fenkel JM, Boelig RC. J Viral Hepat. 2025 Sep;32(9): e70060. doi: 10.1111/ jvh.70060. PMID: 40757762; PMCID: PMC12320570. A Rare Case of Fluid OverloadAssociated Large B-Cell Lymphoma in a Patient with Hepatitis C Cirrhosis. Shelukar S, Agarwal A, Gross J, Truscello D, Flerova E, Gesiotto Q,

Quantitative Contrast-enhanced Ultrasound Evaluation of Hepatocellular Carcinoma Radioembolization. Wessner CE, Chong W, Berreby G, Delaney LJ, Forsberg F, Lyshchik A, O'Kane P, Liu JB, Anton K, Topper SR, Civan J, Maley W, Keith SW, Shaw CM, Eisenbrey JR. Invest Radiol. 2025 Oct 31. doi: 10.1097/ RLI.0000000000001255. Epub ahead of print. PMID: 41178005. Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomizedcontrolled trial. Levy C, Abouda GF, Bilir BM, Bonder A, Bowlus CL, Campos-Varela I, Cazzagon N, Chandok N, Cheent K, CortezPinto H, Demir M, Dill MT, Eksteen B, Fenkel JM, Gilroy R, Ko HH, Jacobson IM, Kallis Y, Kugelmas M, Luketic V, Mangia A, MontanoLoza AJ, Mukhopadhya A, Olveira A, Patel BC, Pietrangelo A, Pradhan F, Salcedo M, Shiffman ML, Sprinzl K, Swann R, Thorburn D, Thuluvath PJ, Trivedi PJ, Turnes J, Zein CO, Gomes da Silva H, Jaitly S, Miller B, Milligan C, Tavenard A, Kowdley KV. J Hepatol. 2026 Jan;84(1):7485. doi: 10.1016/j.jhep.2025.04.025. Epub 2025 May 10. PMID: 40350321. Laboratory monitoring in patients with moderate to severe plaque psoriasis. Fenkel JM, Osborne JA, Armstrong AW, Strober

N OTA B L E ACH I E V E M E N T S More than 50% of Division physicians were recognized as Philadelphia Magazine “Top Docs” DR. KOWALSKI - Recipient of the ASGE Distinguished Educator Award and the SKMC Career Educator Award DR. MOLESKI - Leader in the Society for the Study of Celiac Disease and instrumental in Jefferson’s Celiac Center earning designation as a Unit of Excellence (1 of 10 in the U.S.) DR. KAMAL - Chair, Editorial Review Board, Gastrointestinal Endoscopy DR. KUMAR - President, Delaware Valley Society of Gastrointestinal Endoscopy DR. SASS - President-Elect, Philadelphia County Medical Society DR. FENKEL - Vice Chair, AASLD Hepatitis C Special Interest Group DR. HALEGOUA - National leadership roles within AASLD and the DILI Network DR. POLICARPO - Recipient of the prestigious Digest Cystic Fibrosis Award from the Cystic Fibrosis Foundation

Department of Medicine 2025 Annual Report

22 B, Stein Gold L, Cameron M, Lebwohl M. J Dermatolog Treat. 2025 Dec;36(1):2583227. doi: 10.1080/09546634.2025.2583227. Epub 2025 Dec 4. PMID: 41346021. Hepatitis C treatment during pregnancy: time for a practice change. Dutra K, Fenkel JM. Am J Obstet Gynecol MFM. 2026 Feb;8(2):101865. doi: 10.1016/j. ajogmf.2025.101865. Epub 2025 Dec 7. PMID: 41365430. Closing the Communication Gap: Assessing the Alignment Between UME and GME Competencies. Wilson AM, Berg K, Douglas A, Caruso J, Diemer G, Day K, Frasso R, Herrine SK, Abraham D. Am J Med Qual. 2025 Sep-Oct 01;40(5):235-242. doi: 10.1097/ JMQ.0000000000000254. Epub 2025 Jun 12. PMID: 40505090. Editorial: Cephalosporin-Induced Liver Injury-Interesting but Tricky. Authors' Reply. Vuppalanchi R, Hoofnagle JH, Rockey DC, Bonkovsky HL, Li YJ, HalegouaDeMarzio D, Fontana RJ, Koh C, Odin J, Barnhart H; DrugInduced Liver Injury Network (DILIN). Aliment Pharmacol Ther. 2025 Nov;62(10):1038-1039. doi: 10.1111/apt.70331. Epub 2025 Aug 12. PMID: 40793870; PMCID: PMC12584584. Clinical and Genetic Associations in Cephalosporin-Induced Liver Injury: Insights from the Drug-Induced Liver Injury Network. Vuppalanchi R, Li YJ, Rockey DC, HalegouaDeMarzio D, Fontana RJ, Bonkovsky HL, Koh C, Odin J, Barnhart H, Hoofnagle JH; Drug-Induced Liver Injury Network (DILIN). Aliment Pharmacol Ther. 2025 Nov;62(10):1012-1022. doi: 10.1111/ apt.70284. Epub 2025 Jul 20. PMID: 40685563; PMCID: PMC12543336. Reply: Herbal-Induced Liver Injury Identification and Prevention. Halegoua-DeMarzio D, Navarro V. Liver Int. 2025 Apr;45(4):e16160. doi: 10.1111/liv.16160. Epub 2024 Nov 28. PMID: 39605235.

Meeting Report: Herbal and Dietary Supplement Safety Surveillance Summit. Halegoua-DeMarzio D, Stolz A, Avula B, Khan I, Navarro V. Drug Saf. 2025 Dec;48(12):14251431. doi: 10.1007/s40264-02501589-8. Epub 2025 Aug 9. PMID: 40783601; PMCID: PMC12573236. De novo Hepatitis B Virus Infection in a Post-transplant Patient Causing Stage 4 Cirrhosis Necessitating Retransplant. Josloff K, Young B, Hersh M, Bheemreddy A, Lee S, Halegoua-Demarzio D. ACG Case Rep J. 2025 May 16;12(5): e01704. doi: 10.14309/ crj.0000000000001704. PMID: 40386537; PMCID: PMC12084112. Endoscopic retrograde cholangiopancreatography and primary sclerosing cholangitis: a retrospective study of a highvolume program. Leung KK, Youssef M, Xiao Y, Streutker C, Gulamhusein A, Hansen B, Calo N, May G, Mosko J, Hirschfield GM. J Can Assoc Gastroenterol. 2025 Aug 6;8(6):228-234. doi: 10.1093/ jcag/gwaf018. PMID: 41393988; PMCID: PMC12698213. Status of training in the use of lumen-apposing metal stents for therapeutic endoscopic ultrasound during advanced endoscopy fellowship: a survey questionnaire. Xiao Y, Hayat M, Mohammed AS, Abbasi A, Pathak S, Chandan S, Ramai D, Jain D, Hasan MK, Arain MA, Kadkhodayan KK, Cosgrove N, Yang D. IGIE. 2025 Sep 5;4(4):338-344.e3. doi: 10.1016/j. igie.2025.09.003. PMID: 41647815; PMCID: PMC12850793. Pancreatic endotherapy and quality of life in chronic pancreatitis. Kamal F. Gastrointest Endosc. 2025 Jul;102(1):87-88. doi: 10.1016/j. gie.2025.01.029. PMID: 40518236. Comparing Endoscopic Treatment Modalities for Gastric Antral Vascular Ectasia: Efficacy, Safety, and Outcomes in a Network Meta-analysis. Gangwani MK, Haghbin H, Hasan F, Dillard J,

Jaber F, Dahiya DS, Ali H, Kamal F, Hayat U, Lee-Smith W, Sohail A, Inamdar S, Aziz M, Adler DG. J Clin Gastroenterol. 2025 Jul 1;59(6):555-561. doi: 10.1097/ MCG.0000000000002057. PMID: 39312519. Utility of repeat colonoscopy attempt after failed colonoscopy: a systematic review and pooled analysis. Saeed A, Qamar U, Tsambikos E, Yousuf S, Kamal F, Mahmood S, Madhoun M, Aziz M, Ali IA. Gastrointest Endosc. 2025 Nov 14: S0016-5107(25)02198-4. doi: 10.1016/j.gie.2025.11.022. Epub ahead of print. PMID: 41242470. Role of Proton Pump Inhibitors in Prevention of Upper Gastrointestinal Bleeding in Patients on Dual Antiplatelet Therapy: Systematic Review and Meta-Analysis. Saeed A, Haider M, Yousuf S, Ahmad S, Fine M, Yazdani A, Hayat U, Noverati N, Khan MA, Gangwani MK, Aziz M, Farooq U, Kamal F. Am J Ther. 2025 May-Jun 01;32(3): e256-e261. doi: 10.1097/ MJT.0000000000001834. Epub 2024 Dec 4. PMID: 40338683. Bowel preparation quality in patients using glucagon-like peptide-1 agonists: a systematic review and meta-analysis. Ahmed Z, Iqbal A, Arif SF, Campbell C, Fehlman J, Allen DJ, Lee Smith W, Khalil B, Kamal F, Iqbal U, Nawras A, Alastal Y, Adler DG. Gastrointest Endosc. 2026 Feb;103(2):235-240.e5. doi: 10.1016/j.gie.2025.08.027. Epub 2025 Aug 20. PMID: 40846241. Histological Outcomes of Pharmacological Interventions in Eosinophilic Esophagitis for Adults and Children: A Network Meta-analysis of Randomized Controlled Trials. Aziz M, Haghbin H, Gangwani MK, Fatima R, Sohail AH, Ali H, Alyousif ZA, Dahiya DS, Lee-Smith W, Beran A, Kamal F, Nawras A. J Clin Gastroenterol. 2025 May-Jun 01;59(5):433-442. doi: 10.1097/ MCG.0000000000002017. Epub 2024 May 6. PMID: 38701235.

Cholangioscopy miniforcepsassisted cannulation: another tool in the toolbox for difficult cannulation. Noverati N, Argueta PP, Kamal F. VideoGIE. 2025 May 31;10(10):511-513. doi: 10.1016/j. vgie.2025.05.011. PMID: 41142710; PMCID: PMC12546664. Air Cholangiography versus Contrast Cholangiography in Patients with Hilar Biliary Obstruction: A Systematic Review and Meta-Analysis. Tarar ZI, Farooq U, Gandhi M, El Alayli A, Chaudhry A, Kamal F, Singh B, Ghouri YA, Thosani N. GE Port J Gastroenterol. 2025 Sep 3. doi: 10.1159/000547420. Epub ahead of print. PMID: 41064649; PMCID: PMC12503753. Efficacy and Safety of Endoscopic Through-the-Scope Suture System for Gastrointestinal Defects: A Systematic Review and Metaanalysis. Aziz M, Haghbin H, Gangwani MK, Beran A, Dahiya DS, Ali H, Sohail AH, Lee-Smith W, Hamdani SU, Kamal F, Adler DG. J Clin Gastroenterol. 2025 Apr 1;59(4):361-368. doi: 10.1097/ MCG.0000000000002019. PMID: 39008567. Peroral Endoscopic Myotomy for Achalasia Among the Elderly Population: A Systematic Review and Meta-Analysis. Hayat U, Kamal F, Memon A, Sadiq SM, Rana UI, Gangwani MK, Ali H, Gopalakrishnan K, Obuch JC, Adler DG. J Clin Gastroenterol. 2025 Feb 10. doi: 10.1097/ MCG.0000000000002103. Epub ahead of print. PMID: 39918254. Entanglement of an over-thescope full-thickness endoscopic suturing device during stent fixation: a case series of adverse events and rescue strategies. Duffey K, Kamal F, Loren D, Kumar A. VideoGIE. 2025 Sep 1;11(1):3134. doi: 10.1016/j.vgie.2025.08.011. PMID: 41584628; PMCID: PMC12827023.

Department of Medicine 2025 Annual Report

23 Endoscopic treatment modalities for colonic diverticular bleeding: A systematic review with direct and network meta-analyses. Tarar ZI, Gandhi M, Inayat F, Farooq U, Singh B, Chaudhry A, Muhammad A, Zain A, Kamal F. World J Gastrointest Endosc. 2025 Aug 16;17(8):109313. doi: 10.4253/wjge. v17.i8.109313. PMID: 40838159; PMCID: PMC12362541. Safety and efficacy of same-day discharge after gastric peroral endoscopic myotomy for gastroparesis: a systematic review and meta-analysis. Saeed A, Haider M, Hayat MH, Ali IA, Radlinski M, Kamal F, Mahmood S. Gastrointest Endosc. 2025 Nov 17: S00165107(25)02170-4. doi: 10.1016/j. gie.2025.11.011. Epub ahead of print. PMID: 41237864. Transoral outlet reduction for the treatment of dumping syndrome after Roux-en-Y gastric bypass: a systematic review and metaanalysis. Hayat U, Shah R, Kamal MU, Kiani M, Saeed A, Ali H, Gangwani MK, Mirza W, Kamal F, Khan YI, Adler DG. Gastrointest Endosc. 2026 Mar;103(3):581-585. doi: 10.1016/j. gie.2025.09.036. Epub 2025 Sep 25. PMID: 41015270. Risk of Post-polypectomy Bleeding After Colorectal Endoscopic Mucosal Resection in Patients with Chronic Kidney Disease: A Propensity-Matched Analysis of the US Collaborative Network. Beran A, Elfert K, Patel FN, Mohamed M, Ramai D, Albakri A, Saleem N, Kamal F, Canakis A, Srour K, Shaikh DH, Thakkar S, Rex DK, BhavsarBurke I, Guardiola JJ. Dig Dis Sci. 2025 Sep;70(9):3102-3109. doi: 10.1007/s10620-025-09122-8. Epub 2025 Jun 1. PMID: 40451998; PMCID: PMC12411577. Lumen-apposing metal stent placement in severe sepsis secondary to afferent limb syndrome. Noverati N, Kamal F. IGIE. 2025 Jan 17;4(1):61-62. doi: 10.1016/j.igie.2025.01.003. PMID: 41648825; PMCID: PMC12850905.

Management of the Disconnected Pancreatic Duct in Pancreatic Necrosis. Wilcox CM, Bang JY, Asombang A, Bennett C, Bi Y, Blogowski W, Buxbaum J, Chandrasekhara V, Chin WS, Conwell D, Coté GA, Gardner TB, Garg P, Guda N, Hawes R, Hernandez-Barco YG, Jonica E, Kedia P, Kowalski T, Kumbhari V, Lee L, Machicado J, Mardini SH, Morgan D, Muniraj T, Navaneethan U, Oza VM, Parekh PJ, Pawa S, Puri R, Rastogi A, Reddy DN, Saumoy M, Sawhney M, Vege SS, Talukdar R, Tarnasky P, Tellez-Avila F, Thakkar S, Thiruvengadam N, Vivian E, Waxman I, Willingham FF, Varadarajulu S; U.S. Pancreatic Disease Study Group. Clin Gastroenterol Hepatol. 2025 Oct;23(11):1878-1887.e3. doi: 10.1016/j.cgh.2025.05.024. Epub 2025 Jul 17. PMID: 40680906. US multicenter outcomes of endoscopic ultrasound-guided gallbladder drainage with lumenapposing metal stents for acute cholecystitis. David Y, Kakked G, Confer B, Shah R, Khara H, Diehl DL, Krafft MR, Shah-Khan SM, Nasr JY, Benias P, Trindade A, Muniraj T, Aslanian H, Chahal P, Rodriguez J, Adler DG, Dubroff J, De Latour R, Tzimas D, Khanna L, Haber G, Goodman AJ, Hoerter N, Pandey N, Bakhit M, Kowalski TE, Loren D, Chiang A, Schlachterman A, Nieto J, Deshmukh A, Ichkhanian Y, Khashab MA, El Halabi M, Kwon RS, Prabhu A, Hernandez-Lara A, Storm A, Berzin TM, Poneros J, Sethi A, Gonda TA, Kushnir V, Cosgrove N, Mullady D, AlShahrani A, D'Souza L, Buscaglia J, Bucobo JC, Rolston V, Kedia P, Kasmin F, Nagula S, Kumta NA, DiMaio C. Endosc Int Open. 2025 Jan 13;13:a24955542. doi: 10.1055/ a-2495-5542. PMID: 39958659; PMCID: PMC11827723. Cold- versus hot-snare endoscopic mucosal resection of colorectal polyps: meta-analysis of randomized controlled trials. Saeed A, Yousuf S, Noverati N, Chen

A, Saleem N, Farooq U, Muniraj T, Persaud A, Xiao Y, Kumar A, Schlachterman A, Kowalski T, Adler D, Kamal F. Gastrointest Endosc. 2025 Jun;101(6):1239-1243.e2. doi: 10.1016/j.gie.2024.12.032. Epub 2024 Dec 25. PMID: 39725332. Safety of same-day discharge after gastric peroral endoscopic myotomy in patients with refractory gastroparesis: an international multicenter study. Salame M, Ichkhanian Y, Hadaki N, Wo JM, Stainko SA, Saito A, Siwiec RM, Nowak TV, Li A, Hwang JH, Yang J, Broucek J, Esfandyari T, Joseph S, Ujiki M, Williams AE, Moremen JR, Gouda Z, Schlachterman A, Hugova K, Martinek J, Geng CX, Podboy A, Wang AY, Lajin M, Miller P, Gregor L, Albunni H, Dewitt JM, Al-Haddad MA. Gastrointest Endosc. 2025 Oct;102(4):595-599. e1. doi: 10.1016/j.gie.2025.02.020. Epub 2025 Feb 19. PMID: 39983999. Peroral endoscopic myotomy as an emergent treatment in hospitalized patients with esophageal motility disorders. Fayyaz F, Roshanshad R, Jagannath P, Almardini M, Bejjani M, Wehbe M, Hernández Mondragón OV, Robles M, Schlachterman A, Le J, Chang K, Dang F, Hwang JH, Li AA, Sadeghi Majd E, Eleftheriadis N, Bechara R, Parvizian M, Yoo IK, Pioche M, Moll F, Kim RE, Canakis A, Othman M, Jawaid S, Khalaf MA, EstremeraArevalo F, Albéniz Arbizu E, Inoue H, Shiwaku H, Lajin M, Chung CS, Seewald S, Pawa R, Pawa S, Khashab M. Gastrointest Endosc. 2026 Jan;103(1):87-94. e1. doi: 10.1016/j.gie.2025.04.021. Epub 2025 Apr 18. PMID: 40254099. Pearls learned from a decade of experience with peroral endoscopic myotomy. Schlachterman A. Gastrointest Endosc. 2025 Apr;101(4):790-791. doi: 10.1016/j.gie.2024.12.027. PMID: 40187852. A New International Scheme for the Classification and Management of Clinical Outcomes Post-gastric

Peroral Endoscopic Myotomy. Clin Gastroenterol Hepatol. Ichkhanian Y, Salame M, Wo JM, Nowak TV, Stainko S, Saito A, Siwiec RM, Kais A, Hwang JH, Li AA, Yang J, Broucek JR, Esfandyari T, Joseph S, Ujiki MB, Williams AE, Moremen J, Gouda Z, Schlachterman A, Hugova K, Martinek J, Geng CX, Podboy A, Wang AY, Lajin M, Gregor L, Miller PM, Al Bunni H, DeWitt JM, Al-Haddad M. 2025 Dec;23(13):2477-2487.e1. doi: 10.1016/j.cgh.2025.03.022. Epub 2025 May 14. PMID: 40378985. Midterm Evaluation of EUSguided Gastroenterostomy for Gastric Outlet Obstruction: An International Collaborative Study. Canakis A, Gaidhane M, Shahid HM, Tyberg A, Miller DC, Bareket R, Chen C, Karagyozov P, Sarkar A, Widmer JL, Artifon EL, Kedia P, Chowdhury S, Chalikonda DM, Dioguardi V, Loren DE, Kowalski TE, Schlachterman A, Kumar A, Chiang A, Cunto D, Robles-Medranda C, Kahaleh M. J Clin Gastroenterol. 2025 Mar 13. doi: 10.1097/ MCG.0000000000002174. Epub ahead of print. PMID: 40071828. Success of different closure modalities of gastrogastric or jejunal-gastric fistulas after EUSdirected transgastric intervention. Boortalary T, Tran T, McDonald N, Kahaleh M, Tyberg A, Shahid H, Sarkar A, Pawa R, Pawa S, Ventura F, Cohen EM, Krafft M, Thakkar S, Singh S, Nasr J, Nimri F, Zuchelli T, Dang D, Piraka C, Hassan KM, Sharaiha RZ, Kumar A, Schlachterman A, Kowalski T, Kamal F. Gastrointest Endosc. 2025 Nov;102(5):671-678. doi: 10.1016/j. gie.2025.03.640. Epub 2025 Mar 20. PMID: 40120863. Efficacy of fully covered selfexpandable metal stents and comparison with conventional management for ERCP-related type II perforations: a systematic review and meta-analysis. Saeed A, Yousuf S, Zain A, Imran H, Tariq M, Fazal MI, Shah J, Radlinski M,

Department of Medicine 2025 Annual Report

24 Gamboa A, Xiao Y, Kumar A, Schlachterman A, Kowalski T, Adler DG, Kamal F. Gastrointest Endosc. 2025 Nov;102(5):738-742. e2. doi: 10.1016/j.gie.2025.05.022. Epub 2025 May 28. PMID: 40446855.

Sethi A, Baumann AJ, Priraka C, Dunst CM, Wagh MS, Al-Haddad M, Gyawali CP, Kantsevoy S, Elmunzer BJ. Clin Gastroenterol Hepatol. 2025 Apr;23(5):776-784. doi: 10.1016/j.cgh.2024.08.024. Epub 2024 Aug 28. PMID: 39214390.

Prophylactic Rectal ESD (Endoscopic Submucosal Dissection) Defect Closure and Post-ESD Clinical Outcomes: An International Multi-Center Study (with Video). Kumar AR, Madaka P, Le J, Ines RD, Tolosa C, Ngamruengphong S, Milne F, Bechara R, Steinberg J, D'Souza LS, Dang F, Samarasena J, Leung G, Lucaciu L, Despott EJ, Barbaro F, Chiappetta M, Inamdar S, Karna R, Bilal M, Tomizawa Y, Alsamman A, Ladd AM, Xiao Y, Kamal F, Schlachterman A, Kowalski T. Dig Dis Sci. 2025 Nov;70(11):38933900. doi: 10.1007/s10620-02509123-7. Epub 2025 Jun 24. PMID: 40553399; PMCID: PMC12627156.

Novel use of rigidizing overtube for direct endoscopic necrosectomy Orlick M, Boortalary T, Kamal F, Schlachterman. Gastrointest Endosc. 2025 Dec 1: S00165107(25)02215-1. doi: 10.1016/j. gie.2025.11.039. Epub ahead of print. PMID: 41338398.

Biliary stenting with and without endoscopic sphincterotomy in patients with malignant biliary obstruction: meta-analysis of randomized controlled trials. Saeed A, Yousuf S, Khan MA, Gangwani MK, Aziz M, Arnab R, Shah J, Kumar A, Schlachterman A, Kowalski T, Kamal F. Eur J Gastroenterol Hepatol. 2025 Mar 1;37(3):257-262. doi: 10.1097/ MEG.0000000000002913. Epub 2025 Jan 29. PMID: 39919001. North American Expert Consensus on the Post-procedural Care of Patients After Per-oral Endoscopic Myotomy Using a Delphi Process. Yang D, Mohammed A, Yadlapati R, Wang AY, Jeyalingam T, Draganov PV, Gonzaga ER, Hasan MK, Schlachterman A, Xu MM, Saeed A, Aadam A, Sharaiha RZ, Law R, Wong Kee Song LM, Saumoy M, Pandolfino JE, Nishimura M, Kahaleh M, Hwang JH, Bechara R, Konda VJ, DeWitt JM, Kedia P, Kumta NA, Inayat I, Stavropoulos SN, Kumbhari V, Siddiqui UD, Jawaid S, Andrawes S, Khashab M, Triggs JR, Sharma N, Othman M,

Efficacy and safety of fully covered self-expandable metal stents in the management of postsphincterotomy bleeding: systematic review and metaanalysis. Saeed A, Yousuf S, Gangwani MK, Aziz M, Ahmed Z, Shah J, Farooq U, Kumar A, Schlachterman A, Kowalski T, Radlinski M, Gamboa A, Kamal F. Gastrointest Endosc. 2025 Jun;101(6):1110-1117.e3. doi: 10.1016/j.gie.2024.12.023. Epub 2024 Dec 21. PMID: 39716535. EUS-guided Dainage of Pancreatic Fluid Collections Using Lumen Apposing Metal Stents with or Without Coaxial Plastic Stents: A Systematic Review and Metaanalysis. Kamal F, Khan MA, Lee-Smith W, Sharma S, Acharya A, Farooq U, Gangwani MK, Saeed A, Aziz M, Hayat U, Saleem N, Kumar A, Schlachterman A, Kowalski T. J Clin Gastroenterol. 2025 Jan 1;59(1):47-53. doi: 10.1097/ MCG.0000000000002080. PMID: 39404654. Economic impact and utilization trends of peroral endoscopic myotomy and endoscopic submucosal dissection. Gervase J, Le J, Robles M, Persaud A, Ansari W, Carrelli D, Liao ZJ, Moore K, Curran H, Kastenberg D, Kamal F, Kowalski T, Kumar A, Xiao Y, Schlachterman A. Gastrointest Endosc. 2025 Nov 1: S00165107(25)02134-0. doi: 10.1016/j. gie.2025.10.038. Epub ahead of print. PMID: 41183600.

Outcomes of endoscopic submucosal dissection for superficial esophageal squamous neoplasms: a multicenter North American experience. Subrahmanyan R, Aihara H, Kumar A, Schlachterman A, Friedland S, Hwang JH, Othman M, Jawaid S, Ferri L, Teshima C, Mosko J, Bechara R, Samarasena J, Yang D, Ujiki M, Tomizawa Y, Joseph AA, Li A, Khalaf MA, Qatomah A, AlShamali H, Dang F, Tavangar A, Rwigema JC, King W, Northern N, Worapongpaiboon R, Almario JA, Tiankanon K, Draganov PV, Ngamruengphong S. Gastrointest Endosc. 2025 Dec 26: S00165107(25)02521-0. doi: 10.1016/j. gie.2025.12.270. Epub ahead of print. PMID: 41456748. Rates of Cancer, Non-curative Resection, Adverse Event and Surgery After Colonic Endoscopic Submucosal Dissection (ESD)Results from a Large International Multicenter Study. Karna R, Sánchez JC, Josloff K, Tran T, Tiankanon K, Ngamruengphong S, Bosch EM, Kalopitas G, Despott EJ, Murino A, Elkholy S, Sherbiny ME, Essam K, Haggag H, Abdallatef AA, Yousef K, Maresca R, Barbaro F, Leung G, Dang F, Tavangar A, Samarasena J, Saeed A, Andrawes S, Tomizawa Y, Bilal M, Sampath K, Xiao Y, Kamal F, Kowalski T, Schlachterman A, Kumar AR. Dig Dis Sci. 2025 Dec 16. doi: 10.1007/ s10620-025-09621-8. Epub ahead of print. PMID: 41402609. Evaluating the outcomes and safety of underwater ampullectomy versus traditional (gas insufflation) ampullectomy (with video). Robles M, O'Malley B, Song C, Havranek B, Yang A, Kamal F, Xiao Y, Schlachterman A, Kowalski T, Kumar A. Gastrointest Endosc. 2026 Jan;103(1):162-166. doi: 10.1016/j.gie.2025.06.043. Epub 2025 Jun 29. PMID: 40592413. Large North American Multicenter Experience on Endoscopic Submucosal Dissection of Rectal Neoplasms Extending to

the Dentate Line. Sharma NR, Gopakumar H, Malik TF, Khan A, Dahiya DS, Vohra I, Zelt CM, Rumple A, Flanagan M, MendozaLadd A, Adam AA, Saeed AB, Othman M, Ngamruengphong S, Arayakarnkul S, Bhatt A, Yang D, Bilal M, Rojas De Leon M, Schlachterman A, Madaka P, Kamal F, Kumar A, Thompson B, Kedia P, Diehl D, Shah S, Sedarat A, Wang AY, Dhaliwal A, Pannu DS, Mizrahi M, Kahaleh M, Andrawes S, Draganov PV. J Clin Gastroenterol. 2025 Oct 29. doi: 10.1097/ MCG.0000000000002265. Epub ahead of print. PMID: 41161699. Effect of Prophylactic Colon ESD (Endoscopic Submucosal Dissection) Defect Closure on Post-ESD Outcomes: An International Multi-Center Retrospective Study. Karna R, Sánchez JC, Josloff K, Tran T, Tiankanon K, Ngamruengphong S, Bosch EM, Kalopitas G, Despott EJ, Murino A, Elkholy S, El Sherbiny M, Essam K, Haggag H, Abdallatef AA, Yousef K, Maresca R, Barbaro F, Leung G, Dang F, Tavangar A, Samarasena J, Saeed A, Andrawes S, Tomizawa Y, Bilal M, Sampath K, Xiao Y, Kamal F, Kowalski T, Schlachterman A, Kumar AR. Dig Dis Sci. 2025 Nov 5. doi: 10.1007/ s10620-025-09518-6. Epub ahead of print. PMID: 41191254. Entero-Enteric Lumen Apposing Metal Stents (LAMS) for Biliary Access in Patients with Altered Anatomy. Chalikonda D, Mitsuhashi S, Shinn B, Tyberg A, Shahid H, Sarkar A, Kahaleh M, Khara HS, Confer B, Kamal F, Chiang A, Schlachterman A, Kumar A, Loren D, Kowalski T. Dig Dis Sci. 2026 Jan;71(1):248-255. doi: 10.1007/ s10620-025-09297-0. Epub 2025 Aug 19. PMID: 40828340.

Department of Medicine

DIVISION OF HEMATOLOGY AND CARDEZA FOUNDATION FOR HEMATOLOGIC RESEARCH The Division of Hematology and Cardeza Foundation for Hematologic Research provides inpatient and outpatient clinical Hematology services, trains students, residents, and fellows in clinical and research aspects of Hematology, runs an NIH-funded research enterprise, and provides administrative support to the Department of Medicine, Sidney Kimmel Medical College, and Thomas Jefferson University Hospital

PAT I E N T C A R E High quality patient care was provided in the Hematology inpatient consult service of TJUH and JHN, and in the JUP outpatient Hematology practice. The Division saw 3,949 outpatients in FY25, an increase of 20% over FY24, and included 1,666 new patient visits. Additionally, we continued to have Centers of Excellence in the Cardeza Foundation Hemophilia and Thrombosis Center, which is federally and statedesignated, and the Hereditary Anemias Center, with its statedesignated Sickle Cell Program. The Special Hemostasis laboratory was supervised by Dr. Rhoades in conjunction with the Department of Pathology. Mark Attilio, PharmD joined the hematology team a little over a year ago and his presence on rounds has provided ongoing support to ensure we are using the most cost-effective and appropriate approaches to medication management.He has also developed a sophisticated system of monitoring the use of opioid medications by people with sickle cell disease while

in house, this system allows us to accurately assess opioid use and make appropriate changes to dosing and conversions to oral medication.

Q UA L I T Y I N I T I AT I V E S Quality improvement projects in the Division of Hematology have primarily focused on our role as stewards for hematology-specific laboratory tests and transfusions of blood products. These projects have included ones aimed at decreasing the ordering of low-value inherited thrombophilia tests, as well our preoperative anemia clinic in which surgical patients with anemia are seen by Hematology and treated preoperatively to improve anemia before surgery, with the goal of avoiding severe anemia, transfusions, and longer length of stay after surgery. We are currently evaluating individuals going for cardiovascular revascularization procedures to see if there is an opportunity to optimize inpatients prior to surgery. Work has also focused on improving outcomes for people with sickle cell disease, with the opening of our infusion clinic in Bodine to help patients avoid an

ED visit.Since September we have had over 150 encounters with an overall admission rate of 1.2% and a time-to-first dose of opioid of 59 minutes.We continue to work with our emergency department colleagues where the time to first dose of pain medications is two hours to try and decrease that time.Finally, we have been working on addressing the need for pre-medication for patients receiving iron infusions and have demonstrated that for most of the patient’s pre-medication is not needed.Without the need for pre-medication, we can decrease the time patients need to be in the infusion clinic; this benefits both the patients and the clinic as it allows for more infusions to be scheduled.

E D U C AT I O N The Hematology-Oncology fellowship has 19 fellows in our 3-year training program. Dr. Lindsay Wilde is the Program Director and Dr. Sanaa Rizk is Associate Program Director. Dr. Rhoades directs the Hematology portion of Medicine Resident teaching, and our faculty make strong contributions to lecturing at fellow noon conferences. Dr.

2025 Annual Report

25

FACU LT Y Sophie Lanzkron, MD, MHS Leandro M. Tocantins, MD - Farid I. Haurani, MD Director, Cardeza Foundation for Hematologic Research Thomas Drake Martinez Cardeza Research Professor in Medicine Division Director

Ashwin Chandar, MD Clinical Assistant Professor Douglass Drelich, MD Assistant Professor Lawrence Goldfinger, PhD Professor of Medicine Director of Basic Science Research Cardeza Foundation for Hematologic Research Director, PhD Program in Molecular Physiology & Translational Medicine Steven McKenzie, MD, PhD Professor of Medicine Peisong Ma, PhD Associate Professor James Michael, PhD Research Assistant Professor Ulhas Naik, PhD Charlotte Drake Cardeza Professor of Medicine Director, Cardeza Center for Hemostasis, Thrombosis and Vascular Biology Ruben Rhoades, MD Assistant Professor of Medicine | Division of Hematology Co-Director, Hemophilia and Thrombosis Treatment Center Sanaa Rizk, MD Clinical Associate Professor Director, Cardeza Foundation Hemophilia and Thrombosis Center Associate Quality Officer, Division of Hematology Amit Srivastava, PhD Associate Professor Timothy Stalker, PhD Assistant Professor Natalie Rosen, MD Clinical Assistant Professor

Department of Medicine 2025 Annual Report

26 Rhoades is the Clinical Medicine Director, Host Defense/Blood Block, JeffMD Phase 1 for first year medical students and leads the inpatient elective for fourth year medical students. Divisional faculty also played major roles in MS, PhD, and MD/PhD student education. Most faculty hold either secondary appointments in basic science departments or membership in graduate groups. Dr. Goldfinger is the Director of the Molecular Physiology and Translational Medicine PhD program in the graduate school. Dr. Lanzkron runs a weekly telementoring conference (ECHO) on sickle cell disease attended by 50-70 clinicians and nurses across the United States.

R E S E A RC H The Cardeza Foundation for Hematologic Research was established in 1939 by Thomas Drake Martinez Cardeza and his wife Mary in honor of Mr. Cardeza’s mother, Charlotte. The purpose is to support Hematology research. Cardeza faculty conduct translational, basic, clinical, and outcomes/ quality research. Translational and basic research in our state-ofthe-art laboratories is based in the Cardeza Center for Hemostasis, Thrombosis, and Vascular Biology. Major efforts involve basic biology, genetics, pharmacogenetics, and pathophysiology of blood platelets and bleeding and clotting disorders. Our faculty are recognized internationally for their work, and they are supported by multiple NIH research grants. Cardeza research involves collaborations with Sidney Kimmel Cancer Center, the Center for Computational Medicine, the Department of Biochemistry and Molecular Biology, the Divisions of Cardiology and Pulmonary Medicine, and the Center for Translational Medicine (CTM).

Cardeza lab research faculty belongs to several MS and PhD programs and are founding leaders with CTM faculty of the PhD Program in Integrative Physiology, with its focus on heart, lung, blood and vascular biology. Hematology clinical research includes work in the Cardeza Hemostasis and Thrombosis Center, a federal and staterecognized center of excellence, and the Hereditary Anemias Center, which includes the Sickle Cell Disease Program. Both industry-sponsored and investigator-initiated clinical trials are being conducted, along with outcomes and quality studies. Dr. Lanzkron is the PI of the GRNDaD registry, the largest sickle cell registry in the US. She is also funded by PCORI, NIH and HRSA. These have led to impactful peer-reviewed publications as listed below. In FY2025 hematology received two Pediatric Award in Clinic Research awards (PACR) in collaboration with colleagues from Nemours. One of these projects is a translational investigation with co-PI’s Dr. Srivastava and Miller looking at extracellular vesicles as a biomarker of silent cerebral infarct in sickle cell disease. The second project with PI’s Drs. Lanzkron and Schultz is looking at severe maternal morbidity in sickle cell disease in Pennsylvania and Delaware. Hematology clinical faculty engage numerous Hematology/Oncology fellows, residents and medical students in these research projects.

P U B L I C AT I O N S Wade SA, Chen EY, Nandi P, Lanzkron SM, Burke AE, Pecker LH. Outcomes of procedures for abortions and early pregnancy loss among people with sickle cell disease: A single-center experience. J Natl Med Assoc. 2025 Feb;117(1):25-31.

Prince EJ, Scott JL, Nwankwoala O, Ali-Houchens L, Alghali MA, Carroll CP, Lanzkron S, Pecker LH. A young adult clinic to support integration into adult sickle cell disease care: If you build it, they will come. Br J Haematol. 2025 Mar 3. doi: 10.1111/bjh.20032. Carroll CP, Prince EJ, Lauriello A, Pecker LH, Lanzkron SM. Acute Pain Treatment in Patients with Sickle Cell Disease Transitioned to Buprenorphine: Evidence of equivalent pain relief. Journal of Sickle Cell Disease. 2025 Apr 15; Kenney MO, Wilson S, Rosser M, Lanzkron S, Kanter J, Padrino S, Desai P, Manwani D, Cohen A, Guarino S, Hagar W, Field J, Little J. Identifying distinct subgroups with severe pain in sickle cell disease: A cluster analysis of the GRNDaD multi-center registry. PLoS One. 2025 May 15;20(5): e0320889 Guarino SH, Jain A, Madisetti M, Rivlin K, Desai PC, Kanter J, Lanzkron S, Manwani D. National Alliance of Sickle Cell Centers consensus standards for transition to adult care in sickle cell disease. Blood Adv. 2025 Sep 23;9(18):4585-4591. Kelly DL, Hunt J, Vyas G, Glassman M, Brown CH, Fang LJ, Wehring HJ, Love RC, Weiner E, Reeves G, Ehret MJ, Nucifora FC Jr, Buchanan RW, Lanzkron S, Barr B, Richardson CM, Wonodi I, Kearns AM, Leistikow N, Liu F, Pugh S, Adams HA, Kreyenbuhl J. A Randomized Controlled Trial of an Extension for Community Healthcare Outcomes (ECHO) Tele-mentoring Program to Increase Clozapine Utilization. Schizophr Bull. 2025 Jun 16: sbaf067. doi: 10.1093/schbul/ sbaf067 Liem RI, Verhovsek M, Wun T, Lanzkron S. ASH sickle cell disease CPKD guidelines report. Blood Adv. 2025 Nov 25;9(22):5692-5694 Chang M, Semakula D, Little JA, Kanter J, Manwani DG, Owusu-Ansah A, Cohen AJ,

Cronin RM, Desai PC, Strouse JJ, Shook LM, Sayani F, LeBlanc D, Treadwell MJ, Betensky M, Guarino SH, Mandernach MW, Anderson AR, Jacob SA, Saccente S, Raj AB, Alvarez OA, Saif Ur Rehman S, Shah S, Lanzkron SM. Grandchildren of GRNDaD: Shifts in disease-modifying therapy at the adolescent transition in sickle cell disease. Br J Haematol. 2025 Sep;207(3):1070-1075. Ong SS, Nampomba A, Rahman S, Thangamathesvaran L, Reilly G, Ma J, Vaidya J, Lanzkron S, Scott AW. Macular Thinning and Microvasculature Abnormalities in Children with Sickle Cell Disease: A Longitudinal Analysis. Ophthalmol Sci. 2025 Jun 24;5(6):100862. McGill LS, González MLS, Bediako SM, Lanzkron SM, Yu L, Beach MC, Campbell CM. Impact of diseaseand race-based discrimination in healthcare on pain outcomes among adults living with sickle cell disease in the United States: The mediating roles of internalized stigma and depressive symptoms. Stigma Health. 2024 Sep 30:10.1037/sah0000581. Jacob SA, Frei-Jones M, SaifUr-Rehman S, Hulbert ML, O'Brien ARW, Strunk C, Villella A, Talati R, Owusu-Ansah A, Coyne F, McGann PT, Rai P, Miller R, Rampersad A, Sakhalkar V, Bhasin N, Manwani D, Lanzkron S, Kanter J. National Alliance of Sickle Cell Centers Consensus Recommendations on Sickle Cell Disease Health Maintenance: A Consensus Statement. JAMA Netw Open. 2025 Nov 3;8(11): e2543421. Morakis MM, Huang L, McKay GN, Lanzkron S, Pecker LH, Durr NJ. Sickle cell visualization in vivo in humans: microvascular occlusion formation and hemorheological indices. medRxiv [Preprint]. 2025 Sep 30:2025.09.27.25336804. Jenkins A, Vangala S, McIntosh M, LeGros R, Lanzkron S, Fiscella K. National landscape of pediatric

Department of Medicine 2025 Annual Report

27

GRANTS LAWRENCE GOLDFINGER, PHD NIH R33HL173910 2024-2026 “RNA-based therapeutics for hemostasis and thrombosis” Role: Multi-Principal Investigator TOTAL AWARD: $1,092,000 DIRECT COSTS: $700,000 LAWRENCE GOLDFINGER, PHD AHA 24PRE1194157 2024-2025 “Deciphering the roles of ADAM17 translation in platelet function” Role: Mentor, for Shayan Askari TOTAL AWARD: $67,388 LAWRENCE GOLDFINGER, PHD NIH R01HL159006 2021-2026 “Function and regulation of constitutive translation in platelets” Role: Principal Investigator TOTAL AWARD: $1,560,000 DIRECT COSTS: $1.000,000 LAWRENCE GOLDFINGER, PHD NIH R01HL172942 2025-2029 “Short inhibitory RNAs in platelet and megakaryocyte function” Role: Principal Investigator TOTAL AWARD: $2,209,652 DIRECT COSTS: $1.416,444 PEISONG MA, PHD AHA 24PRE1195534 2024-2025 “GRK5 and GRK6 are critical regulators of hemostasis and thrombosis” Role: Mentor, for Xuefei Zhao TOTAL AWARD: $67,388 PEISONG MA, PHD AHA 24TPA1297638 2024-2027 “GRK5 in thrombin signaling” Role: Principal Investigator TOTAL AWARD: $300,000 DIRECT COSTS: $272,727 PEISONG MA, PHD ASH A26-0045-001 2025-2026 “GRK5 regulation of GPCR signaling in platelets” Role: Principal Investigator TOTAL AWARD: $150,000

JAMES MICHAEL, PHD AHA 24CDA1276922 2024-2027 “Mechanisms and roles of inflammasome-mediated signaling in heparin-induced thrombocytopenia” Role: Principal Investigator TOTAL AWARD: $231,000 DIRECT COSTS: $210,000 JAMES MICHAEL, PHD WWSmith H2401 2025-2026 “Mechanisms that regulate thrombosis in heparin-induced thrombocytopenia” Role: Principal Investigator TOTAL AWARD: $125,000 DIRECT COSTS: $113,636 JAMES MICHAEL, PHD NIH R01HD112076 2025-2029 “Dose based aspirin pharmacokinetics and pharmacodynamics in pregnancy and association with pregnancy outcomes” Role: Co-Investigator (Rupsa Boelig PI) TOTAL AWARD: $75,000 ULHAS NAIK, PHD NIH R01HL173436 2025-2029 “Platelets as regulator of non-neurological complications of ischemic stroke” Role: MPI-Principal Investigator TOTAL AWARD: $3,119,808 DIRECT COSTS: $2,000,000 AMIT SRIVASTAVA, PHD NIH R01HL173436 2025-2029 “Platelets as regulator of non-neurological complications of ischemic stroke” Role: MPI-Principal Investigator TOTAL AWARD: $3,119,808 DIRECT COSTS: $2,000,000 AMIT SRIVASTAVA, PHD DOD W81XWH2110682 2021-2026 “Platelet-Derived Extracellular Vesicles for Hemorrhage Control and Prevention of Hemorrhagic Shock” Role: Principal Investigator TOTAL AWARD: $1,122,139 DIRECT COSTS: $719,320

AMIT SRIVASTAVA, PHD Craig T. Neilsen Foundation 1349389 2025-2027 “Non-Invasive Interventions and Biomarker Identification for Respiratory Recovery in Chronic SCI” Role: Co-Investigator TOTAL AWARD: $31,460 TIMOTHY STALKER, PHD NIH R33HL173910 2024-2026 “RNA-based therapeutics for hemostasis and thrombosis” Role: Multi-Principal Investigator TOTAL AWARD: $1,092,000 DIRECT COSTS: $700,000 TIMOTHY STALKER, PHD NIH R01HL176891 2025-2029 “Integration of platelets and coagulation to maintain hemostasis in vivo” Role: Principal Investigator TOTAL AWARD: $1,830,056 DIRECT COSTS: $1,173,112 TIMOTHY STALKER, PHD NIH R35HL150818 through Kentucky 2021-2027 “Platelet Exocytosis and Endocytosis in Thrombosis and Immunity” Role: Co-Investigator TOTAL AWARD: $291,667 DIRECT COSTS: $186,966 SOPHIE LANZKRON, MD PCORI through Johns Hopkins DI-2021C2-23827 2024-2025 “Implementing the Infusion Clinic Model in Sickle Cell Disease” Role: Principal Investigator TOTAL AWARD: $149,826 DIRECT COSTS: $107,018 SOPHIE LANZKRON, MD PCORI through University of Rochester BPS-2023C1-31041 2024-2030 “Comparative Effectiveness of MRD HCT and NT-DMT for Pediatric Sickle Cell Disease (WeDecide)” Role: Co-Investigator TOTAL YEARLY AWARD: $241,611 DIRECT COSTS: $172,579

SOPHIE LANZKRON, MD NIH R01HL177199 through North Carolina 2025-2029 “Hypoxemia with Sleep in Sickle Cell Anemia-Prevalence, Clinical and Cellular Impact & Response to Therapy: A Multi-Site Prospective Study Accessing New Collaborative Pathways” Role: Multi-Principal Investigator TOTAL AWARD: $2,850,098 JEFFERSON DIRECT COSTS: $314,508 SOPHIE LANZKRON, MD HRSA through Johns Hopkins 6U1EMC27864-11-02 2024-2026 “Sickle Cell Treatment Demonstration Program” Role: Principal Investigator TOTAL AWARD: $387,035 DIRECT COSTS: $216,740

Department of Medicine 2025 Annual Report

28 and adult inpatient sickle cell disease care. Blood Adv. 2025 Nov 21: bloodadvances.2025018089. Munda E, Rhoades R. Clinical utility and costs of inpatient hereditary thrombophilia testing following acute VTE: A 5-Year retrospective study. J Thromb Thrombolysis. 2025 Oct 5. Askari S, Goldfinger LE. Roles of miR-223 in Platelet Function and High On-Treatment Platelet Reactivity: A Brief Report and Review .Genes (Basel). 2025 Mar 6;16(3):312. Del Carpio-Cano F, Songdej N, Guan L, Mao G, Goldfinger LE, Wurtzel JGT, Lee K, Lambert MP, Poncz M, Rao AK. Transcription factor RUNX1 regulates coagulation factor XIII-A (F13A1): decreased plateletmegakaryocyte F13A1 expression and clot contraction in RUNX1 haplodeficiency. Res Pract Thromb Haemost. 2025 Jan 16;9(1):102680 Lazar S, Wurtzel JGT, Askari S, Cooper M, Zhao X, Ma P, Goldfinger LE. Argonaute2 modulates megakaryocyte development and sex-specific control of platelet protein expression and reactivity LE. Sci Rep. 2025 Jan 28;15(1):3590. Wurtzel JGT, Gray BD, Pak KY, Zhao X, Ma P, McKenzie SE, Tanujaya M, Rizzo V, Del CarpioCano F, Rao AK, Lee-Gau Chong P, Goldfinger LE. Phosphatidylserine-blocking nanoparticles inhibit thrombosis without increased bleeding in mice. J Thromb Haemost. 2025 Jan;23(1):108-122 Yarman Y, Zhao X, Ma P. Nuclear Receptors in Platelet Activation and Thrombosis in Hypercholesterolemia. Circ Res. 2025 Apr 11;136(8):827-829. Boelig RC, Michael JV, Tawk A, Zhan T, Chan JSY, Kraft WK, McKenzie SE. Platelet proteaseactivated receptor 4 genotype and response to aspirin in pregnancy.

Blood Vessel Thromb Hemost. 2025 Jun 30;2(3):100085 Boelig RC, Tawk A, Zhan T, Kraft WK, McKenzie SE, Michael J. Platelet-Associated microRNAs as Markers of Aspirin Response and Pregnancy Outcome in Pregnancies at High-Risk for Preeclampsia. Am J Perinatol. 2025 Aug 26; doi: 10.1055/a2677-6668. [Epub ahead of print] PubMed PMID: 40858153. Boelig RC, Foecke Munden E, Zhan T, McKenzie SE, Kraft WK. Pharmacodynamics of Aspirin Through Gestation: Predictors of Aspirin Response and Association with Pregnancy Outcome, a Prospective Cohort Study. Clin Transl Sci. 2025 Mar;18(3): e70167. doi: 10.1111/cts.70167.PMID: 40040304 McKenzie, S.E., Michael, J.V., Goldfinger, L.E. Platelet FcgRIIA Receptor, in Platelets in Thrombotic and Non-thrombotic Disorders, ed. Paolo Gresele, José A López, Dominick J. Angiolillo, Clive P. Page, Springer Nature, 2025. Stalker TJ. Platelet interactions with the vessel wall: the kinetics of hemostatic plug formation. In Platelets in Thrombotic and Nonthrombotic Disorders, P Gresele, J Lopez, D Angiolillo, and C Page, editors. Springer Nature, 2025. Kumskova M, Flora GD, Nayak MK, Budnik I, Jain A, Patel RB, Jha AB, Ghatge M, Chauhan N, Michael JV, McKenzie SE, Sharathkumar A, Staber JM, Lentz SR, Chauhan A. Platelet defects in patients and mice with Ehlers-Danlos syndrome. Blood. 2025 Nov 24; doi: 10.1182/blood.2025029912. Nigam A, Manjuprasanna VN, Naik MU, Naik UP. Platelet spreading and clot retraction are regulated by 2 distinct αIIbβ3 outside-in signaling pathways. J Pharmacol Exp Ther. 2025 Jan;392(1):100012 House C, Huang Z, Shankar KN, Young SJ, Roberts ME, Diamond

SL, Tomaiuolo M, Stalker TJ, Lu L, Sinno T. From imaging to computational domains for physics-driven molecular biology simulations: Hindered diffusion in platelet masses. PLoS Comput Biol. 2025 Jul 7;21(7): e1012853 Gopal SS, Kaur M, Lanzkron S, Srivastava AK. The Breakdown of Neurovascular Barriers: Molecular Mechanisms of Tight Junction Dysfunction. Mol Neurobiol. 2025 Dec 9;63(1):273.

Department of Medicine 2025 Annual Report

DIVISION OF HOSPITAL MEDICINE

29

FACU LT Y

The mission of the Division of Hospital Medicine is “to deliver the highest value clinical care and medical education in a safe learning and working environment that cultivates respect and wellbeing for all patients and team members.

Our Clinical Staff By the Numbers

Vice Chair for Inpatient Services Division Director

Faculty Breakdown Instructor 16%

Advanced Practice Clinicians (APCs) 14

Professor 5% Associate Professor 7%

Physicians 44

Assistant Professor 73%

Hospital Medicine at a Glance CLINICAL

FY25

FY24

GROWTH

Inpatient Discharges

5,846

4,869

+977

Observation Volume

2,742 (1,925 Clinical Conversions)

2,321 (1,321 Clinical Conversions)

+421

Transfers to Methodist

1,977

1,460

+517

Length of Stay (LOS)

7.85

8.17

-0.32 -0.09

Case Mix Index (CMI)

1.75

1.84

% 30 Day Readmission Rate w/ exclusions (Overall)

12.43%

11.21%

% 30-Day IP Readmission Rate (HF)

12.41%

10.17%

PATIENT SAFETY & QUALITY

FY25

FY24

Peer Review (Cases Reviewed)

37

38

Resulted in system level change

Rebecca Jaffe, MD

11

Mortalities, PSI, HAC, Infection Control cases, other complications and proactive case scans

88

81

HAPI

11

12

CAUTI

4

4

CLABSI

4

4

C.DIFF

8

11

OPERATIONS & FINANCE

FY25

FY24

GROWTH

VIZIENT BENCHMARK

Initial - Billing Level 3

82.6%

80.6%

+2%

78%

Subsequent – Billing Level 3

53.5%

51.9%

+1.6%

58%

wRVUs

122,118

115,135

+6.1%

Lily Ackermann, MD Clinical Associate Professor Section Lead, Co-management, Onboarding Lauren Ammerman, MD Clinical Assistant Professor Heather Baran, DO Clinical Instructor Joshua Bernard, MD Clinical Instructor Dianna Cheney-Peters, MD Clinical Assistant Professor Medicine Sub-Internship Director Clinical Skills Thread Director, Sidney Kimmel Medical College Jillian Cooper, MD Clinical Assistant Professor Robert DeGrazia, MD Clinical Assistant Professor Gretchen Diemer, MD Clinical Professor Vice Chair of Education, Department of Medicine Senior Associate Dean for GME Marie DiMattia, DO Clinical Assistant Professor Colin Dunn, MD Clinical Instructor Philip Durney III, MD Clinical Assistant Professor Section Lead, Jefferson Addiction Multidisciplinary Service Assistant Program Director for Addiction Medicine Fellowship Hanna Sofie Ellingsen, MD Clinical Assistant Professor Course Director Evidence Based Medicine Comfort Elumogo, MD Clinical Assistant Professor Gamal Fitzpatrick, MD Clinical Assistant Professor Jonathan Foster, MD Clinical Assistant Professor Associate Program Director POCUS Fellowship

Department of Medicine 2025 Annual Report

30 CO M P L E T E D / O N G O I N G I N I T I AT I V E S

ADVANCES IN CLINICAL CARE (PATHWAYS) The Division of Hospital Medicine collaborated with the VTE Committee to develop an institution‑specific DVT prophylaxis protocol for orthopedic hip fracture patients, addressing the higher incidence of DVT and PE in this population. This initiative originated through interdisciplinary work with fracture services and Vascular Medicine and has since expanded via the VTE Committee to include additional orthopedic surgical procedures. We are actively participating in the Leapfrog Collaborative VTE Reduction Project for head fracture patients, leading cross‑site coordination with the Vascular Medicine group and the VTE Committee to reduce thromboembolic events. In response to operating room delays at Center City, Hospital Medicine physician Lily Ackermann, MD partnered with Orthopedic Anesthesia, the VTE Committee, and the Emergency Department to establish an expedited trauma evaluation pathway and expanded OR access for geriatric hip fracture patients. We co-developed a comprehensive geriatric fracture pathway with Trauma Surgery and Emergency Medicine to support Level I Trauma Center accreditation and ensure medically complex geriatric fracture patients are managed on the primary medicine service with expedited evaluation through the trauma pathway. Our Division developed a multidisciplinary clinical pathway for ESRD patients with tertiary hyperparathyroidism in collaboration with

ENT, Endocrinology, and Nephrology, aimed at preventing life‑threatening hypocalcemia and reducing prolonged hospitalizations and ICU admissions. JAMS Our Division Addiction Medicine Section Lead, Phil Durney, led the JAMS team in the development and refinement of clinical protocols, including the Sublocade process, expanded use of order sets, integration of full agonist strategies, and implementation of IV dexmedetomidine in intermediate care units. Our team built an integrated partnership across ED, Hospital Medicine, ICU, and JMH transfer teams to optimize acute withdrawal management and reduce safety events for patients with substance use disorders. We supported Hospital Medicine teams in managing ad hoc SUD‑related clinical issues and implemented responsive faculty development and support strategies. We contributed to multiple publications focused on hepatitis C (JAMS infectious disease initiatives), care coordination, and rapid methadone induction protocols. Our Division partnered with Department of Health leadership and a citywide consultative group to develop best‑practice guidelines for alpha‑2 agonist– based withdrawal management.

OTHER QUALITY AND PATIENT SAFETY REPORTS Peer Review: Key Highlighted Projects The Division of Hospital Medicine developed a VTE prophylaxis dot phrase and implemented it within hospital‑wide progress note templates, enabling visibility into missed VTE prophylaxis

doses over the prior 48 hours and improving clinician awareness and response. We implemented education and clinical application of new SSTI guidelines in collaboration with Antimicrobial Stewardship leadership, with focused attention on high‑frequency scenarios such as infected wounds in patients with substance use disorders. Our team optimized EPIC systems related to antiplatelet management to reduce the risk of inadvertent double dosing and associated perioperative hemorrhage or hematoma. We reviewed and refined preferred opioid selection for patients with ESRD based on pharmacokinetic and pharmacodynamic principles to reduce complication risk. We partnered with the Infectious Disease Peer Review Committee to improve safety for patients discharged on antimicrobials, resulting in automatic incorporation of ID sign‑off notes—including dosing, stop dates, and follow‑up recommendations— into after‑visit summaries for outpatient providers and home infusion teams. We collaborated with Interventional Radiology leadership to redesign the IR biopsy consult order, prompting primary teams to coordinate with IR on NPO status, prophylaxis/ anticoagulation, and antiplatelet management, and clearly identify responsible contacts; added IR procedural guidelines to the ONE Intranet for clinician reference. Heart Failure Care Improvements Dr. Alan Kubey assumed a key leadership role in a system‑wide heart failure care improvement initiative spanning 12 hospitals and more than 17,000 patients,

FACU LT Y Alexis Gerber, MD Clinical Assistant Professor Section Lead, GI Co-Management Service Maura Huffner, MD Clinical Assistant Professor Claire Ketchem, MD Clinical Instructor Joanne Kim, MD Clinical Instructor Ryan King, MD Clinical Assistant Professor Alan Kubey, MD Clinical Assistant Professor Section Lead, Continuous Improvement & High Value Care Timothy Kuchera, MD Clinical Assistant Professor Associate Program Director, Internal Medicine Residency Patrick Kukulich, MD Clinical Assistant Professor Natalie Margules, MD Clinical Assistant Professor Section Lead, Active Bed Management Elise Paquin, MD Clinical Assistant Professor Nimesh Patel, MD Clinical Instructor Lakshmi Ravindran, MD Clinical Assistant Professor Jeffrey Riggio, MD Clinical Professor Associate CMIO, Epic@Jeff Marcel Robles, MD Clinical Instructor Nicholas Runeare, MD Clinical Assistant Professor Elias Simon, MD Clinical Assistant Professor Seema Singh, MD Clinical Assistant Professor John Stewart, MD Clinical Assistant Professor Section Lead, Gold Medicine Luis Taboada, MD Clinical Assistant Professor Ashley Traczuk, MD Clinical Assistant Professor Jennifer Valentine, MD Clinical Assistant Professor Associate Program Director, Internal Medicine Residency JeffMD Phase 3 Medicine Pathway Director, Sidney Kimmel Medical College Rebecca Vento, MD Clinical Assistant Professor Section Lead, Night Medicine

Department of Medicine 2025 Annual Report

31

Hospital Medicine spearheaded the design and implementation of EHR‑embedded clinical decision support, including evidence‑based order sets, GDMT optimization tools, and redesigned templated notes. We combined education, incentives, and EPIC‑based decision support resulted in a 32% reduction in mortality index and an 11% reduction in 30‑day readmissions, demonstrating measurable improvement in patient outcomes. COMPASS Dr. Rachelle Nelson led COMPASS, a program that supports a small but highimpact patient population with complex psychosocial needs, behavioral challenges, frequent readmissions, and prolonged hospital stays In those enrolled in this program we have seen the successful discharge of 4 patients with LOS >100 and reduction of readmissions for patients who are high utilizers. Billing Education & Feedback In collaboration with Revenue Cycle, Hospital Medicine conducted a series of educational sessions focused on practical billing tips and best practices to support accurate and optimized provider billing. To reinforce learning and drive improvement, a provider‑level feedback report was launched mid‑FY25, offering individualized insights into billing patterns over time and benchmarking performance against FY24 performance, group average and Vizient average—promoting accountability, consistency, and data‑informed practice improvement.

R E D U C T I O N TO R E A D M I S S I O N S [CO M PA S S]

FACU LT Y 17.50 15.00 12.50 Readmissions

aligning inpatient care with current guideline‑directed therapy through enterprise collaboration.

10.00 7.50 5.00 2.50 0.00 JB

CR

ESRD

Patients

MEDICAL OFFICER OF THE DAY (MOD) Transitional Care Launched in March 2025, the JMH Transitional Care program was developed to support patients accepted for transfer to Methodist Hospital who remain temporarily in the TJUH Emergency Department awaiting bed availability. Transitional Care improves patient safety and experience by establishing clear clinical ownership, addressing time‑sensitive needs, and maintaining continuity of care while avoiding duplication of full admission work. Operationally, the program helps reduce ED boarding strain, supports efficient transfers, and ensures equitable standards of care regardless of admitting location.

E D U C AT I O N UME: The Division of Hospital Medicine plays a key role in the education of medical students. Members of the Division with formal educational roles oversee and evaluate all the required and elective rotations within the Department of Medicine and counsel all students pursuing internal medicine residency, with all Structured Letters of Evaluation

(required for IM residency applicants) written by division faculty. In FY25, the division welcomed 244 third-year medical students to its teaching services as part of the medicine clerkship, and an additional 65 fourth-year students for their medicine subinternship. The popularity of the hospital medicine rotation has resulted in all students now being assigned for a two-week period, effectively doubling the number of learners annually.In a new endeavor division nocturnists provided valuable hands-on education for sub-interns, allowing them to participate in cross-coverage, respond to rapid response teams (RRTs) and codes, and manage patient admissions. In addition, whenever students face challenges during their clinical rotations in Medicine, remediation takes place on a hospital medicine service given standards for high-quality instruction, faculty dedication to personalized learning plans, and comprehensive feedback for students. GME: Faculty members are also actively involved in medical education research and curriculum development within the GME program These include a focus on the transition of trainees to independent practice; quality and safety education; and the night educational

Jenny Wang, MD Clinical Assistant Professor Section Lead, Peer Review, CDI Improvement TaReva Warrick-Stone, DO Clinical Assistant Professor Alexis Wickersham, MD Clinical Associate Professor Associate Program Director, Internal Medicine Vice Chair for Wellbeing, Department of Medicine Lim Wong, MD Clinical Assistant Professor Medicine Pathway Gateway Lead Facilitator Alyssa Yeager, MD Clinical Assistant Professor Jillian Zavodnick, MD Associate Professor Medicine Clerkship Director Associate Program Director, Internal Medicine Residency

Department of Medicine 2025 Annual Report

32 experience. As one example of division success, the transition to practice project boasted two AAMC innovation grants including one in the emerging field of precision education, and has been presented nationally through workshops, podium presentations, and peer reviewed manuscripts. Fellowship: In FY25 we maintained the Point of Care UltraSound fellowship in partnership with Emergency Medicine, Pulmonary Critical Care, and General Internal Medicine. We transitioned the Program Director position to Hospital Medicine and continue to have two fellows annually. We have a high rate of hiring fellows to full employment, and those not hired have become local leaders in developing and implementing POCUS curricula in other health systems. Hospital Medicine regularly recruits physicians directly out of residency, many of whom are entering both their first attending role and Jefferson simultaneously. To support these early‑career faculty, the division maintains a comprehensive orientation and onboarding program. This includes a structured buddy system, a longitudinal onboarding curriculum (“mini school”), and expanded guidance for first‑ and second‑year faculty on academic promotion. In FY25, the division strengthened pathways for early faculty engagement by creating a directory of collaboration opportunities with clinical, education, and operations leaders, supporting involvement in projects that promote future scholarship. To help faculty identify and develop areas of interest early, a “speed mentoring” event was introduced to connect new hires with division leaders across clinical care, operations, education, and quality improvement. Onboarding was further expanded to include shadowing division leaders

within each clinical service team, providing deeper exposure to division operations and leadership roles. Together, these initiatives support professional growth and facilitate a successful transition into academic medicine at Jefferson. During FY25, the division continued and expanded its CME‑granting Grand Rounds series across regional hospital medicine groups, supporting faculty development, local CME‑eligible lectures, and inter‑institutional speaker exchange. The Visiting Professor program was formally established, hosting a Hospital Medicine research leader for focused mentorship, networking, and learner engagement.

R E S E A R C H & S E L EC T P U B L I C AT I O N S Damle, Nehar MD, PharmD; Kamanu, Chukwuemezie MD; Vento, Rebecca A. MD, MPH; DeSimone, Joseph A. Jr. MD. RIME Redefined: Adenovirus and the Spectrum of Mucocutaneous Disease. Infectious Diseases in Clinical Practice 34(1):e1512, January 2026. | DOI: 10.1097/ IPC.0000000000001512 Knees M, Flynn SJ, Hsiang EY, Kubey AA. Is secure messaging an effective tool for inpatient communication? J Hosp Med. Published online May 29, 2025. Stewart, J., Ackermann, L., Merli, G.J., Spyropoulos, A.C. (2025). Venous Thromboembolism: Risk Assessment and Prophylaxis in the Medically Ill. In: Grodzin, C.J., Merli, G.J., Ross, C.B., Rosovsky, R. (eds) PERT Consortium Handbook of Pulmonary Embolism. Springer, Cham. https://doi.org/10.1007/9783-030-70904-4_51-1 Dunn, C.T., Brandon, W., Jacob, A., Zhang, S., Gao, A., Torres, F., Lawrence, A., Timofte, I., Bollineni, S., Mohanka, M., Wait, M., Peltz, M., Heid, C., Huffman, L., Ring,

S., Murala, J., Keshavamurthy, S., Weston, A.J. and Kaza, V. (2024), Anti-Thymocyte Globulin as a Therapy for Chronic Lung Allograft Dysfunction: A SingleCenter Experience. Clinical Transplantation., 38: e15461. https://doi.org/10.1111/ctr.15461 Huo S, London K, Murphy L, Casey E, Durney P, Arora M, McKeever R, Tasillo A, Goodstein D, Hart B, Perrone J. Notes from the Field: Suspected Medetomidine Withdrawal Syndrome Among Fentanyl-Exposed Patients Philadelphia, Pennsylvania, September 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2025 May 1;74(15):266-268. doi: 10.15585/mmwr.mm7415a2. PMID: 40310762; PMCID: PMC12045483. Ackermann LL, Chadha J, Sweigart JR, Bowman J, Marzano N, Barkoudah E; SHM RCU – Education Committee. Clinical knowledge for hospital medicine through structured clinical offerings. J Hosp Med. 2025 Jun;20(6):655-660. doi: 10.1002/ jhm.70023. Epub 2025 Mar 4. PMID: 40035406. London, K. S., Durney, P., WarrickStone, T., Alexander, K., & Kahoud, J. L. (2025). Decreased Effectiveness of a Novel Opioid Withdrawal Protocol Following the Emergence of Medetomidine as a Fentanyl Adulterant. BioMed, 5(2), 13. Kuchera T, Zavodnick J, Diemer G. Aligning Competencies Without Abandoning PPD. Accepted for publication in Academic Medicine 2025 Vaile JR, Connolly WC, Zavitsanos AP, Isch EL, Zavodnick J, McMahon HA. XylazineAssociated Wounds: A Scoping Review of Clinical Presentation and Management. Accepted for publication in Advances in Skin and Wound Care 2025. Diemer G, Kuchera T, Zavodnick J, Frasso R, Jaffe R. Ready or Not, Here We Come: A Qualitative Study of the Transition from

Graduate Medical Education to Independent Practice. Journal of Graduate Medical Education. 2025;17(1):71-80. Zavodnick J, Adamczyk A, Diemer G, Kuchera T, Leonard N, Jaffe R. Transition from Graduate Medical Education to Independent Practice: A Scoping Review. Academic Medicine 2025;100(2):239-247. Benau E, Zavodnick J, Jaffe R. Initial evidence of reliability and validity of an Implicit Association Test assessing attitudes toward individuals who use substances. Am J Drug Alcohol Abuse. January 31, 2024;50(1):64-74. doi:10.1080 /00952990.2023.2300398

Department of Medicine

DIVISION OF INFECTIOUS DISEASES AND ENVIRONMENTAL MEDICINE The Division of Infectious Diseases is comprised of a core of clinical faculty who provide consultative expertise across the spectrum of infections and syndromes managed within the Thomas Jefferson University system. Members of the Division provide all ID consultative activities at Thomas Jefferson University Hospital, Jefferson Hospital for Neurosciences, Methodist Hospital, and Wills Eye Hospital. In addition, comprehensive HIV care services are provided by a Ryan White Care Act-supported outpatient program. The Division has established and continues to develop a group of core programs, both clinical and non-clinical, that form a blueprint for future direction.

Infectious Diseases Division Programs CLINICAL Clinical Center City

All

Methodist

Royer*, Hancock (Almost all faculty)

Solid Organ Transplant ID Program

Belden*, Coppock, Royer, Moss, Tucker

HIV/AIDS

Coppock*, Braden, DeSimone, Gancher, Green, Livinsky, Support staff

Bone Marrow Transplant ID Program

Flomenberg*, Moss

COpAT

Brugger & Taupin*, Carr, Phillips, Livinsky

APC

Brugger*, Carr, Green, Hancock, Livinsky

Orthopedic Infections

Belden*, Brugger, Carr, Gancher, Hess, Kramer, Taupin, Zurlo

Lankenau

Gilbert**

NTM

Tucker*, Novick, Livinsky, Zurlo

SUD

Kramer*, Novick, Seval, Taupin, Tucker, Zurlo

NON-CLINICAL Fellowship Program

Weber*, Novick

Education

Moss*, Weber, Tucker, Novick

Infection Control/Prevention

Flomenberg*, Gancher, Hess

Antimicrobial Stewardship

Hess*, Gancher, Braden

Research

Flomenberg*, Coppock, Belden

ID Interest Group

Moss*, Coppock, Weber, DeSimone, Novick

Drexel Collaboration

Zurlo*, Seval, Coppock

Patient Safety/Quality

Taupin*, Braden

TJUH ID P&T Subcommittee

Hess*, Belden, Flomenberg, Gancher, Royer, Tucker, Zurlo

Pandemic Preparedness

Zurlo*, Flomenberg, Gancher, Hess, Taupin

*Signifies Lead

**Lankenau Faculty

2025 Annual Report

33

FACU LT Y John Zurlo, MD Professor of Medicine The W. Paul and Ida Havens Professorship of Infectious Diseases Clinical Advisor of Pandemic Preparedness for the Jefferson Enterprise Division Director

Katherine Belden, MD Associate Professor of Medicine Director, Solid Organ Transplant ID Program Elizabeth Braden, MD Clinical Assistant Professor of Medicine Associate Director, HIV/AIDS Program Dagan Coppock, MD Associate Professor of Medicine Associate Director, Solid Organ Transplant ID Program Director, HIV/AIDS Program Joseph A. DeSimone, MD Professor of Medicine Phyllis R. Flomenberg, MD Professor of Medicine Infection Control Officer, Jefferson University Hospitals Elizabeth Gancher, MD Clinical Associate Professor of Medicine Associate Medical Director, Antimicrobial Stewardship Program and Infection Control/Prevention Bryan D. Hess, MD Clinical Associate Professor of Medicine Director, Antimicrobial Stewardship Program Carolyn Kramer, MD Clinical Assistant Professor of Medicine Thread-Director, Medical School Curriculum (through 12/30/24) Sean Moss, MD Clinical Assistant Professor of Medicine Associate Director, Solid Organ Transplant ID Program Thread-Director, Medical School Curriculum (beginning 1/1/25)

Department of Medicine 2025 Annual Report

34 CLINICAL

FACULTY Fifteen clinical faculty members provide consultative support to the medical staff of Jefferson University Hospital, Jefferson Hospital for Neurosciences, Methodist Hospital, and Wills Eye Hospital and/or specialty care of patients with HIV/AIDS. One additional faculty member works for the Division on a part-time basis (Dr. Nikhil Seval). Dr. Seval is a faculty member at the Drexel HIV Partnership where 90% of his job description involves outpatient HIV care. He is hired by the Jefferson ID division for the remaining 10% of his effort in which he provides inpatient infectious disease consultations for the population of patients with infections related to substance use disorder (SUD). Dr. Dagan Coppock remains in the leadership role for the HIV/AIDS program at Jefferson.One faculty member, Dr. Carolyn Kramer, left the division in January 2025 to pursue another position.

ADVANCED PRACTICE CLINICIANS (APC) A total of five APCs work in the Division, led by Ms. Caroline Clark Brugger as Lead APC. Ms. Brugger and Ms. Carr, along with a dedicated nurse, Tom Phillips, manage a large number of patients receiving complex outpatient antimicrobial therapy (COpAT), averaging around 115-140 patients at any given time, the majority being those with orthopedic-related infections including periprosthetic joint infections and osteomyelitis. The physician lead for COpAT is Dr. Daniel Taupin with Ms. Brugger serving as the APC lead. COpAT patients are typically seen first as inpatients and transitioned to the outpatient setting with a formalized handoff structure that

is seamless. The team follows weekly laboratory results for each patient watching for antibioticassociated toxicities and serves as the principal contact for patients, their families, and outpatient pharmacies and visiting nurses who serve these patients. Ms. Sarah Green works full-time in our HIV/AIDS program. Ms. Molly Hancock works exclusively at Methodist Hospital working on our inpatient infectious diseases consult service. Mr. Ross Livinsky was hired to assist in our pandemic management program working closely with the group arranging monoclonal antibody infusions during COVID and directed testing and treatment for MPox for the Jefferson Enterprise. He continues in a standby role for future pandemics.He works in our HIV/AIDS program and manages COpAT for a select group of patients managed in our NTM infections program. The Division continues to see a high volume of requests for inpatient consultations which has, in turn, driven RVU generation. The number of new consults in FY 25 was 5,507, down slightly from 5,886 in FY 24.The Division saw 18,999 return inpatient visits and 4,124 outpatient visits, both increased from the prior year. RVU generation has increased dramatically from 49,923 in FY 21 to 72,993 in FY25.

H I V/A I D S P R O G R A M The Division provides outpatient treatment for a variety of infectious diseases, including HIV/AIDS. The HIV/AIDS program receives grants awarded through the City of Philadelphia Department of Public Health and the Department of Health and Human Services (Ryan White Care Act) to provide HIV medical care, case management, and outreach for the entire HIV patient population along with

gynecological care for female patients. Comprehensive HIV care is offered to all patients presenting to the Jefferson program regardless of their insurance status. Dr. Dagan Coppock is the Program Director and Dr. Elizabeth Braden serves as Associate Director for the program. We continue our relationship with the Drexel HIV Partnership clinic located several blocks from Jefferson. As part of this relationship, we share faculty, create links for the Partnership HIV patients to our inpatient and outpatient specialty services, offer our ID trainees an excellent teaching site for their continuity clinics, and develop collaborative research opportunities. Dr. Seval was hired by the Partnership to provide management of HIV patients. He serves as a mentor for two ID fellows who follow patients in their continuity clinics at the Drexel Partnership.

O U T PAT I E N T P R AC T I C E We have now been seeing all our outpatients at the Honickman Center beginning in April 2024. Previously we saw ID outpatients in two locations, 1015 Chestnut St. (non-HIV patients) and 33 S. 9th St. (HIV patients). Our two practices are combined into one clinic site on the 11th floor of the Honickman Center. It has been a long-term goal to bring all our ID outpatients to one outpatient location. We manage four types of outpatient clinics: •

General ID patients

•

HIV-infected patients

•

Solid organ transplant patients

•

Non-tuberculous mycobacterial infected patients.

FACU LT Y Elizabeth Novick, MD Clinical Assistant Professor of Medicine Associate Program Director, Infectious Diseases Fellowship Training Program Tricia Royer, DO Clinical Assistant Professor of Medicine Associate Director, Solid Organ Transplant ID Program Vice Division Chief, Methodist Hospital Nikhil Seval, MD Adjunct Assistant Professor of Medicine Adjunct Faculty from Drexel University Daniel Taupin, MD Clinical Assistant Professor of Medicine Vice Chair, Quality for the Department of Medicine Director of Quality/Safety for the Division Mollie Tucker, MD Clinical Assistant Professor of Medicine Associate Director, Solid Organ Transplant ID Program Mudit Tyagi, PhD, PGDBT Associate Professor of Immunology Center for Translational Medicine Devin Weber, MD Clinical Assistant Professor of Medicine Program Director, Infectious Diseases Fellowship Training Program

ADVAN CED PRACTICE PROV IDERS Caroline Clark Brugger, CRNP Lead APP for the Division Rachel Carr, PA TJUH Inpatient Services and COpAT Program Sarah Green, CRNP HIV/AIDS Program Molly Hancock, PA Methodist Inpatient Service Ross Livinsky, PA HIV/AIDS Program NTM COpAT Management

Department of Medicine 2025 Annual Report

35 A D M I N I S T R AT I V E

COMPLEX OUTPATIENT ANTIMICROBIAL THERAPY (COPAT)

Infectious Diseases Division faculty members staff hospital positions at Jefferson University Hospital and Methodist Hospital as Infection Control Officers (Dr. Phyllis Flomenberg) and at Magee Rehab Hospital (Dr. Elizabeth Gancher) and for Antibiotic Stewardship. Dr. Bryan Hess directs the Enterprise Antimicrobial Program Center City hospitals along with Drs. Elizabeth Gancher and Elizabeth Braden in conjunction with the TJUH Pharmacy Department. The Antimicrobial Stewardship Program received the prestigious recognition as a Center of Excellence by the Infectious Diseases Society of America (IDSA).Dr. Daniel Taupin serves as the Vice Chair, Quality, Department of Medicine and leads the Patient Safety/Quality Program for the ID Division. Dr. Tricia Royer serves as the Vice Division Chief at Methodist Hospital.

Under the leadership of Dr. Daniel Taupin and Caroline Brugger, an “Episodes of Care” module was designed and implemented in early 2025 that seeks to standardize COpAT management throughout Jefferson Health. It has been incorporated into legacy Jefferson hospitals and will eventually be introduced to Einstein and LVH once their Epic platforms have been installed and/ or aligned.

J E F F E R S O N E N T E R P R I S EW I D E I N I T I AT I V E S

PANDEMIC PREPAREDNESS

Multiple ID Division faculty have taken administrative leads in programs and initiatives that involve the entire Jefferson Enterprise.

ANTIMICROBIAL STEWARDSHIP COUNCIL In addition to the Antimicrobial Stewardship Program at the Center City hospitals, Dr. Bryan Hess leads the Antimicrobial Stewardship Council that includes membership from all Jefferson Health hospitals and focuses on aligning both formularies and guidelines for the treatment of infections.

TEST UTILIZATION COMMITTEE This program is jointly led by Dr. Daniel Taupin and by Dr. Courtney Komar, Associate Director of the TJUH Clinical Microbiology Laboratory. The overarching goal of this group is to help clinicians order the right test at the right time through the avoidance of underuse, overuse, and misuse of clinical testing services.

This program is led by Dr. John Zurlo along with the newly appointed Vice President of Enterprise Emergency Preparedness, Mr. Ryan Hay. The goal of the program is to maintain preparedness for future pandemics and pathogens of special significance throughout Jefferson Health.

E D U C AT I O N The wide array of clinical problems seen by infectious disease specialists at Thomas Jefferson and Methodist Hospitals provides an outstanding environment for training medical students, house staff, and clinical fellows. Students, residents, and clinical fellows are provided education in infectious diseases care primarily on a dedicated

teaching service. The infectious diseases elective remains one of the most popular among 4th-year medical students. A major project was completed to create a more formalized structure to the 4th year elective to include an orientation welcome pack, a series of lectures on key infectious diseases topics, and basics of clinical microbiology. The division expanded the ID elective offerings for 4th year medical students effectively doubling the available slots from 2 to 4. We now have students rotating with us on four of our consultation services for two, 2-week blocks. We plan to further increase the student census to 7 students beginning in the 2026-27 academic year.Following the departure of Dr. Carolyn Kramer, Dr. Sean Moss has taken over as thread leader for the medical school Microbiology/ Immunology block.

a continued fall in the number of applicants to fellowship positions nationally.This past year was no exception.We did not match any of our three open training positions but were able to recruit three excellent trainees after the match. We have continued to make changes to the program that we believe will make our program more desirable: •

We have created a pandemic preparedness teaching module for ID fellows and for infection preventionists.

•

We have expanded our continuity care clinic opportunities to include the Drexel HIV/AIDS Partnership. Two of our fellows began their continuity clinics there beginning July 2023.

•

We have added a minimum of 4 weeks of inpatient clinical training on our SUD inpatient consult service. We also have added an SUD track to our program for interested trainees for 2024.

•

We have created a transplant concentration for interested fellows. One of our fellows who graduated from the program in 2023 has completed this concentration and is now at Vanderbilt University where she is developing a career in transplant infectious diseases.

•

We have created a medical education concentration for fellows interested in developing careers in academic medicine.

•

We offer a combined, 3-year ID-critical care medicine training for fellows who are qualified and interested in this career pathway.

I N F EC T I O U S D I S E A S E S F E L LOW S H I P P R O G R A M The Division continues to sponsor a training program for infectious disease physician trainees. The training program comprises all aspects of infectious diseases and venues that include the inpatient teaching service, other specialty inpatient services (e.g., transplantrelated infections, surgical infections, etc.), outpatient services (e.g., HIV, sexually transmitted infections, etc.), and conferences that include core curriculum, journal club, and guidelines review. With the generous donation from the Havens family, the program added an additional infectious diseases trainee in July 2022. We sought further funding and added another position beginning in July 2023 now increasing our total fellow complement to six. There has been waning interest in careers in ID as evidenced by

Department of Medicine 2025 Annual Report

36 R E S E A RC H The Jefferson ID Division has long been known for its clinical and educational strengths and expertise. While research has always been part of our mission, we have continued to expand our research portfolio. Multiple faculty members have been active in submitting manuscripts for publication and our output of published works has expanded on a yearly basis. In addition, we are moving ahead with participation in multi-centered clinical trials focusing on transplant infections and HIV. Drs. Belden, Coppock, and Flomenberg now lead a team focused on research for the Division. They maintain a catalogue of research projects for our program trainees, as well as medical residents and students who are considering careers in infectious diseases or who simply want to be involved in clinical research. As a division, we have also reached out to develop collaborations with units at Jefferson including Clinical Microbiology and ID Pharmacy and units outside Jefferson, most notably at the Drexel HIV/AIDS Partnership. Our ultimate goal is to focus our research efforts on selected major topics including HIV/ AIDS, transplant-related infections, orthopedic infections, NTM infections, and infections related to substance use disorder.

Q UA L I T Y I N I T I AT I V E S The Division’s quality initiatives center around our major hospital programs that are managed by the Division, namely Infection Control and Prevention led by Dr. Phyllis Flomenberg, and Antimicrobial Stewardship led by Dr. Bryan Hess. Institution-wide quality projects have included C. difficile infection, central line associate bloodstream infections, and improved antibiotic utilization.

Our HIV/AIDS program has created a comprehensive set of quality measures and quality initiatives that have performed well in comparison with other programs in the City of Philadelphia. Dr. Daniel Taupin who joined our division in 2022 has taken a divisional and departmental lead in quality initiatives as part of his job responsibilities. He was selected to be Vice Chair of Quality for the Department of Medicine. He has introduced more formalized training in patient safety and quality to the fellowship.He oversees M&M presentations for the Department of Medicine and works with our fellows in preparing regular M&M presentations for our weekly infectious diseases clinical conferences.

NEW AND ONGOING I N I T I AT I V E S A N D FUTURE PL ANS Substance Use Disorder (SUD). To help meet the growing problem of patients hospitalized with complications of SUD, most particularly those who inject, we staff a seventh infectious diseases consult service focused on this patient group. Serious infections are a major reason for hospitalization for these patients. Our initiative fits in with institutional efforts on multiple fronts to address this problem. We actively coordinate care with the various services including hospitalists and our Jefferson Addiction Multispecialty Service (JAMS). We are pursuing research projects for this patient population. Non-Tuberculous Mycobacteria (NTM): We have worked in setting up a multi-specialty program focusing on patients with nontuberculous mycobacterial lung infections. This is a collaboration that includes the Division of Pulmonary and Critical Care Medicine, Clinical Microbiology, and Infectious Diseases that enhances our existing collaboration with

National Jewish Health in Denver, CO which is a world leader in this and many other lung related diseases. For the ID Division, one of our faculty members, Dr. Mollie Tucker, leads this effort with assistance from Drs. Elizabeth Novick, John Zurlo, and Mr. Livinsky. Solid Organ Transplant: Our Solid Organ Transplant ID Program includes five key faculty members led by Dr. Katherine Belden. All five have had specialized training and experience in transplant ID and have worked closely with the various transplant teams at Jefferson to provide expert consultation both in the pre- and post-transplant settings. The team has worked collaboratively in initiating the lung transplant program at Jefferson. Drexel Collaboration: We have established a collaboration with the Drexel HIV Partnership. We share faculty at each location. Two of our ID fellows have their continuity clinics at the Partnership. We look forward to developing further collaborations on the research front. Methodist Hospital: Dr. Tricia Royer continues in the role of Vice Division Chief at Methodist Hospital. She works closely with our APC (Molly Hancock) and the medical staff to meet the increasing demands for ID support. Citywide Conference: The Division continues to serve as host for the monthly Philadelphia region Citywide ID Conference.

S E L EC T D I V I S I O N PUBLICATIONS (2024-2025)

2025 Finan D, Garg V, Lang L, Royer T, Belden K, Yang S. Cutaneous cytomegalovirus in mixed serostatus kidney transplant patient. SAGE Open Med Case Rep. 2025 May 26; 13:2050313X251341511. doi: 10.1177/2050313X251341511. PMID: 40433627; PMCID: PMC12106971.

Massenzio SS, Kuriyan AE, Milman T, Pecora ND, Pettengill MA, Zurlo JJ, Deaner JD. Isolated vitritis as the presenting feature of disseminated Mycobacterium chelonae subspecies gwanakae, a novel subspecies. Retin Cases Brief Rep. 2025 Feb 12. doi: 10.1097/ ICB.0000000000001733. Epub ahead of print. PMID: 39977845. 2024 Cox AL, Tsang D, Spacek LA, Daskalakis C, Coppock D. The Impact of Telemedicine on Human Immunodeficiency Virus (HIV)-Related Clinical Outcomes During the COVID-19 Pandemic. AIDS Behav. 2024 Jul;28(7):24382443. doi: 10.1007/s10461-02404342-x. Epub 2024 Apr 25. PMID: 38662279; PMCID: PMC11199220. Kramer TS, Soriano A, Tedeschi S, Chen A, Tattevin P, Senneville E, Gomez J, Birlutiu V, Petersdorf S, de Brito V, Gonzalez IS, Belden KA, Wouthuyzen-Bakker M. Should We Use Rifampicin in Periprosthetic Joint Infections Caused by Staphylococci When the Implant Has Been Exchanged? A Multicenter Observational Cohort Study. Open Forum Infect Dis. 2024 Feb (8);11(3): ofae075.

Department of Medicine 2025 Annual Report

DIVISION OF INTERNAL MEDICINE

37

FACU LT Y

The Division of Internal Medicine serves as a cornerstone of Jefferson’s clinical and academic mission, with a focus on primary care. Comprised of more than 40 dedicated physicians, our division works in seamless integration with advanced practice providers and multidisciplinary teams. Together, we deliver holistic primary care while driving excellence in medical education and scholarly inquiry across the institution.

EXECELLENCE IN PATIENT CARE Our division remains steadfast in its mission to provide highcaliber, patient-centric care to the diverse communities of the greater Philadelphia area. In FY25, our clinical footprint across Center City, South Philadelphia, Bala Cynwyd, and Havertown accounted for 108,688 patient encounters. This volume is supported by a sophisticated infrastructure and a steadfast commitment to clinical optimization. CLINICAL PROGRAM HIGHLIGHTS Quality & Population Health: The Division of Internal Medicine is highly focused on primary care quality improvement initiatives.: Dr. Kenneth Lau led a group of resident physicians on a project focused on improving cervical cancer screening rates. The Division also collaborates closely with the enterprisewide Population Health team to achieve quality goals in preventive care and chronic disease management. Expansion of Comprehensive Weight Management: Dr. Janine Kyrillos continues to lead the Jefferson Comprehensive Weight Management program.

With the addition of new faculty like Dr. Nathan Lent, the program has expanded its reach, offering cutting-edge medical weight management and enhancing clinician education in this dynamic field. Diagnostic Innovation with Point of Care Ultrasound (POCUS): As a national vanguard in outpatient Point of Care Ultrasound, the division hosts one of the few Department of Medicine-run POCUS fellowships. Dr. Rebecca Davis oversees this program in collaboration with Dr. Barry Ziring and various interdepartmental faculty. Inclusive & Specialized Medicine: We take pride in our faculty’s deep expertise in serving populations with specialized health needs, including individuals with disabilities (Dr. Michael Stillman), members of the LGBTQIA+ community seeking genderaffirming care (Dr. Sean Hurt), and those with sickle cell disease (Dr. David Axelrod). Advancing Women’s Health: The Women’s Primary and Specialty Care practice provides tailored services for complex conditions like polycystic ovarian syndrome, reproductive health needs, while ensuring streamlined coordination with sub-specialists who focus on women’s health.

EDUCATION LEADERSHIP Internal Medicine faculty are deeply embedded in the training of the next generation of physicians, holding pivotal roles within the JeffMD curriculum at Sidney Kimmel Medical College and integral roles in the education of internal medicine resident physicians.

UNDERGRADUATE MEDICAL EDUCATION (UME) Dr. Nina Mingioni was appointed Assistant Dean for Academic Affairs and UME, maintaining her oversight of Phase 2 Core Clinical Clerkships. Our leadership bench also includes Dr. Susan Truong (CaseBased Learning), Dr. Aparna Sarin (Clinical Experience Course Director), and Dr. John Spandorfer (Associate Dean of Professionalism).

GRADUATE MEDICAL EDUCATION (GME) We provide a rigorous ambulatory foundation for residents through continuity clinics and specialized tracks. Several faculty members across the Division provide ambulatory training to internal medicine residents through preceptorship in continuity clinics and didactic lectures.

Rhea Powell, MD Professor Division Director

David Axelrod, MD Associate Professor Bracken Babula, MD Clinical Associate Professor Associate Chief Medical Informatics Officer Karl T. Benedict III, MD Clinical Assistant Professor Joseph Boselli, MD Clinical Associate Professor Elizabeth Boyle, MD Clinical Assistant Professor John Caruso, MD Professor Senior Associate Dean, Graduate Medical Education and Affiliates Alaina Chodoff, MD Clinical Assistant Professor Edgar Chou, MD Clinical Associate Professor Carissa Cicchinelli, MD Clinical Assistant Professor Jennifer T. Cowan, MD Clinical Assistant Professor Rebecca Davis, MD Clinical Associate Professor Associate Program Director, Internal Medicine Residency Associate Program Director, EM/IM Point of Care Ultrasound Fellowship Marjorie Friedman, MD Clinical Instructor Mark Graham, MD Professor Sean Hurt, MD Clinical Assistant Professor Rong Ji, MD Clinical Assistant Professor Keino Johnson DO Clinical Instructor Michael Kaufman, MD Clinical Assistant Professor Sunaina Kaushal, MD Clinical Assistant Professor Barbara S. Knight, MD Clinical Assistant Professor Benjamin Krempley, MD Clinical Assistant Professor

Department of Medicine 2025 Annual Report

38 PRIMARY CARE TRACK Directed by Drs. Ojeda and Davis, this track remains a highly sought-after program for top-tier residents who seek to focus their educational experiences to prepare them for a career in primary carerelated fields.

JEFFERSON HOSPITAL AMBULATORY PRACTICE Drs. Knight and Lee are responsible for overseeing the continuity clinical care experience for over 70 resident physicians who practice at the Jefferson Hospital Ambulatory Practice.

WOMEN’S HEALTH TRACK Launched this year by Drs. Nair and Boyle, this new residency track welcomed five inaugural residents into a curriculum featuring monthly lectures, journal clubs, and multidisciplinary rotations in urology, gynecology, and other specialties. Dr. Swati Shroff also provides essential leadership for the clinical experience within the Women’s Primary Care practice.

RESEARCH AND SCHOLARSHIP Our faculty are active contributors to the national medical dialogue, sharing insights at major forums and in high-impact journals.

NATIONAL PRESENTATIONS Notable contributions in FY25 included Dr. Rebecca Davis’s POCUS presentations at the American College of Physicians and the Society of General Internal Medicine (SGIM) annual meetings. Dr. Sean Hurt’s lecture on LGBTQIA+ health

equity at the Jefferson Alumni Symposium, and Dr. Bracken Babula’s national talks on medical informatics.

PROFESSIONAL DEVELOPMENT Our faculty continue to hone their leadership skills through prestigious national programs, including Dr. Jonathan Zaid’s participation in SGIM’s LEAHP program and Dr. Kenneth Lau’s enrollment in the Association of Chiefs and Leaders in General Internal Medicine’s LEAD program focused on leadership development in academic internal medicine. These scholarly activities, as well as the publications noted below, demonstrate the Division's commitment to advancing knowledge and improving healthcare and medical education.

PUBLICATIONS AND PRESENTATIONS Lauriello A, Laoteppitaks C, Cherney AR, Papanagnou D, Mingioni N, Zhang XC. Does Evaluation Transparency Affect the Authenticity of Clinical Evaluation Scoring for Medical Students in EM Rotations? [Poster] Council of Residency Directors in Emergency Medicine, Seattle WA, March 2025 Morse LR, Battaglino RA, Nguyen N, DeVries B, Welch A, Battaglino AL, Linnman C, Stillman M, Wudlick R, Glossner J, Anderton G, Goldstein R, Falci SP. Brivaracetam for spinal cord injury-related neuropathic pain: results of a pilot doubleblinded, randomized, placebocontrolled clinical trial. Pain Rep. 2025 Jun 16;10(4): e1301. PMID: 40528843; PMCID: PMC12173286.

FACU LT Y Janine V. Kyrillos, MD Clinical Associate Professor Director, Jefferson Comprehensive Weight Management Program Christine Laine, MD Clinical Associate Professor Hillary Landon, MD Clinical Assistant Professor Kenneth Lau, MD Clinical Assistant Professor Nathan Lent, MD Clinical Assistant Professor Director, Jefferson Comprehensive Weight Management Program Albert Lee, MD Clinical Assistant Professor Associate Program Director, Internal Medicine Residency Nidhi Master, MD Clinical Instructor Amanda Matheson, MD Clinical Assistant Professor Nina Mingioni, MD Professor Director, Phase 2 Core Clinical Rotations, Sidney Kimmel Medical College Yuan Mirow, MD Clinical Instructor Shailajah Nair, MD Clinical Associate Professor Director, Integrated Program in Women's Health Jason C. Ojeda, MD Clinical Associate Professor Director, Internal Medicine Primary Care Program Associate Program Director, Internal Medicine Residency Kyong B. Park, MD Clinical Assistant Professor Aparna Sarin, MD Clinical Associate Professor Physician Director of Clinical Experience, Sidney Kimmel Medical College Katherine Sherif, MD Professor Vice Chair for Academic Affairs Aleksandr Shpigel, MD Clinical Assistant Professor Swati Shroff, MD Clinical Associate Professor Christine V. Soutendijk, MD Clinical Assistant Professor John Spandorfer, MD Professor Associate Dean of Professionalism in Medicine Michael Stillman, MD Professor

Ashley K. Summer, MD Clinical Assistant Professor Susan Truong MD Clinical Associate Professor Director of Case Based Learning, Sidney Kimmel Medical College Jonathan Zaid, MD Clinical Assistant Professor Barry Ziring, MD Clinical Associate Professor

Department of Medicine 2025 Annual Report

39 Qaseem A, Goldzweig CL, Campos K, Watts B, Choi EI, Tierney S, Fitterman N, Powell R, Andrews RA and the Performance Measurement Committee of the American College of Physicians. The Nuances of Performance Measurement and Clinical Guidelines. Annals of Internal Medicine. Dec 2024. doi:10.7326/ANNALS-24-0209 Stillman M. et al. Internal Medicine Residents' SelfDescribed Knowledge of General Internal Medical Versus Disability-Focused Concerns: An Exploratory Study. Disabil Health J. 2025 Feb

N OTA B L E ACH I E V E M E N T S The excellence of our faculty was recognized by both the community and the institution this past year: Philadelphia Magazine "Top Docs" Seventeen faculty members were named to the 2025 list, including: BRACKEN BABULA, MD JOSEPH BOSELLI, MD EDGAR CHOU, MD JENNIFER COWAN, MD SEAN HURT, MD JANINE KYRILLOS, MD CHRISTINE LAINE, MD

To L, Lin S, Stillman M. Candiduria due to Candida Glabrata in an Elderly Diabetic on an SGLT-2 Inhibitor. Austin J Clin Case Rep. 2025;12(2):1352 Wilson, AM., Douglas A, and Spandorfer J. “Reliability and Validity of the Respect Factor in Student Evaluations of Clinical Educators.” Academic Medicine (2024): 10-1097.

ALBERT LEE, MD NINA MINGIONI, MD YUAN MIROW, MD SHAILAJA NAIR, MD KATHERINE SHERIF, MD ALEKSANDR SHPIGEL, MD CHRISTINE SOUTENDIJK, MD JOHN SPANDORFER, MD ASHLEY SUMMER, MD BARRY ZIRING, MD Institutional Awards NINA MINGIONI, MD Jefferson Award for Outstanding Teaching. CHRISTINE SOUTENDIJK, MD 2025 SKMC Outstanding Clinician in Primary Care, awarded to a physician who has distinguished themselves in the evidence-based, clinical practice of medicine and the doctor-patient relationship. JONATHAN ZAID, MD 2025 Physician Excellence Rising Star Award, highlighting emerging physician leaders at Jefferson. MICHAEL STILLMAN, MD SKMC Department of Medicine “Heal with Equity” Award, recognizing projects with a community impact and a focus on improving health equity.

Department of Medicine 2025 Annual Report

DIVISION OF NEPHROLOGY

41

FACU LT Y

The Division of Nephrology continues its mission of education, research, and clinical care under the leadership of Pooja Singh, MD, MBA. We continue to publish in prestigious, peer-reviewed journals and offer a Transplant Nephrology Fellowship that has been approved by the American Society of Transplantation.

PAT I E N T C A R E Our goal remains to provide the highest level of service to our patients as well as our colleagues. We strive to deliver these services with care, professionalism, teamwork, and respect. Our inpatient clinical activities remain robust among the Renal Dialysis Consult, Renal Medical Consult, and Renal Transplant Consult Services. The inpatient dialysis service provides treatment for an estimated 700-800 patients per month. We provide Medical Directorship for four outpatient dialysis units and patient care to seven chronic units, one transition of care unit, one home unit, and four long-term care facilities. Our outpatient service is a vital part of our patient care mission. In FY25, the division saw 11,732 outpatients, which is a 7% increase from FY24. Of these, 1,703 were new patient visits, 1,022 were telehealth visits. In addition to the ambulatory practice the division saw 3,548 outpatient dialysis patients in FY25. We provide Medical Directorship at Magee Rehabilitation and patient care. Under the Direction of Dr. Seyed Hamrahian, the Division of Nephrology retained Certification as the Jefferson Comprehensive Hypertension Center from the American Heart Association. This certification was made effective August 22, 2022,

through August 23, 2025. We held successful annual Jefferson Hypertension Symposiums in 2019, 2020 and 2021.

TR ANSPL ANT O U TCO M E S F Y 2 5 Under the leadership and direction of Dr. Paula Martinez, the Kidney Transplant Program at TJUH currently has approximately 527 patients on the waitlist (kidney, kidney/pancreas, and pancreas). Our transplant list continues to grow, with a total of 116 new patients added to the waitlist during FY25. We have increased our referral volumes from 870 referrals in FY24 to 973 in FY25. Our living donor transplant program more than doubled its live donor transplants and went from 16 live donor transplants in FY23 to 30 in FY25. We completed a total of 109 kidney transplants overall in FY25. Thanks to our excellent team, our transplant program maintained higher than expected patient and allograft survival and has sustained SRTR tier 4 for FY25 and projected to increase to STRT tier 5 for the next cycle (since Jan 2017 Jefferson has been top tier in region, with ratings in the tier 4-5 for the past 8 years) Additionally, in FY25 following a change in regulations that eliminated the race-based calculations of eGFR, we have continued to apply for adjusted

wait time for our African American patients. As a result of the program’s work, 334.13 years of time have been adjusted for our patients which has translated in 67 transplants. The Nicoletti Kidney Transplant Center, which opened in December 2016, is a comprehensive multidisciplinary center wherein patients and live donors can come to be evaluated for transplantation and donation in one location. The hallmark of the Center, relocated to the Honickman building in May 2024, is the Living Donation Education Program. The Living Donor Education Program is a customized education and coaching program conducted once monthly to assist patients in finding a living donor, which has been proven effective nationally. Holding steadfast to our commitment of eliminating the financial burden of living donations, The Jefferson Transplant Institute is a Living Donor Circle of Excellence Center and became part of the National Kidney Registry’s Donor Care Network Centers of Excellence. We are the only Living Donor Circle of Excellence Center in the Philadelphia area and 1 of the 3 programs considered Donor Shield Center. Through these partnerships, the Jefferson Transplant Institute has reinforced its strong commitment to providing the highest level of care and support to living kidney donors.

Pooja Singh, MD, MBA Beatrice F. Nicoletti Professor of Medicine Division Director

Hasan Arif, MD Clinical Associate Professor Xiaoying Deng, MD Clinical Assistant Professor Bonita Falkner, MD Emeritus Professor Jesse Goldman, MD Clinical Professor Rakesh Gulati, MD Clinical Professor Maitreyee Gupta, MD Clinical Associate Professor Fitsum Hailemariam, MD Clinical Assistant Professor Seyed Hamrahian, MD Professor Dustin Le, MD Clinical Assistant Professor Omar Hussein Maarouf, MD Associate Professor Maria Paula MartinezCantarin, MD Professor Jerry McCauley, MD Professor Prashamsa Shenoy, MD Clinical Assistant Professor Hannah Troutman, DO Clinical Assistant Professor Jingjing Zhang, MD Associate Professor

ADVAN CED PRACTICE CLIN ICIA N Christine Chmielewski, CRNP Ashley Czepiga, CRNP Bethany Hartnett, CRNP

Department of Medicine 2025 Annual Report

42 During FY25, the Kidney Transplant Program continues to see patients conveniently in Egg Harbor Township, NJ, at Voorhees, NJ, and at Lankenau Medical Center to service patients following the closure of the Mainline Kidney Transplant Program. We have transitioned our nononcology infusions to the Honickman Infusion Center, which allows our newly transplanted patients to have fluid infusions, electrolytes and blood transfusions on the same day of clinic visits without having to leave the building. Since its inception, the HH infusion center successfully provides between 30-50 infusions monthly for our transplant team, which has helped to avoid referral to hospital observations and admissions due to electrolyte imbalances, anemia or dehydration in our growing posttransplant population. We have continued to expand our Kidney Care Access Program which provides employees and their dependents with comprehensive, expedited access to kidney care, from proactive screening for early chronic kidney disease to kidney transplantation by identifying those with CKD and offering a fast-tracked evaluation process. The program has currently 62 patients enrolled and the program has resulted in 17 patients being added to our waiting list and 5 patients transplanted. With the collaboration of our Infectious Disease Partners lead by Dr. Dagan Coppock and our transplant nephrologist Dr. Maitreyee Gupta, we continue to participate in the HIV Organ Policy Equity (HOPE) research study. This study allows HIV positive waitlisted patients to receive HIV positive kidney offers. The goal of this research is to increase knowledge about the safety, efficacy, and effectiveness of solid organ transplantation

(SOT) utilizing HIV- positive donors in HIV-positive recipients. Although HIV to HIV kidney, liver and liver-kidney transplants are no longer required to be conducted as research since December 2024, we continue our HOPE study to facilitate expansion into other solid organ transplants including heart and lung transplants in the future. In FY25, our transplant team welcomed Dr. Prashamsa Shenoy as faculty, Dr. Hatem Najar as transplant fellow and at the enterprise level, Dr. James Guarrera has joined the abdominal transplant service line as Executive Director for Jefferson Transplant Institute & Enterprise Leader, for the Transplant Service Line, at Jefferson Health. Dr. Martinez Cantarin was promoted to Professor of Medicine in 2025. In collaboration with our Einstein and Lehigh Valley partners, we also successfully launched an Enterprise Nephrology & Kidney Transplant Updates symposium that took place on September 2025. This professional development seminar will be offered yearly as a forum to disseminate nephrology and transplant advances through our enterprise and to our collaborating partners. Starting July 2025, the Jefferson transplant program has been selected to participate in the IOTA program (Increase Organ Transplant Access Model) by CMS. The program aims to increase access to life-saving kidney by incentivizing kidney transplant hospitals to improve their care delivery capabilities and efficiency as well as quality of care. We have implemented several working groups to monitor the performance of the program in the 3 domains metrics which includes organ acceptance rate ratios, graft survival rates and number of transplants.

We have grown our valuebased Kidney care umbrella by our ongoing partnership with IBC, Davita’s clinical incentive program, to build upon value base kidney care metrics such as home dialysis starts, optimal starts via AV fistula/graft and access to transplantation. We have ongoing participation with the CKCC models, and we are interval and strive as a Transplant provider. Looking forward to FY 2025, we are looking forward to welcoming Dr. Anthony Watkins – who is joining our transplant team as Enterprise Kidney Transplant Surgical Leader and to continue to work together to push live donor transplantation and increase access to kidney transplant through our network.

Q UA L I T Y I N I T I AT I V E S The past year has been an exceptional period for our quality improvement initiatives, encompassing acute kidney injury (AKI), chronic kidney disease (CKD), end-stage renal disease (ESRD), and transplant care. These efforts have been integral to enhancing workflows, safety protocols, patient satisfaction, and overall care delivery. Below is a detailed account of our accomplishments and ongoing projects:

EDHD PATHWAY PROGRAM The Patient Triage and ED Transfers project is an ongoing initiative aimed at improving patient flow and enhancing care for ESRD patients. One of the key components of this project is the implementation of expedited transfers for ESRD patients from the Emergency Department (ED) to the Acute Dialysis Unit (ADU). This initiative has significantly reduced ED congestion, enabling a more efficient triage process and better overall management of patient care.

N E W G R A N T S/ CL I N I C A L T R I A L S OMAR MAAROUF Use of VX-147 in treating ApoL1 related kidney disease. Vertex Pharmaceuticals OMAR MAAROUF Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study (TIGRIS). Spectral DiagnosticCoPI with Dr. Baram M. PAULA MARTINEZCANTARIN 09/2024-06/2029 The Philadelphia Program for Mentored Research Training in Kidney, Urologic, and Hematologic Diseases (PERFORM-KUH U2C/ Tl1) NIH/NIDDK, Jefferson Site PI, Amount direct cost: $1,388,645/5 years JINGJING ZHANG A Multicenter, Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept JINGJING ZHANG A Phase 3, Randomized DoubleBlind Placebo-Controlled Study of Povetacicept in Adults with Immunoglobulin A Nephropathy

Department of Medicine 2025 Annual Report

43 This program has currently triaged approximately 80-85 patients over the years that it has been in place. Currently we’re still handling about 14-15 patients. The expedited transfers have been especially beneficial for patients who do not have access to an outpatient dialysis unit due to behavioral or compliance issues. By swiftly transferring these patients to the ADU, we can ensure they receive the necessary dialysis treatment without further delays, preventing potential complications and hospital readmissions. This approach not only improves patient care but also alleviates pressure on the ED, allowing for more effective use of hospital resources. Overall, the ongoing success of this project highlights its positive impact on both patient outcomes and hospital operations, reinforcing the commitment to providing efficient, timely, and compassionate care for patients with end-stage renal disease.

HOME DIALYSIS PROGRAM The home dialysis program has experienced significant growth, reflecting a commitment to expanding patient-centered care and increasing access to home dialysis options. The Center for Specialty Care in South Philadelphia now serves as a hub for training and educating in-center dialysis patients about transitioning to home dialysis modalities. This initiative has enabled patients to take greater control of their treatment, enhancing their quality of life and improving clinical outcomes. The program has been successfully training patients for peritoneal dialysis (PD) patient and is planned to start training patients for home hemodialysis in early March 2026, marking critical milestones in the expansion effort. Collaboration with the Baxter PD Task Force has been instrumental,

particularly during the nationwide shortage of hemodialysis IV fluids and peritoneal dialysis solutions. Leveraging the expertise of Dr. Maarouf, the team effectively navigated these supply challenges, ensuring continuity of care for patients and avoiding disruptions in treatment. This collaboration underscores the resilience and adaptability of the program in the face of systemic challenges. These developments highlight the division’s strategic focus on growing home dialysis options, which aligns with broader healthcare goals of improving patient autonomy, better health outcomes, reducing hospitalization rates, and promoting cost-effective care. As the program continues to expand, it aims to serve as a model for innovative and patientcentered nephrology care, with plans to train more patients and further refine support systems for those transitioning to home dialysis modalities. The collaboration with DaVita dialysis has been pivotal in enhancing the efficiency and accessibility of renal replacement therapy for newly diagnosed patients. Through this partnership, the focus has been on streamlining the initiation process for outpatient hemodialysis, ensuring that patients who are ready to start renal replacement therapy can do so seamlessly in an outpatient setting. This initiative reduces delays in care, minimizes hospital admissions, and provides patients with a more convenient and patient-centered experience. By leveraging DaVita’s extensive infrastructure and expertise, the program aims to improve the continuity and quality of care for individuals starting dialysis.

Model, a national initiative designed to increase the use of home dialysis and kidney transplants. Within this framework, the focus has been on promoting pre-transplants, facilitating living donor transplants, and encouraging transitions to home dialysis modalities, such as peritoneal dialysis and home hemodialysis. These efforts align with the broader goals of improving patient outcomes, enhancing quality of life, and reducing the overall costs associated with ESRD care. The partnership with DaVita and participation in the ETC Model represent a concerted effort to innovate and adapt nephrology care to meet the evolving needs of patients. By integrating these initiatives, the division continues to set benchmarks in providing efficient, patient-centered, and forward-thinking renal care.

MAGEE REHABILITATION The safety enhancements at Magee Rehabilitation, initiated last year, have significantly improved patient care and outcomes. These initiatives, including renal dosing guidelines for medications like Pregabalin, Gabapentin, Vancomycin, and Gentamycin, as well as updated heart failure management protocols and the addition of essential medications such as Lokelma, Veltassa, UreNa, and Droxidopa to the formulary, have effectively mitigated the risks of adverse outcomes. By focusing on tailored medication management and thorough reconciliation processes, these measures have played a crucial role in ensuring patient safety and delivering high-quality care.

MULTI-SPECIALTY CLINICS ETC MODEL In addition, the division is actively participating in the End-Stage Renal Disease Treatment Choice (ETC)

The multi-specialty clinic initiative aims to foster collaboration between Rheumatology, Urology, and Nephrology to provide

comprehensive care for complex patient populations, specifically those with lupus nephritis and kidney stone disease. For lupus patients, Rheumatology and Nephrology will work together to address the overlapping and systemic complications of the disease, with a focus on optimizing management of lupus nephritis, monitoring disease progression, and tailoring immunosuppressive therapies. This integrated approach ensures that patients receive holistic care that encompasses both autoimmune and renal health. For kidney stone patients, Nephrology and Urology will collaborate to create a streamlined care pathway. This will include advanced diagnostic evaluation, metabolic testing, and individualized treatment plans. The clinic will prioritize both acute management of stone episodes and long-term prevention strategies, such as dietary modifications, medical therapies, and surgical interventions when necessary. By bringing together specialists from these disciplines, the multispecialty clinic aims to enhance patient outcomes, reduce healthcare fragmentation, and provide a seamless and patientcentered care experience for these complex conditions.

E D U C AT I O N The division’s faculty members serve as the educational resource for students, interns, residents, and fellows year-round. Subspecialty fellows, as well as students and house staff rotating through our service, participate in didactic lecture series in Nephrology, basic and clinical research, journal club, clinical case conference, mortality and morbidity conference, and kidney biopsy conference. Our fellowship program continues to offer a Transplant Nephrology

Department of Medicine 2025 Annual Report

44 Fellowship (PGY 6) approved by the American Society of Transplantation. The purpose of this fellowship program is to be able to graduate UNOScertified transplant nephrologist from Jefferson and enhance the prestige and visibility of our transplant program. The effectiveness of our educational mission is evidenced by a renewed interest in Nephrology as a career option for the Jefferson medical residents.

R E S E A RC H Drs. Singh and Martinez encourage faculty in the continued development of clinical research activities. Our faculty and fellows are actively involved in both basic science and clinical research projects.

P U B L I C AT I O N S Rosner B, Cook NR, Glynn RJ, Bress A, Derington AG, Bonita Falkner, Allen N. Use of Censored Data Methods to Estimate Blood Pressure Percentiles in US Adults. Am J Epidemiol. 2024 Sep 17: kwae363. doi: 10.1093/aje/ kwae363. Online ahead of print. PMID: 39289167 Hamdani G, Urbina EM, Daniels SR, Bonita Falkner, Ferguson MA, Flynn JT, Hanevold CD, Ingelfinger JR, Khoury P, Lande MB, Meyers KE, Samuels J, Mitsnefes M. Higher Blood Pressure is Associated with Increasing Number of Subclinical Target Organ Injuries in Healthy Youth: The Ship Ahoy Study. Hypertension 2025; 82:992-1001. (Published online February 27, 2025.) https://doi.org/10.1161/ hypertensionaha.124.23018 Hanevold CD, Seo JD, Daniels SR, Bonita Falkner, Ferguson MA, Flynn JT, Ingelfinger JR, Khoury PR, Lande MB, Meyers KE, Mitsnefes M, Samuels J, Urbina EM. Ambulatory blood pressure

variability in prediction of target organ injury: The SHIP AHOY study. Pediatric Nephrology. 2025 May 19. doi: 10.1007/s00467-02506803-4. Online ahead of print. Ananthamohan K, Brady TM, Arif M, Daniels SR, Bonita Falkner, Ferguson M, Flynn J, Hanevold C, Hooper SR, Ingelfinger JR, Lande M, Martin LJ, Meyers KE, Mitsnefes M, Rosner B, Samuels JA, Kuffel G, Zillox MJ, Chen QM, Becker RC, Urbina EM, Sadayappan S. A Multiomics Approach to Defining Target Organ Injury in Youths with Primary Hypertension: The SHIP AHOY Cohort. Journal of the American Heart Association 2025; 14: e037649. DOI: 10.1161/ JAHA.124.037649 1 Hernandez-Moreno CJ, Bonita Falkner, Keith SW, Gidding SS, Thaker VV. Association of Glucose Response Shape in OGTT with Markers of Pancreatic Health and Inflammation Across Diverse Ages. Journal Clinical Endocrinology and Metabolism. 2025 Agu 5: dgaf435 doi: 10.1210/clinem/dgaf435 published ahead of print. PMID: 40810440 Bonita Falkner, Alexander BT, Nuyt AM, South AM, Ingelfinger J. Cardiovascular Health Starts in the Womb. Hypertension. 2024; 81:2016-1026. doi: 10.1161/ HYPERTENSIONAHA. Online July 29, 2024, ahead of print124.21359 PMID:39069922 Filippone EJ, Gulati R, Farber JL. Contemporary review of IgA nephropathy. Front Immunol. 2024 Aug 12; 15:1436923. doi: 10.3389/ fimmu.2024.1436923. eCollection 2024. PMID: 39188719 Filippone EJ, Gulati R, Farber JL. The road ahead: emerging therapies for primary IgA nephropathy. Front Nephrol. 2025 Feb 4; 5:1545329. doi: 10.3389/ fneph.2025.1545329. eCollection 2025.PMID: 39968279 Maitreyee Gupta, Hatem Najar, & Kiran Goli. Reclaiming Reproductive Health in Kidney Transplantation: A

Clinical Imperative. Kidney News, 17(12), 20-21 2025. Hatem Najar, Kiran Goli, M. Paula Martinez Cantarin. Parvovirus B19 infection in kidney transplant recipients. Annals of Internal Medicine: Clinical Cases (AIMCC). 2025 May 6. Doi: 10.7326/aimcc.2024.1156. Online ahead of print Islam R, Roche ME, Lin Z, Whitaker-Menezes D, Diaz-Barros V, Serrano E, M. Paula Martinez Cantarin, Philp NJ, Basu Mallick A, Martinez-Outschoorn U. TOMM20 as a driver of cancer aggressiveness via oxidative phosphorylation, maintenance of a reduced state, and resistance to apoptosis. Mol Oncol. 2025 Feb 25. doi: 10.1002/18780261.70002. Online ahead of print. PMID: 39996379 Le D, Singh R, Kim, B, et al. Primary Care Use and Clinical Outcomes Among Patients Initiating Hemodialysis. American Journal of Kidney Disease. 2025 Oct;86(4):437-447.e1 06/2025 Le D, Kim B, Li Y, Lee, M, et al. Neighborhood Built Environments and Home Dialysis Utilization: Urbanicity-Dependent Patterns and Implications for Policy. American Journal of Kidney Disease. 2025 Jun;85(6):737-744 Le D, Aklilu AM, Menez S, Baker ML, et al. Early, Individualized Recommendations for Hospitalized Patients with Acute Kidney Injury: A Randomized Clinical Trial. JAMA. 2024 Dec 24;332(24):2081-2090 Dustin Le, Grams M, Coresh J, Shin J. Sacubitril-Valsartan in Patients Requiring Hemodialysis. JAMA Network Open. 2024 Aug 1;7(8): e2429237 Aqeel F, Cammarata M, Dustin Le, Geetha D. Pneumocystis jiroveci Pneumonia Prophylaxis in patients with ANCA Vasculitis on Rituximab maintenance therapy. Glomerular Diseases, 2024 Jul 26;4(1):152-158

N OTA B L E ACH I E V E M E N T S 2025 Philadelphia Magazine, Top Doctors : HASAN ARIF, MD JESSE GOLDMAN, MD RAKESH GULATI, MD HASAN ARIF Sidney Kimmel Medical College Career Education Award: Awarded in June 2025 SEYED MEHRDAD HAMRAHIAN 2025 Certificate of recognition as the Medical Director of CMS 5-star rated chronic dialysis unit center RAKESH GULATI Philanthropic, gifts in honor 2025 50K for HC and 25K for Burke directorship. DUSTIN, LE American Society of Nephrology Quality Committee. Intern ( -> full member 1/2026) OMAR MAAROUF Implementing the EDHD pathway M. PAULA MARTINEZ-CANTARIN Promotion to Professor June 2025

CO M M U N I T Y S E RV I CE BETHANY HARTNETT Gift of Life Donor Dash in April 2025 JINGJING ZHANG PKD walk 2024

Department of Medicine 2025 Annual Report

45 Najar H, Evans J, Vedula S, Keiffer G, Zhang J. Acute kidney injury after treatment with arsenic trioxide. Clin Nephrol Case Stud. 2025 Dec 11; 13:84-88. doi: 10.5414/CNCS111813. PMID: 41409234; PMCID: PMC12706870. Le D, Najar H, Backer Z, et al. Association of Primary Care Use with Kidney Transplantation Among US Patients Already on Hemodialysis. Journal of the American Society of Nephrology. 2025;36(10S). doi: 10.1681/ ASN.2025yrrhkg8f Najar H, Gianni T, Goli KM, Hailemariam FT, Martinez Cantarin MP, Gupta MM. Successful Kidney Transplantation in a Patient with Genetic Hypertension Due to a Pathogenic KLHL3 Mutation: A Case Report. Journal of the American Society of Nephrology. 2025;36(10S). doi:10.1681/ASN.2025aec0z3bv Goli K, Najar H, Shenoy P, Gulati R, Gupta M. Innovative AI-Driven Transplant Board Review Series: Enhancing Fellow Engagement and Learning in Nephrology Fellowship Training. American journal of transplantation. 2025;25(8). doi: 10.1016/j. ajt.2025.07.431 Hatem Najar, Kiran Goli, Maria Paula Martinez Cantarin. Parvovirus B19 Infection in Kidney Transplant Recipients. AIM Clinical Cases.2025;4:e241156. [Epub 6 May 2025]. doi:10.7326/ aimcc.2024.1156 Najar H, Hailemariam FT, Yadav A. Acute Kidney Failure: An Atypical Presentation of Gordon Syndrome. Journal of the American Society of Nephrology. 2024;35(10S). doi: 10.1681/ASN.2024hc04dyhd Najar H, Rashid U, Zhang J, Arif H, Maarouf OH. Aquapheresis: An Alternative Method of Controlled Fluid Removal in the Setting of Hypervolemia and Refractory Gout in Sickle Nephropathy. Journal of the American Society

of Nephrology. 2024;35(10S). doi:10.1681/ASN.2024q6eyqh22 Marrssa Samuels,B.A., Omar Maarouf, M.D., Wing Zeng, Mehrdad Hamrahian, M.D., Neera K. Dahl,,M.D., Ph.D., Jingjing Zhang, M.D. Autosomal Dominant Polycystic Kidney Disease Without Apparent Family History: A SingleCenter Experience. Clin Nephrol. 2025 April 2nd

L EC T U R E S BY I N V I TAT I O N Dustin Le, Johns Hopkins Center for Drug Safety & Efficacy. Pharmacoepidemiology in End Stage Renal Disease 10/21/2024 Dustin Le, Johns Hopkins Renal Disease Interest Group. Primary Care and Kidney Transplantation in ESRD 02/05/2025 Omar Maarouf - Nov 2024 - RRT in the post-op period – SICU Omar Maarouf - Mar 2025 - RRT in brain injury -- neuroICU M. Paula Martinez-Cantarin, Lankenau Institute for Medical Research (LIMR), Wynnewood PA. Guest Lecturer. December 2024 (Inflammo-Metabolic Reprogramming in Kidney Disease)

A B S T R AC T S Hatem Najar, Urmiya Rashid, Jingjing Zhang, Hasan Arif, Omar H Maarouf. Aquapheresis: An Alternative Method of Controlled Fluid Removal in the Setting of Hypervolemia and Refractory Gout in Sickle Nephropathy: TH-PO377, ASN 2024 Hatem Najar, Julia Evans, Sai Sedula, Gina Keiffer, and Jingjing Zhang. Acute kidney injury after treatment with Arsenic trioxide. NKF, 2025 Boston Horan S, Mavridis A, Nasir-Moin M, O'Neill G, Muhunthan G, Shirodkar M, Charlene Deng, Kania L, Haddad R, Fitsum Hailemarian, Roth C, Lallas C, Gomella P,

Metwalli AR. Radiology report language significantly influences the rate of subsequent workup for adrenal incidentalomas. Abstract AUA 2025 Mavridis A, Nasir-Moin M, Horan S, Buckner M, Rifkin J, Shirodkar M, Charlene Deng, Kania L, Haddad R, Fitsum Hailemariam, Roth C, Lallas C, Gomella P, Metwalli AR. Rates of adequate testing for cortisol hypersecretion and diagnosis of mild autonomous cortisol secretion (MACS) in a single institution series of adrenal incidentalomas. 2025 AUA abstract Nasir-Moin M, Horan S, Mavridis A, Buckner M, Hostetler J, Shirodkar M Charlene Deng, Kania L, Haddad R, Fitsum Hailemariam, Roth C, Lallas C, Gomella P, Metwalli AR. Very low rates of adequate evaluation of adrenal incidentaloma by both urologists and endocrinologists: a single institution experience. 2025 AUA abstract

P O S T E R P R E S E N TAT I O N Kiran Goli, Prashamsa Shenoy, Maitreyee Gupta, Maria P Martinez-Cantarin, Rakesh Gulati, Pooja Singh. Future of Transplant Centers: Leveraging Integration of Transplant Institutes to Mitigate Professional Shortages and Enhance Patient Outcomes. Poster presentation at CeOT, Cutting Edge Organ Transplantation conference, Scottsdale, AZ 2025.

OT H E R S C H O L A R LY WO R K Rakesh Gulati, Faculty at HUP glomerular workshop for regional nephrology fellows, Rakesh Gulati, Faculty at NKF mid Atlantic renal fellow symposium Rakesh Gulati, CJASN - Faculty for trainee Peer Review Program Omar Maarouf, Faculty at UPenn glomerular workshop for regional nephrology fellows

Omar Maarouf, Faculty at ASN-ITE through NBME Omar Maarouf, Faculty at NKF MidAtlantic Renal Fellow Symposium Omar Maarouf, Amyloidosis Clinic

Department of Medicine

DIVISION OF PULMONARY, ALLERGY & CRITICAL CARE MEDICINE The Division of Pulmonary, Allergy and Critical Care Medicine and the Jane & Leonard Korman Respiratory Institute (KRI) have continued to grow in services and footprint. Since 2018, when the KRI was created, the division engaged in an aggressive strategy that resulted in the recruitment of new faculty; an increase in the number of physician extenders, nurses and medical assistants; the establishment of a robust clinical trials enterprise; and the development of many new clinical programs of excellence. Today, the division houses 36 faculty, including three basic scientists, and four training programs distributed throughout multiple clinics and two hospitals. The Division is considered one of the strongest clinical, research, and education programs in the region. Thanks to these and related efforts, the Thomas Jefferson University Hospital was again ranked in the top 50 (#35) in Pulmonology by U.S. News and World Report. PAT I E N T C A R E The Division is home to nationally recognized programs with excellence across ILD, lung cancer screening, critical care, cystic fibrosis, bronchiectasis/ NTM, asthma, COPD, sarcoidosis, pulmonary embolism, chronic respiratory failure, interventional pulmonology, lung transplant, allergy, and chronic cough. Interstitial Lung Disease (ILD): Over the past year, we strengthened enterprisewide integration through joint multidisciplinary conferences, hosted our 3rd ILD Symposium, revamped the fellow curriculum, secured a $4M multi-institutional DoD IPF grant, and maintained Pulmonary Fibrosis Foundation accreditation. Faculty members were also invited to speak at the annual PFF meeting. Lung Cancer Screening & Nodule Program: Under Dr. Julie Barta’s leadership, the program continues to generate high-impact publications and

successfully hosted the 14th Annual Lung Cancer Screening Summit and the 13th Annual Lung Cancer Symposium. Efforts to expand population-based screening and NIH-funded research remain a priority. Interventional Pulmonology (IP): We opened new bronchoscopy suites at both Methodist and Center City, advanced recruitment of an additional IP physician, and held our first enterprise-wide IP operations meeting. We expanded pleural clinic access and supported system-wide deployment of robotic bronchoscopy (>1,000 cases to date), bronchoscopic lung volume reduction (>100 cases), and ICU tracheostomy (>75 cases). Cystic Fibrosis (CF): We maintained CF Foundation accreditation (July 2025), opened a Lehigh Valley satellite site to support transition to adult care, secured CF Foundation and DIGEST-CF grants, and added a part-time dietitian.

Bronchiectasis/NTM: We achieved accreditation in the Bronchiectasis and NTM Care Center Network as the Jefferson Multidisciplinary NTM Center, expanded multidisciplinary access, and will host our inaugural Bronchiectasis Symposium in April 2026. Lung Transplantation: The program completed 11 transplants, listed additional patients, improved referral pathways, and expanded recruitment. Growth continues as we await CMS approval. Sarcoidosis: We strengthened multidisciplinary collaboration with cardiology, expanded infliximab access, established monthly case conferences, and maintained FSR designation. Asthma and COPD: Under the leadership of Dr. Evertz and Dr. Baig, our programs standardized biologic prescribing, expanded asthma education, implemented AIRQ screening, and are preparing to launch VizAI to enhance COPD identification and referral pathways.

2025 Annual Report

47

FACU LT Y Ross Summer, MD Ludwig Kind Professor of Medicine CEO, Jane & Leonard Korman Respiratory Institute Division Director Lead, Respiratory Collaborative

Bharat Awsare, MD Clinical Associate Professor Volunteer Faculty Saqib Baig, MD Clinical Associate Professor Co-Director of Bronchiectasis COPD Program Director of Physiology Michael Baram, MD Professor Director, In-Patient Research Director, Post-ICU Clinic Julie Barta, MD Associate Professor Co-Director, Lung Cancer Program George Belecanech, MD Clinical Assistant Professor Lead, Allergy Program Ryan Belecanech, MD Clinical Assistant Professor Co-Lead, Pulmonary Vascular Program Vincent Chan, MD Assistant Professor Prarthna Chandar, MD Clinical Assistant Professor Director, Interventional Pulmonology Deepak Deshpande, PhD Professor Director, Center for Translational Research and Pulmonary Research Linda Earle, MD Assistant Professor Gautam George, MD Associate Professor Co-Director, ILD Program Associate Program Director, Pulmonary & Critical Care Fellowship Ritu Grewal, MD Associate Professor

Department of Medicine 2025 Annual Report

48 Critical Care: We increased Methodist ICU volume through direct transfers, assumed oversight of the PCU to enhance nighttime support, and advanced our participation in PERT trials. Simulation and POCUS Education: Under Dr. West’s leadership, our simulation and POCUS educational programs continue to expand. Chronic Cough: We launched a new Chronic Cough Clinic with multidisciplinary ENT/ SLP collaboration, submitted national abstracts, developed standardized care pathways, and hosted our first Chronic Cough Symposium. Chronic Respiratory Failure: We streamlined authorization processes for chronic respiratory failure therapies and partnered on an ALS-focused NIH grant. Allergy and Immunology: We recruited new faculty in Center City and New Jersey, advanced integration of allergy operations across the Philadelphia–Southern New Jersey region and are actively recruiting two additional allergists.

Q UA L I T Y I N I T I AT I V E S The Division of Pulmonary, Allergy and Critical Care Medicine is committed to advancing patient safety and quality across the full spectrum of pulmonary and critical care. Projects are selected for their clinical impact and alignment with divisional priorities, while also serving as experiential learning opportunities for fellows. In addition to divisional efforts, our faculty lead multiple safety and quality initiatives detailed below. Ventilator Liberation (“Extubation Bundle”): The MICU implemented an interdisciplinary extubation bundle to reduce avoidable ventilator days. The intervention improved collaboration around

ventilator liberation and significantly reduced duration of mechanical ventilation. Increasing Uptake of Respiratory Vaccines in High-Risk Patients (e.g., IPF): Identified barriers including decentralized scheduling, documentation gaps, and provider knowledge deficits. Process mapping, provider education, and documentation tools led to a ~15% improvement in influenza vaccination documentation rates. Standardizing ICU-to-Ward Transitions (ICU-PAUSE): Developed and implemented a standardized electronic transfer tool (ICU-PAUSE SmartPhrase). Pre-/post-surveys demonstrated improved understanding of ICU course, greater satisfaction with handoffs, and enhanced perceived quality of transitions, particularly after targeted education. Management of Poorly Controlled Asthma (AIRQ Implementation): Adopted the Asthma Impairment and Risk Questionnaire (AIRQ) to identify high-risk patients. Among those with poorly controlled scores, ~72% had therapy modified or escalated. AIRQ is now standard practice in asthma clinics. Reducing CRRT Downtime in the MICU: Addressing temporary dialysis catheter failure and machine downtime to reduce infection risk and improve efficiency. Interventions include a nursing citrate-lock protocol and structured dialysis review during rounds; data collection is ongoing. Timely Referral of ILD Patients for Lung Transplant: Supporting early referral in collaboration with the newly established transplant program through provider surveys, education, decisionsupport tools, and EMR-based prompts for advanced lung disease.

Improving Nebulizer Hygiene in Non-CF Bronchiectasis: Assessing baseline cleaning practices and implementing structured patient education with follow-up surveys to reduce infection risk and exacerbations. Division faculty also collaborates on institution-wide efforts to reduce COPD readmissions, improve heart failure outcomes, reduce catheter-associated infections, and lower mortality, length of stay, and readmissions in MICU and pulmonary inpatients.

E D U C AT I O N The Division houses four training programs. The ACGMEaccredited Pulmonary–Critical Care Medicine Fellowship is a three-year program with five fellows per class, and the one-year Critical Care Fellowship trains one to two fellows annually. Our Point-of-Care Ultrasound (POCUS) Program provides advanced ultrasound training for fellows and has recently expanded to include residents. The Division also supports the Allergy/Immunology Fellowship based at Christiana Care in Delaware. We are proud that our fellows pursue advanced subspecialty training or transition into impactful clinical and academic careers. Faculty remain deeply committed to education, structured mentorship, and integration of research into training, with ongoing evaluation of mentorship outcomes. Division members are also actively engaged in teaching and mentoring medical students at Sidney Kimmel Medical College. Beyond graduate medical education, the Division provides robust community outreach, including patient support groups and public lectures. Signature

FACU LT Y Robert Hilton, MD Clinical Assistant Professor Director of MICU Acting Vice Chair, Methodist Hospital Jeffrey Hoag, MD Professor Section Chief, Jefferson Northeast Director, Adult Cystic Fibrosis Center Jonathan Iaccarino, MD Associate Professor Gregory Kane, MD Jane & Leonard Korman Professor of Pulmonary Medicine Chair, Department of Medicine Behram Khan, MD Lead, Sarcoidosis Program Clinical Assistant Professor Daniel Kramer, MD Clinical Assistant Professor Associate Director, Fellowship Program David LaRosa, MD Clinical Assistant Professor Michael Lippmann, MD Professor Volunteer Faculty Salvatore Mangione, MD Associate Professor Director, Physical Diagnosis Course Christopher McGrath, MD Clinical Assistant Professor Jessica Most, MD Clinical Associate Professor Volunteer Faculty Vani Mulkareddy, MD Assistant Professor Ajay Nayak, PhD Assistant Professor David Oxman, MD Associate Professor Damaris Pena Evertz, MD Clinical Assistant Professor Director, Severe Asthma Program Raymond Penn, PhD Robley Dunglison Professor of Pulmonary Research Director, Pulmonary Research, Jane and Leonard Korman Respiratory Institute Vice Chair, Research Tonio Pera, PhD Assistant Professor Rafael L. Perez, MD Professor Director, Sarcoidosis Program Julian Rosé, MD Clinical Assistant Professor of Medicine

Department of Medicine 2025 Annual Report

49 programs include the Annual Lung Cancer Screening Summit, Annual Lung Cancer Symposium, and Annual Pulmonary Fibrosis Update. The Division also contributed to the launch of a new Respiratory Therapy Program in Philadelphia and Denver.

R E S E A RC H Division faculty and trainees work closely with basic scientists on translational research, with fellows actively contributing to these initiatives. Our Clinical Trials Program remains strong, conducting 20–25 trials and registries, either independently or in collaboration with the Jefferson Clinical Research Institute, across pulmonary fibrosis, asthma, pulmonary hypertension, sarcoidosis, critical care, COPD, and other obstructive airway diseases. Basic science efforts focus on airway, matrix, epithelial, and fibroblast biology, leveraging advanced in vitro, ex vivo, and in vivo models, including genetically engineered animal systems. Since July, we have expanded our clinical trial team to six research coordinators and increased trial volume by 40%. The program now generates approximately $2 million annually in direct funding.

N OT E A B L E AC H I E VM E N T S We celebrated faculty promotions at the Associate and Professor levels, and our faculty continues to receive award recognition in education, research and clinical care.

P U B L I C AT I O N S Saidy S, Iqbal A, Baig SH. Pulse Oximetry Discrepancies and Occult Hypoxemia in ICU Patients: Predictors and Clinical Outcomes. J Intensive Care Med. 2025 Dec;40(12):1269-1278. doi: 10.1177/08850666251351594.

Epub 2025 Jul 16. PMID: 40665879. Baig SH, Lee JD, Yoo EJ. Patient outcomes after interhospital transfer: the impact of early intensive care unit upgrade. Hosp Pract (1995). 2025 Feb;53(1):2470107. doi: 10.1080/21548331.2025.2470107. Epub 2025 Feb 28. PMID: 40015954. Baig SH, Sirapu S, Johnson J. Hospitalized Non-Tuberculous Mycobacterial Pulmonary Disease Patients and Their Outcomes in the United States: A Retrospective Study Using National Inpatient Sample Data. Chronic Obstr Pulm Dis. 2025 Mar 27;12(2):146-157. doi: 10.15326/jcopdf.2024.0568. PMID: 39933561; PMCID: PMC12147827. Editors Charles J. Grodzin, Geno J. Merli, Charles B. Ross and Rachel Rosovsky. Chapter Author: ECMO special considerations. PERT Consortium Handbook of Pulmonary Embolism - Research, Care, and Management. In production Butcher, Brad W., Lindsey R. Morris, and Michael Baram. “Fundamentals of PICS.” PostIntensive Care Syndrome, edited by Brad W. Butcher, Cambridge University Press, 2026, Chapter 2. doi. org/10.1017/9781009501477.003 Li, Heyi, Michael Baram, and Brad W. Butcher. “Bundles and Checklists.” Post-Intensive Care Syndrome, edited by Brad W. Butcher, Cambridge University Press, 2026, Chapter 11. doi. org/10.1017/9781009501477.012. Madara, John C., and Michael Baram. “A Brief History of ICU Follow-Up Clinics.” Post-Intensive Care Syndrome, edited by Brad W. Butcher, Cambridge University Press, 2026, Chapter 27. doi. org/10.1017/9781009501477.028. Khaing, Phue, James Uricheck, and Michael Baram. “InfectionRelated Pulmonary Embolism

Treatment.” PERT Consortium Handbook of Pulmonary Embolism: Research, Care, and Management, edited by Charles J. Grodzin, Geno J. Merli, Charles B. Ross, and Rachel Rosovsky, Springer, 2025, pp. 1–18, https:// doi.org/10.1007/978-3-03070904-4_58-1. Charles Ross, Colin Hinkamp, Nirmal, Michael Baram. “ECMO special considerations.” PERT Consortium Handbook of Pulmonary Embolism: Research, Care, and Management, edited by Charles J. Grodzin, Geno J. Merli, Charles B. Ross, and Rachel Rosovsky, Springer, 2025, in production. Choi E, Shusted CS, Yang H, Evans H, Katcher J, Shieh Y, Vachani A, Rendle K, Barta JA. Impact of Race and Acculturation on Lung Cancer Screening Eligibility: A Multi-Center Lung Cancer Cohort Study. American Journal of Respiratory and Critical Care Medicine 2025; accepted, in press. Katcher JG, Shusted CS, Bhatt P, Ruane BM, Markle J, Kane GC, Wen KY, Juon HS, Barta JA. Lung Cancer Diagnoses Among Lung Cancer Screening Participants with Family History of Lung Cancer. Clinical Lung Cancer 2025, accepted, in press. Cui L, Lee J, Miller J, Tang M, Abedian S, Altorki NK, Crupi RS, Groner L, Lindeman NI, Pinheiro LC, Tamimi RM, Villena-Vargas J, Vachani A, Barta JA, Gao HO, Sholle E, Solomon JP, Garcia CA, Choi E, Shieh Y. Design and Creation of a Racially Diverse Lung Cancer Registry with Detailed Genomic and Environmental Annotation. Cancer Epidemiology, Biomarkers & Prevention 2025, Oct 31. PMID 41171411. Julie A. Barta, MD, ATSF Revised 2026.1.15 Evans HM, Landy R, SHusted CS, Ruane B, Anderson E, Giamboy T, McMullen M, Kane GC, Juon HS, Barta JA. Variation in Lung Cancer Risk Distribution by Race

FACU LT Y Valeria Santibanez, MD Assistant Professor Michael Scharf, MD Clinical Associate Professor Director of Pulmonary Vascular Program Neeraj Sinha, MD Clinical Professor Medical Director, Lung Transplantation Michael Unger, MD Professor Volunteer Faculty Urvashi Vaid, MD Associate Professor Director of Foundations in Clinical Medicine Marcia Watson, DO Clinical Assistant Professor Director, Methodist Pulmonary Ambulatory Clinics Sandra Weibel, MD Clinical Assistant Professor Director of TJUH In-patient Pulmonary Care Frances Mae West, MD Associate Professor Director, Fellowship Program Co-Director, Internal Medicine Point-of-Care Ultrasound Fellowship Co-Director, JeffPERT: Jefferson Pulmonary Embolism Response Team Erika Yoo, MD Associate Professor Director of TJUH MICU Director, Critical Care Program

Department of Medicine 2025 Annual Report

50 Across Modified PLCOm2012 Risk Models Among Lung Cancer Screening Participants. Annals of the American Thoracic Society 2025, Sep 17. PMID 40961323. Barta JA, Arenberg D, Backhus L, Detterbeck F, Gould MK, Nair VS, Pasquinelli M, Powell CA, Sandler K, Silvestri G, Triplette M, Vachani A, Wiener RS, Mazzone JP. Components Necessary for HighQuality Lung Cancer Screening: A 10-Year Update. CHEST 2025, Jun 17: S0012-3692(25)00700-7. PMID 40553813. Alfaro MK, Shusted CS, Giamboy T, Kane GC, Evans NR, Ruane BM, Dimino M, Gatson- Anderson E, Muse E, McMullen M, Kinsey AM, Murray S, McNair C, Barta JA. Using an Integrated Digital Framework to Standardize and Expand a Multi-Site Lung Cancer Screening Program. Journal of Clinical Oncology – Clinical Cancer Informatics 2025, Jun 9: e2400322. PMID 40561373. Carter-Bawa L, Prosper A, Barta JA. Beyond Early Detection – Reframing Radiology’s Role in Lung Cancer Care. Journal of the American College of Radiology 2025. 22(12): 1445-1447. Choi E, Barta JA. Use of Lung Cancer Trends for Global and Public Health Priorities. Lancet Respiratory Medicine 2025; Feb 14 Online ahead of print, doi: 10.1016/S2213- 2600(25)000426. PMID 39961326. Hassan HJ, Belecanech RG et al. Effects of Implementing a Standardized Risk Stratification and Triage Workflow for an Established Pulmonary Embolism Response Team. Ann Am Thorac Soc 22, 1484-1492 (2025). Belecanech RG, et al. Many Uncertainties Remain in the Longterm Care of SCD-PH. Am J Respir Crit Care Med. Accepted for publication November 24, 2025 (Blue-202511-2721LE).

Baig SH, Dong MQ, Sirapu S, Chan V. Round34: AttendingModerated Tabletop Gameplay to Enhance Resident Team Dynamics During Inpatient Rounds. J Grad Med Educ. 2026 Feb;18(1):43-50. doi: 10.4300/ JGME-D-25-00606.1 o Cosimini M, Zarandi A, Edwards SL,

Regorafenib pulmonary toxicity: A case of cavitary lung disease and ARDS treated with infliximab. Dong M, Kramer M, Gandhi T, George G. Respir Med Case Rep. 2025 Oct 17;58:102302. doi: 10.1016/j.rmcr.2025.102302. eCollection 2025.PMID: 41210153 Free PMC article.

Stiver ML, Chan V, Augustin O, Blain B, Chan TM. Print, Play, and Learn: Cataloging Card and Board Games for Medical Education from 1980 to 2025. Cureus; 17(12): e99203. Dec 2025. doi: 10.779/ cureus.99203

High-flow oxygen therapy in ILD exacerbations: an imperfect therapy. Spritzer K, Roman J, Summer R, George G. Ann Am Thorac Soc. 2026 Feb 1;23(2):161-163. doi: 10.1513/ AnnalsATS.202505-526VP.PMID: 41134995 No abstract available.

Hoag J, Chan V. Cystic Fibrosis in the Young and Old: The Future is Precision Medicine. Journal of Precision Respiratory Medicine. Feb 2025. doi: 10.2500/ jprm.2025.8.240012 The Diagnostic Utility of Bilateral Bronchoalveolar Lavage Cellular Analysis for Interstitial Lung Disease: A Retrospective SingleCenter Study. El Fadel O, Roman J, Kramer D, Chandar P, Summer R, George G. J Bronchology Interv Pulmonol. 2026 Feb 20;33(2): e01059. doi: 10.1097/ LBR.0000000000001059. eCollection 2026 Apr 1. PMID: 41718447 No abstract available. Reply to Fernández et al. Comment on "Goudra et al. Anesthesia for BronchoscopyAn Update. J. Clin. Med. 2024, 13, 6471". Goudra B, Sundararaman L, Chandar P, Green M. J Clin Med. 2025 Oct 30;14(21):7709. doi: 10.3390/jcm14217709.PMID: 41227105 Free PMC article. The Diagnostic Utility of Bilateral Bronchoalveolar Lavage Cellular Analysis for Interstitial Lung Disease: A Retrospective SingleCenter Study. El Fadel O, Roman J, Kramer D, Chandar P, Summer R, George G. J Bronchology Interv Pulmonol. 2026 Feb 20;33(2): e01059. doi: 10.1097/ LBR.0000000000001059. eCollection 2026 Apr 1. PMID: 41718447 No abstract available.

Hoag JB and Chan V. Cystic Fibrosis in the Young and Old: The Future is Precision Medicine. Journal of Precision Respiratory Medicine 2025: 8(1): 9-14. Transfusion of Fresh Frozen Plasma and Platelets in Critically Ill Adults: An American College of Chest Physicians Clinical Practice Guideline. Coz Yataco A, Soghier I, Hébert PC, Belley Cote E, Disselkamp M, Flynn D, Halvorson K, Iaccarino JM, Lim W, Lindenmeyer CC, Miller PJ, O’Neil K, Pendleton KM, Vande Vusse L, Ouellette DR. Chest. 2025 Sep;168(3):661–676. doi: 10.1016/j.chest.2025.02.029. Epub 2025 Mar 10. PMID: 40074060. Free PMC article. Review. Acquisition and Handling of Endobronchial Ultrasound Transbronchial Needle Samples: An American College of Chest Physicians Clinical Practice Guideline. Gilbert CR, Dust C, Argento AC, Feller Kopman D, Gonzalez AV, Herth F, Iaccarino JM, Illei P, O’Neil K, Pastis N, Rivera MP, Sholl L, Silvestri GA, Thiboutot J, Wahidi MM, Yasafuku K, Yarmus LB. Chest. 2025 Mar;167(3):899–909. doi: 10.1016/j.chest.2024.08.056. Epub 2024 Sep 27. PMID: 39343294.

Red Blood Cell Transfusion in Critically Ill Adults: An American College of Chest Physicians Clinical Practice Guideline. Coz Yataco AO, Soghier I, Hébert PC, Belley Cote E, Disselkamp M, Flynn D, Halvorson K, Iaccarino JM, Lim W, Lindenmeyer CC, Miller PJ, O’Neil K, Pendleton KM, Vande Vusse L, Ouellette DR. Chest. 2025 Feb;167(2):477–489. doi: 10.1016/j.chest.2024.09.016. Epub 2024 Sep 26. PMID: 39341492. Free PMC article. Review. George G, El Fadel O, Chandar P, Kramer D, Roman J, Summer R. "The Diagnostic Utility of Bilateral Bronchoalveolar Lavage Cellular Analysis for Interstitial Lung Disease: A Retrospective Single-Center Study." Journal of Bronchology and Interventional Pulmonology. January 2026. Venketasan B, Roman J, Kramer D. “Cardiac Sarcoidosis: A Concise Review of the Evolving Role of Diagnostic Imaging.” American Journal of Medical Sciences. November 2025. Adams P, Kramer D. “A Rare Case of Chilaiditi Syndrome as a Driver of Chronic Respiratory Failure. Respirology Case Reports. October 2025. Mangione S. Reply to Fanti and Ascolese's Letter-to-the-Editor re. "Did Jesus Die of Takotsubo Cardiomyopathy? A Medical Revisiting of the Gospels". 40(6):1457, J Gen Intern Med. 2025 May. Mangione S, Lockwood CJ. Aequanimitas for Our Time. Am J Med. 2025 May;138(5):767768. doi: 10.1016/j. amjmed.2024.11.036. Mangione S. The Fluff of Medicine: The Intangibles that Make the Difference. Pharos Alpha Omega Alpha Honor Med Soc. Summer 2025: 43-48. From Eyes to Airways: Comprehensive Imaging of

Department of Medicine 2025 Annual Report

51

N E W G R A N T S / CL I N I C A L T R I A L S SPONSOR: BOEHRINGER INGELHEIM PHARMACEUTICALS INC. DUKE UNIVERSITY Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype Prospective Outcomes (ILD-PRO) Registry PI: Summer

SPONSOR: VIZ.AI, INC. VIZCOPD03 A Multicenter Study of the Impact of a COPD Identification and Referral System on Patient Follow Up and Outcomes after an Acute COPD Exacerbation Resulting in an Emergency Department Visit or Hospitalization” PI: Summer

SPONSOR: BRISTOL-MYERS SQUIBB COMPANY. IM027068 A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis PI: Summer

SPONSOR: UNITED THERAPEUTICS CORP. RIN-PF-305 A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis (TETON-PPF) PI: Dr. Santibanez

SPONSOR: BRISTOL-MYERS SQUIBB COMPANY IM0271015 A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis PI: Summer

SPONSOR: TEMPUS AI, INC. TP-CA-008 MOMENTOUS study (Impact of an ECG AI Model on the Diagnosis of Pulmonary Hypertension) PI: George

SPONSOR: AVALYN PHARMA INC. AP01-007 A Placebo-Controlled Study of Inhaled Pirfenidone in Progressive Pulmonary Fibrosis PI: Summer SPONSOR: AVALYN PHARMA INC. AP-LTE-008 A Multinational, Long-Term, Open-Label Extension Study of Subjects Who Have Participated in Avalyn Pharma Studies of Inhaled Antifibrotic Agents (AP-LTE-008 [SAIL]) PI: Summer SPONSOR: TREVI THERAPEUTICS, INC. NAL03-301 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Chronic Cough in Participants with Idiopathic Pulmonary Fibrosis PI: Summer

SPONSOR: PURETECH LYT 100, INC. LYT-100-2025-301 A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults With Idiopathic Pulmonary Fibrosis (SURPASS-IPF) PI: George SPONSOR: ABBVIE INC. M25-268 Idiopathic Pulmonary Fibrosis: A Phase 2a Platform Study of Investigational Products for the Treatment of Adult Subjects PI: George SPONSOR: VERACYTE, INC. DHF-009-050 / Nightingale Clinical Utility of Management of Patients with CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab Classifier PI: Barta

SPONSOR: ASTRAZENECA. D5989C00001/THARROS A Study Evaluating the Efficacy of Breztri/Trixeo on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS PI: Barta SPONSOR: DELFI DIAGNOSTICS, INC. CASCADE-LUNG. Cancer Screening Assay using DELFI; A Clinical Validation Study in Lung PI: Barta SPONSOR: ASTRA ZENECA UK LIMITED. COPD IN LCS REGISTRY Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management PI: Barta SPONSOR: JEFFERSON HEALTH & EARLY COLLABORATION JH02025 Identification of lung cancer in never-smoking individuals using a non-invasive volatile organic compound (VOCs) biological platform with urine specimens PI: Barta SPONSOR: BOEHRINGER INGELHEIM INTERNATIONAL GMBH 1397-0014 A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY® Study) PI: Baig SPONSOR: REGENERON R668-COPD-2491 A randomized, double blind, placebo-controlled study comparing the efficacy of dupilumab to standard care (SOC) treatment following hospitalization for a severe COPD exacerbation. PI: Baig SPONSOR: SIONNA THERAPEUTICS SION-719-202 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of SION-719 In People with Cystic Fibrosis Dr. Hoag

SPONSOR: SANOFI US SERVICES, INC. ACT18301 A randomized, Phase 2, double-blind, placebo-controlled, parallel-group, 2-arm study to investigate the efficacy, safety, and tolerability of subcutaneous lunsekimig (SAR443765) in adult participants with high-risk asthma who are not currently eligible for biologic treatment PI: Pena SPONSOR: GSK 214579 Global Multicenter Observational Study to Prospectively Describe the Real-World Effectiveness of Depemokimab in Patients with Asthma with Type 2 Inflammation STRIDE-A PI: Pena SPONSOR: NIH THROUGH UNIVERSITY OF MARYLAND. CHILL FIXED PRICE Cooling to Help Injured Lungs (CHILL) Phase IIB Randomized Control Trial of Therapeutic Hypothermia in Patients with ARDS PI: Baram SPONSOR: SPECTRAL MEDICAL, INC. SDI-PMX-NA003 / TIGRIS TRIAL Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study PI: Baram SPONSOR: NS PHARMA, INC. NS863A-P2-01 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Arterial Hypertension (PAH) PI: Scharf SPONSOR: UNITED THERAPEUTICS CORP. ADP9811-301; ROR-PH-301 A Study Evaluating the Efficacy And Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients (ADVANCEoutcomes) PI: Scharf

Department of Medicine 2025 Annual Report

52 Eosinophilic Angiocentric Fibrosis. Mulkareddy V, Tuluc M, Scharf ML.Am J Respir Crit Care Med. 2025 Nov;211(11):2203-2205. doi: 10.1164/rccm.202409-1709IM. PMID: 40720827 Dupilumab Beyond the Airway: Decreased Morbidity in a RealWorld Analysis. Anisman EJ, Short S, Tam E, Bitner BF, Alani A, Rosen M, Rabinowitz M, Evertz DP, Toskala E, Nyquist GG. Int Forum Allergy Rhinol. 2026 Feb 6. doi: 10.1002/alr.70111. Online ahead of print. PMID: 41649402 Santibanez V, Mathur A, Zatakia J, Ng N, Cohen M, Bagiella E, Brown SA, Rosas IO, Patel NM, Olson A, Li P, Padilla M. Early nintedanib deployment in COVID-19 interstitial lung disease (ENDCOVI): study protocol of a randomised, double-blind, placebo-controlled trial. BMJ Open Respir Res. 2025 Apr 10;12(1):e002323. doi: 10.1136/bmjresp-2024-002323. PMID: 40216412. Santibanez V. Combined pulmonary fibrosis and emphysema: From radiology to reality - Rethinking progression and prognosis. Am J Med Sci. 2025 Feb 8: S0002-9629(25)00919-X. doi: 10.1016/j.amjms.2025.02.004. Epub ahead of print. PMID: 39929275. Santibanez, V., Patrawalla, P. Utilization of simulators, healthy volunteers, patients. Springer, “Echocardiography and Ultrasonography in the ICU: A Comprehensive Text”. August 2025 George, G., Santibanez, V., Summer, R., Roman, J., The Lung Mesenchyme. With Editors, Murray & Nadel's Textbook of Respiratory Medicine, Eighth Edition. Elsevier. 2025 Mulkareddy, V, Tuluc M, Scharf ML. From Eyes to Airways: Comprehensive Imaging of Eosinophilic Angiocentric Fibrosis. Am J Respir Crit Care Med 211, Iss 11: 2203-2205, 2025.

E Perez, G Grossman and ML Scharf. Impact of Inhaled Epoprostenol on ICU Length of Stay and Mortality When Used for Pulmonary Hypertension in a Single Academic Medical CCU and MICU. (Presented at the American College of Chest Physicians Meeting, Chicago, 2025).

Venkatesh A, Camacho D, Summer R, Dong M. New therapies, new challenges: Cystic lung disease after cancer immunotherapy. Respir Med Case Rep. 2026 Jan 2; 59:102356. doi: 10.1016/j.rmcr.2025.102356. Epub 2026. PMID: 41631188. Free PMC article.

E Perez, S Busarajan and ML Scharf. Physicians and Other Medical Specialists Spend Their “Pajama Time” Working After Hours in the Electronic Health Record. Am J Respir Crit Care Med 2025;211: A1448. (Presented at the American Thoracic Society Meeting, San Francisco, 2025).

Schonewald B, Xie C, Engel A, Summer R, Loizidis G. Chronic rhinosinusitis is a risk factor for interstitial lung disease in Sjogren's syndrome. BMC Pulm Med. 2025 Nov 10;25(1):515. doi: 10.1186/ s12890-025-03992-4. PMID: 41214590. Free PMC article.

Urinothorax and Empyema: Presentation of an Unusual Complication of a Rare Condition. Fox N, Fox N, Chakravorty S, Sinha N. Case Rep Pulmonol. 2025 Dec 17; 2025:5592208. doi: 10.1155/ crpu/5592208. eCollection 2025. PMID: 41476697 Regina Jung; Alicia Ali; Tricia Royer; Mollie Tucker; Neeraj Sinha. Therapeutic and pharmacokinetic challenges with treatment of non-tuberculous mycobacteria infection in a lung transplant recipient: a case series. Submission to Clinical Transplantation. Fox N, Fox N, Chakravorty S, Sinha N. Urinothorax and Empyema: Presentation of an Unusual Complication of a Rare Condition. Case Rep Pulmonol. 2025 Dec 17; 2025:5592208. doi: 10.1155/ crpu/5592208. PMID: 41476697; PMCID: PMC12752847 El Fadel O, Roman J, Kramer D, Chandar P, Summer R, George G. The Diagnostic Utility of Bilateral Bronchoalveolar Lavage Cellular Analysis for Interstitial Lung Disease: A Retrospective SingleCenter Study. J Bronchology Interv Pulmonol. 2026 Feb 20;33(2): e01059. doi: 10.1097/ LBR.0000000000001059. Epub 2026 Apr 1. PMID: 41718447. No abstract available.

Spritzer K, Roman J, Summer R, George G. High-flow oxygen therapy in ILD exacerbations: an imperfect therapy. Ann Am Thorac Soc. 2026 Feb 1;23(2):161–163. doi: 10.1513/AnnalsATS.202505526VP. PMID: 41134995. No abstract available. Engel A, Xie C, Summer R, Loizidis G. The risk of interstitial lung disease in psoriatic arthritis versus psoriasis: a retrospective nationwide database analysis (2014–24). Rheumatol Adv Pract. 2025 May 27;9(3):rkaf059. doi: 10.1093/rap/rkaf059. PMID: 40520447. Free PMC article. Basu A, Pommerolle L, Arif M, Meliton AY, Udofia I, Wu D, Mutlu GM, Gochuico BR, Summer R, Adegunsoye A, Burnham EL, Cinar R. Elevated blood anandamide levels in acute COVID-19 pneumonia with respiratory failure. Am J Med Sci. 2025 Sep;370(3):271–277. doi: 10.1016/j. amjms.2025.06.003. Epub 2025 Jun 4. PMID: 40480300. Free article. Fares J, El Fadel O, Zhao J, Sun J, Li M, Roman J, Loizidis G, Summer R. Response. Chest. 2025 Apr;167(4): e144–e145. doi: 10.1016/j.chest.2024.11.029. PMID: 40210324. No abstract available. Engel A, Summer R, Roman J. Hermansky-Pudlak Syndrome in the United States. Chest. 2025

NEW GRANTS / CL I N I C A L T R I A L S SPONSOR: NIH THROUGH UNIVERSITY OF MARYLAND. CHILL FIXED PRICE Cooling to Help Injured Lungs (CHILL) Phase IIB Randomized Control Trial of Therapeutic Hypothermia in Patients with ARDS PI: Baram SPONSOR: SPECTRAL MEDICAL, INC. SDI-PMX-NA003 / TIGRIS TRIAL Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study PI: Baram SPONSOR: NS PHARMA, INC. NS863A-P2-01 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Orally Administered NS-863 in Participants with Pulmonary Arterial Hypertension (PAH) PI: Scharf SPONSOR: UNITED THERAPEUTICS CORP. ADP9811-301; ROR-PH-301 A Study Evaluating the Efficacy And Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients (ADVANCEoutcomes) PI: Scharf

Department of Medicine 2025 Annual Report

53 Moriarty JM, Schiro BJ, Dohad SY, Tamaddon H, Davis HC, Shavelle DM, Chrysant GS, Iliadis EA, Dexter DJ 2nd, Ciampi Dopazo JJ, Holden A, West FM, Keeling B, Sharp ASP, Weinberg I. Periprocedural Results and Right Ventricular Outcomes of Computer Assisted Vacuum Thrombectomy Treatment of Acute Pulmonary Embolism: Interim Analysis of 300 Patients From the STRIKE-PE Study. J Am Heart Assoc. 2025;14(17): e039975. doi:10.1161/ JAHA.124.039975 I participated in research activity planning and critical revision of the article. Baig SH, Lee JD, Yoo EJ. Patient outcomes after interhospital transfer: the impact of early intensive care unit upgrade. Hosp Pract (1995). 2025 Feb;53(1):2470107. PMID 40015954. Betti S, Bell H, Glatt J, Yoo EJ, Oxman DA. An analysis of exposure keratopathy cases to promote changes in eye care practice in intensive care units. Am J Medical Quality. 2025 Apr 25. PMID 40279241. Kazi AW, Chun P, Oxman D, Yoo EJ. Surrogate trust in the intensive care unit: What can we do better? Healthcare. 2025 May 20;13(10):1189. PMID 40428025. Chun P, Perez E, Cheung M, Treacy T, Zahustecher N, Mohammed R, McDonough G, Mallozzi M, George BJ, Yoo EJ. Reason for intubation and development of ventilator associated events in a medical intensive care unit: the impact of pulmonary versus non-pulmonary causes of intubation. Resp Care. 2025 May 21. PMID 40397655. Brill-Edwards M, Hamilton WC, Yoo EJ, Costello J, Koenig GJ, Cohen MJ, Marks JA. Angioedema: Is ICU admission warranted? A single institution assessment. J Crit Care Med (Targu Meres). 2025 Jul 31;11(3):240-46. PMID 40765548.

Jul;168(1):156–159. doi: 10.1016/j. chest.2025.01.022. Epub 2025 Jan 31. PMID: 39892717. No abstract available. Fares J, El Fadel O, Zhao J, Li M, Sun J, Roman J, Loizidis G, Summer R. Mortality and Health Outcomes Among Patients with Sarcoidosis Treated with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Chest. 2025 Mar;167(3):772–780. doi: 10.1016/j. chest.2024.09.009. Michalec B, Papanagnou D, Raj L, Lundgren H, Watkins KE, Marsick VJ, Ziring D, Vaid U. Exploring the presence and roles of humility when experiencing situations of uncertainty. AEM Educ Train. 2025;9: e11055. https://doi. org/10.1002/aet2.11055 Dong M, Uricheck J, Vaid U. Pulmonopoly: A GameBased Approach to Teach and Reinforce Basic Concepts of Pulmonary Medicine to Medical Students". MedEdPORTAL. 2025 Feb 21; 21:11493. doi: 0.15766/ mep_2374-8265.11493. eCollection 2025.PMID: 39991754 Fernandez A, Asoodar M, Laynor G, Peedin A, Ratliff JB, Vaid U, Karmarkar SA, Sur M, van KranenMastenbroek V, Papanagnou D, Majoie MHJM, Balmer DF, Thammasitboon S. Education Research: EEG Instruction: Findings from a Scoping Review. Neurol Educ. 2025 Oct 24;4(4): e200255. doi: 10.1212/ NE9.0000000000200255. PMID: 41169758; PMCID: PMC12570072. Patrawalla P, West FM, Ramesh N, Mayo P, Sodhi A. Best Practices for a Competencybased Curriculum in Critical Care Ultrasonography for Fellows. ATS Sch. 2025;6(2):149-161. doi: 10.34197/ats-scholar.20240088PS I participated in activity planning and execution, drafting and critical revision of the article.

Moriarty JM, Schiro BJ, Dohad SY, Tamaddon H, Davis HC, Shavelle DM, Chrysant GS, Iliadis EA, Dexter DJ 2nd, Ciampi Dopazo JJ, Holden A, West FM, Keeling B, Sharp ASP, Weinberg I. Periprocedural Results and Right Ventricular Outcomes of Computer Assisted Vacuum Thrombectomy Treatment of Acute Pulmonary Embolism: Interim Analysis of 300 Patients From the STRIKE-PE Study. J Am Heart Assoc. 2025;14(17): e039975. doi:10.1161/ JAHA.124.039975 I participated in research activity planning and critical revision of the article. Baig SH, Lee JD, Yoo EJ. Patient outcomes after interhospital transfer: the impact of early intensive care unit upgrade. Hosp Pract (1995). 2025 Feb;53(1):2470107. PMID 40015954. Betti S, Bell H, Glatt J, Yoo EJ, Oxman DA. An analysis of exposure keratopathy cases to promote changes in eye care practice in intensive care units. Am J Medical Quality. 2025 Apr 25. PMID 40279241. Kazi AW, Chun P, Oxman D, Yoo EJ. Surrogate trust in the intensive care unit: What can we do better? Healthcare. 2025 May 20;13(10):1189. PMID 40428025. Chun P, Perez E, Cheung M, Treacy T, Zahustecher N, Mohammed R, McDonough G, Mallozzi M, George BJ, Yoo EJ. Reason for intubation and development of ventilator associated events in a medical intensive care unit: the impact of pulmonary versus non-pulmonary causes of intubation. Resp Care. 2025 May 21. PMID 40397655. Brill-Edwards M, Hamilton WC, Yoo EJ, Costello J, Koenig GJ, Cohen MJ, Marks JA. Angioedema: Is ICU admission warranted? A single institution assessment. J Crit Care Med (Targu Meres). 2025 Jul 31;11(3):240-46. PMID 40765548.

Department of Medicine 2025 Annual Report

DIVISION OF RHEUMATOLOGY

55

FACU LT Y

The Division of Rheumatology at Thomas Jefferson University stands as one of the region's most distinguished academic rheumatology programs, with 67 years of dedicated service to patients living with complex systemic autoimmune disorders. Over nearly seven decades, the Division has cultivated a culture grounded in clinical excellence, scholarly inquiry, and a deep commitment to advancing the care of patients with some of medicine's most challenging conditions. The faculty's commitment to multidisciplinary engagement is reflected in the structure of its clinics, its educational partnerships, and research portfolio. The transition to Honickman Center for Multidisciplinary Care marked a transformative milestone, providing a modern, purposebuilt environment in which rheumatology patients, fellows, faculty, nurse practitioners, nurses, and ancillary staff can thrive together.

C L I N I C A L E XC E L L E N C E The Division's clinical program is defined by depth and specificity. The faculty has developed a robust program of specialized clinics that address the nuanced needs of patients with rare and complex autoimmune diseases. These clinics are recognized by both referring clinicians and patients as centers of expertise — drawing trainees seeking learning opportunities and patients seeking efficient, expert, and accessible care.

SPECIALIZED CLINICS — CENTER CITY (HONICKMAN BUILDING) Scleroderma Clinic: Directed by Dr. Fabian Mendoza, offering comprehensive management of systemic sclerosis and its multiorgan manifestations.

Systemic Lupus Erythematosus (SLE) Clinic: Directed by Dr. Marianthi Kiriakidou, providing expert longitudinal care for patients with lupus. Neuro-Ocular Inflammatory Disease Clinic: This is the only clinic of this kind in Philadelphia. Dr. Chantel Park provides specialized outpatient consultative care for rare inflammatory conditions affecting the eye and central nervous system. Dr. Park also directs a multidisciplinary quarterly conference uniting rheumatology, ophthalmology, neurosurgery, neurology, neuroradiology, and neuropathology. Interstitial Lung Disease in Connective Tissue Disorders (ILD-CTD) Clinic: Codirected by Dr. Timothy Wilson (Rheumatology) and Drs. Ross Summer and Gautam George (Pulmonary Medicine), exemplifying the Division's model of seamless cross-specialty collaboration. Integrative Medicine Clinic: Dr. Yiu Tak Leung (one of the few dual board-certified in rheumatology and integrative medicine physicians in the United States), offers a uniquely holistic perspective on autoimmune disease management. Rheumatology-Dermatology Collaborative Clinic: A first in Philadelphia, monthly

multidisciplinary clinic codirected by Dr. Andres Ponce and Dr. Sherry Yang (Dermatology), with participation from Dr. Fabian Mendoza and Dr. Sweta Subhadarshani(Dermatology), addressing the cutaneous manifestations of autoimmune disease.

COMMUNITY OUTREACH LOCATIONS Beyond Center City, the Division extends its reach through satellite locations fully integrated into multispecialty practices. At Bala Cynwyd, Drs. Yiu Tak Leung, Fabian Mendoza, and Chantel Park provide both general and specialized rheumatology care. At the Navy Yard, Drs. Amanda Nussdorf, Andres Ponce, and Marta Bean deliver accessible, high-quality outpatient rheumatology services to a broader patient population.

E D U C AT I O N & M E N TO R S H I P Under the direction of Dr. Andres Ponce, the Rheumatology Fellowship Program continues to attract highly qualified candidates, training two fellows per year in a rigorous and supportive learning environment. The program's consistent success in recruitment reflects the strength of faculty mentorship

Marianthi Kiriakidou, MD Associate Professor of Medicine Associate Fellowship Program Director Division Director

Marta Bean, MD Clinical Assistant Professor Yiu Tak Leung, MD, PhD Clinical Assistant Professor of Medicine Michele Meltzer, MD Clinical Associate Professor, Adjunct Fabian Mendoza, MD Associate Professor of Medicine Amanda Nussdorf, MD Clinical Assistant Professor Chantel Park, MD Clinical Assistant Professor Andres Ponce, MD Clinical Assistant Professor Fellowship Program Director Stavros Savvas, MD Clinical Assistant Professor Timothy Wilson, MD Assistant Professor of Medicine

Department of Medicine 2025 Annual Report

56 and the breadth of clinical and scholarly opportunities available to trainees.

offering trainees, residents, and students meaningful pathways to scholarly contribution.

The Division's educational reach extends well beyond fellowship training. Faculty members teach and mentor medical students, Internal Medicine residents, and residents rotating through Women's Health specialties. Participating in Jefferson's Jeff MD curriculum and the Internal Medicine subspecialty lecture series, the faculty ensure that the next generation of physicians receives a strong foundation in rheumatological disease. Dr. Chantel Park's membership on the core team of Jeff MD instructors reflects the Division's investment in undergraduate medical education at the highest level.

Fabian Mendoza MD

Notably, the Division supports Jefferson's international collaboration with the Università Cattolica del Sacro Cuore MD International Program in Rome. In 2024 and 2025, rotating students from Italy joined the Division, a step that broadens the program's global educational impact and fosters cross-cultural academic exchange. Rotating internal medicine residents and medical students gain exposure to a broad spectrum of inpatient and outpatient rheumatology cases and are actively encouraged to participate in research projects, ensuring that scholarly engagement begins early in their training. Dr. Bean and Dr. Nussdorf coorganized the first musculoskeletal ultrasound introductory course for rheumatology fellows in our Program.

R E S E A RC H Research activity within the Division spans translational science, clinical investigation, and quality improvement —

•

Cinical Collaborative Research Ultrasound assessment of microvasculature disease in Systemic Sclerosis-related Raynaud's phenomenon Respiratory weakness in scleroderma; ultrasound assessment of peripheral arteries in SSc Clinical trials in systemic sclerosis, funded from pharmaceutical companies and foundations

osteoporosis prevention in high-risk patients. These efforts reflect a commitment not just to clinical care, but to measurable, system-level improvement in patient outcomes. Current quality improvement efforts are advancing under the leadership of Dr. Marta Bean, with an ongoing focus on osteoporosis prevention and the safe management of high-risk medications and the monitoring for cardiovascular risk factors in patients treated with high risk immune modulators. Fellows are active participants in these projects, ensuring that the culture of continuous improvement is embedded from the earliest stages of training.

Timothy Wilson MD

S C H O L A R LY AC T I V I T Y •

Biomarkers in Rheumatoid Arthritis-Associated Interstitial Lung Disease

•

Biomarkers in Preclinical Rheumatoid Arthritis

•

Temporal artery biopsy descriptive cohort: investigating clinical and serologic differences in patients with positive versus negative biopsies at Jefferson.

•

Dermatomyositisassociated ILD descriptive cohort (multi-institutional collaboration).

•

Nailfold capillaroscopy in non-scleroderma CTD-ILD and interstitial pneumonia with autoimmune features

Q UA L I T Y I M P R OV E M E N T The Division maintains an active and faculty-engaged quality improvement program. Past initiatives have addressed disease activity monitoring in Lupus and Rheumatoid Arthritis, smoking cessation counseling in Rheumatoid Arthritis, and

The following peer-reviewed publications and meeting abstracts were authored or coauthored by Division faculty and fellows during this period.

PEER-REVIEWED PUBLICATIONS Jimenez SA, Mendoza FA, PieraVelazquez S. A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways. Front Immunol. 2025 Apr 16;16:1551911. Doi: 10.3389/fimmu.2025.1551911. PMID: 40308583.

MEETING ABSTRACTS — ACR CONVERGENCE 2025 Perdomo W, Welch S, Wilson T. Diagnostic Utility of Temporal Artery Biopsy in Giant Cell Arteritis: A Single Center Experience. Arthritis Rheumatol. 2025;77(suppl 9). Abstract 0763. Thomas Jefferson University, Philadelphia, PA. Mendoza F, Perdomo W, Wilson T, Jimenez S. Respiratory Muscle Weakness in a Systemic Sclerosis Cohort. Arthritis Rheumatol.

N OTA B L E ACH I E V E M E N T S 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025 Philadelphia Magazine Top Doctors MARIANTHI KIRIAKIDOU, MD 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025 Castle Connolly Top Doctors MARIANTHI KIRIAKIDOU, MD 2024, 2025 Castle Connolly Top Doctors ANDRES PONCE MD 2019, 2020, 2021, 2022, 2023, 2024, 2025 Exceptional Women In Medicine MARIANTHI KIRIAKIDOU, MD

Department of Medicine 2025 Annual Report

57 2025;77(suppl 9). Abstract 2480. Thomas Jefferson University, Philadelphia, PA.

CO N C LU S I O N In summary, the Division of Rheumatology at Thomas Jefferson University brings together a faculty with broad expertise in autoimmune disease, a commitment to trainee development, and an active research program. Across its clinical, educational, and scholarly activities, the Division continues to build on a 67-year history of service to patients and the academic medicine community. From the highly specialized clinics serving patients with rare autoimmune diseases, to the fellows mentored into the next generation of academic rheumatologists, to the translational research advancing the understanding of systemic sclerosis and interstitial lung disease — the Division embodies what a modern, mission-driven academic rheumatology program can be.

Department of Medicine 2025 Annual Report

CENTER FOR TRANSLATIONAL MEDICINE

59

FACU LT Y Deepak Deshpande, PhD

On July 1st, 2023, Deepak Deshpande was named Director of the Center, replacing Raymond Penn, who remains in his role as Vice-Chair of Research in the Department of Medicine. During FY 2025, Dr. Elham Javed was promoted to Research Instructor. Most research and educational opportunities remain the same in the Center for Translational Medicine since the last report. Since the development of the new medical school curriculum, opportunities for teaching medical school students have been limited, although teaching in the new Molecular Physiology and Translational Medicine graduate school programs has increased.

Extramural Research Grant Funding FY13 - FY26 $7,000,000

$6,000,000

$5,000,000

$4,000,000

$3,000,000

$2,000,000

$1,000,000

$0

FY13

FY14

FY15

FY16

FY17

FY18

Directs

FY19

FY20

FY21

FY22

ICD's

FY23

FY24

FY25

FY26

Professor Director, Center for Translational Medicine

Tung Chan, PhD Research Assistant Professor Seo-Hee Cho, PhD Associate Professor Jason Choi, PhD Assistant Professor Boopathi Ettickan, PhD Assistant Professor Ajay Nayak, PhD Assistant Professor Tonio Pera, PhD Assistant Professor Shey-Shing Sheu, PhD William Wikoff Smith Professor of Cardiovascular Research Ross Summer, MD Professor Jianxin Sun, PhD Professor Mudit Tyagi, PhD Associate Professor Bin Wang, PhD Associate Professor Elham Javed, PhD Research Instructor

Department of Medicine 2025 Annual Report

60 E D U C AT I O N Dr. Deshpande teaches in the SKMC JeffMD program while Drs. Penn, Pera, Wang, Choi, Ettickan, Tyagi and Chan teach multiple classes in different graduate programs. Drs. Penn, Deshpande, Pera, Nayak, Choi, and Chan are founding faculty in the Integrative Physiology graduate program and will be directing courses and lecturing in the coming year. Due to our research success, we continue to attract excellent graduate students and Postdoctoral Fellows. We currently have five graduate students, three Research Associates and four Post-doctoral Fellows. We are confident that this robust graduate and post-graduate training will continue. Moreover, our faculty members are actively participating in our school’s teaching for medical and graduate students. In summary, we continued to succeed in achieving our research and education missions of the department. It is our goal to further build the Center for Translational Medicine in the coming years to maintain and enhance our international reputation as leaders in translational research.

I N S T I T U T I O N A L S E RV I C E Drs. Deshpande, Ettickan, and Chan are serving on TJU’s Institutional Committee on Animal Care and Use committee. Drs. Deshpande and Nayak are serving on the Committee of Admission (JeffMD) Drs. Nayak, Choi and Deshpande are involved in Committee of Admission for various graduate programs.

P U B L I C AT I O N S Shah SD, Deshpande DA. Biased Orthosteric Agonism and Allosteric Modulation: Emerging Strategies for Developing New Class of β-Agonists for Obstructive Airway Diseases. Am J Respir Cell Mol Biol. 2025 Oct;73(4):489-499. Conaway S Jr, Richard J, Deshpande DA. Spatiotemporal calcium signaling patterns underlying opposing effects of histamine and TAS2R agonists in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2025 Jul 1;329(1): L70-L83. Jayaram A, Galande S, Sharbati S, Deshpande D, Pawar K. Profile of tRNA-derived short noncoding RNAs during monocyte differentiation and their role in macrophage survival. RNA Biol. 2025 Dec;22(1):1-9. Nayak AP. E3 Ubiquitin Ligases and Asthma Relief. Am J Respir Cell Mol Biol. 2025 Oct 10:10.1165/rcmb.2025-0532ED. Villalba DR, Jannu AK, Javed E, Dandekar I, Wang R, Deshpande DA, An SS, Panettieri RA Jr, Tang DD, Penn RB, Nayak AP. Ovarian Cancer G proteincoupled receptor-1 signaling bias dictates anti-contractile effect of benzodiazepines on airway smooth muscle. Respir Res. 2025 May 13;26(1):183 Jannu AK, Penn RB. Channeling Relaxation through Multiple Means: TMEM16A Antagonism for Asthma. Am J Respir Cell Mol Biol. 2025 May;72(5):466-468. Villalba DR, Jannu AK, Javed E, Dandekar I, Wang R, Deshpande DA, An SS, Panettieri RA Jr, Tang DD, Penn RB, Nayak AP. Ovarian Cancer G proteincoupled receptor-1 signaling bias dictates anti-contractile effect of benzodiazepines on airway smooth muscle. Respir Res. 2025 May 13;26(1):183

Chen M, Cui M, Yang Y, Wang B. Stage-dependent effects of moderate treadmill exercise on cartilage preservation and subchondral bone remodeling in mouse osteoarthritis progression. Osteoarthritis Cartilage. 2025 Dec;33(12):14541464. doi: 10.1016/j. joca.2025.08.014. Epub 2025 Sep 4. PubMed PMID: 40914549. (Impact factor: 9.0) Jhun BS, O-Uchi J, Rhee B, Ahrari A, DeMichaelis N, Jeon KI, Booth DM, Sheu SS. Sarcoplasmic ReticulumMitochondria Microdomains: Hugging and Kissing in the Heart. Am J Physiol Cell Physiol. 329(2):C599-C610, 2025. Eyenga P, Sheu SS. Nitric Oxide Does Not Improve Liver Mitochondrial Function 48 Hours Antioxidants, Volume 14, Issue 7, 868, 2025. Fernandez-Sanz C, De la Fuente S, Nichtova Z, Ferderico M, Duvezin-Caubet S, Lanvermann S, Tsai HY, Xin Y, Csordas G, Wang W, Mourier A, and Sheu SS. Highly Oligomeric DRP1 strategic positioning at MitochondriaSarcoplasmic Reticulum Contacts in Adult Murine Heart through ACTIN anchoring. Cells, 14(16):1259, 2025. Sergio De la Fuente, SheyShing Sheu, Celia FernandezSanz. Sarcoplasmic reticulummitochondria contacts: impact on cardiac physiology and mitochondrial fitness. Cells, 11;14(22):1762, 2025. Gisela Beutner, Huoy-Jen Yuh, Ilan Goldenberg, Douglas C Wallace, George A Porter Jr, Arthur J Moss, Shey-Shing Sheu. Low magnetic fields stimulate cardiac mitochondrial bioenergetics with a bell-shaped response: Possibly via a radical pair mechanism. Computational and Structural Biotechnology Journal, 30:144, 2025.

N OTA B L E ACH I E V E M E N T S DEEPAK DESHPANDE, PHD Chosen to serve as a standing member of the Pulmonary Injury, Repair and Remodeling (PIRR) study section RAYMOND PENN, PHD Awarded the P01 in September 2025 JIANXIN SUN, PHD Dr. Xiujuan Zhang from Dr. Sun’s Lab won the travel award from the American Heart Association AJAY NAYAK, PHD Appointed Chair of the Allergic Fungal Respiratory Diseases Committee, American Academy of Allergy, Asthma and Immunology

Department of Medicine 2025 Annual Report

61 Mudit Tyagi, Ulhas Naik, Kratika Tyagi, Madhulika Sharma, Gagan Kaushal, Alok Bhushan, Michael Bukrinsky, and Priya Tyagi; HIV Infection, Neurotoxicity, Inflammation, Premature Aging, and Therapeutic Challenges to PLWH: An Overview. Int. J. Mol. Sci. 2026, 27(5), 2192; https://doi. org/10.3390/ijms27052192 Sharma AL, Zhu E, Padyala R, Parikh K, Tyagi M; Protocol for nucleo-cytoplasmic fractionation of mammalian cells to study protein translocation via immunoblotting. Star Protoc. 2025 Dec 10;6(4):104265. doi: 10.1016/j.xpro.2025.104265. Online ahead of print. PMID: 41379621, DOI: 10.1016/j. xpro.2025.104265. Mackenzie Thornton, Nicole Sommer, Mercedes McGonigle, Anil Kumar Ram, Sireesha Yerrathota, Henrietta Ehirim, Aakriti Chaturvedi, Johnny Dinh Phan, Anubhav Chakraborty, Praveen V Chakravarthi, Sumedha Gunewardena, Mudit Tyagi, Jaya Talreja, Tao Wang, Pravin Singhal, Pamela V Tran, Timothy A Fields, Patricio E Ray, Navneet K Dhillon, Madhulika Sharma; Notch3 deletion regulates HIV-1 gene expression and systemic inflammation to ameliorate chronic kidney disease. Disease Model Mech. 2025 Feb 1;18(2): DMM052056. PMID: 39910908, PMCID: PMC11892680, DOI: 10.1242/dmm.052056, Epub 2025 Feb 25. Sikder K, Phillips E, Bouhrira N, Mothy D, Wang N, Bonne G, Margulies KB, Choi JC. Cardiac fibroblasts counterbalance cardiomyocytes in LMNA cardiomyopathy pathogenesis. bioRxiv [Preprint]. 2025 Jul 21:2025.06.05.657412. doi: 10.1101/2025.06.05.657412. PMID: 40692701

Choi JC. Perinuclear organelle trauma at the nexus of cardiomyopathy pathogenesis arising from loss of function LMNA mutation. Nucleus. 2025 Dec;16(1):2449500. doi: 10.1080/19491034.2024. 2449500.

NEW GRANTS RAYMOND PENN, PHD 1PO1HL180318 (PI: Raymond Penn Project PI: Deepak Deshpande) 9/20/2025-7/31/2030 Direct Cost $2,022,438 Total Costs $2,456,717 Title: Exploiting emerging ideas in G protein-coupled receptor biology and pharmacology to treat asthma The overall goal is to use new concepts of signaling such as biased agonism, allosteric modulation, and selective inhibition/activation, to identify new drug targets and molecules to treat asthma. JIANXIN SUN, PHD 1R01HL179441-01A1 (PI: Sun, scored: 6%) 04/01/2026 – 3/31/2031 Title: Role of isoAsp-induced protein damage in diabetic angiogenesis The overall goal of this proposal is to investigate protein aging in diabetes and delayed wound healing, and to explore novel therapeutic approaches that target protein repair to enhance angiogenesis.

Department of Medicine

GRADUATE MEDICAL EDUCATION PROGRAMS IN INTERNAL MEDICINE

2025 Annual Report

63

FACU LT Y Christopher Henry, MD

The Department of Medicine is poised to train both academic and practice leaders through advanced clinical training and active mentorship provided by an outstanding clinical and research faculty. Currently, the Department trains 129 residents and over 50 subspecialty fellows. The program focuses on outstanding clinical training, but there is particular emphasis on training future clinician educators, clinical researchers, physician-scientists, as well as practicing physicians for the community.

M I S S I O N S TAT E M E N T Our mission is to provide excellent training in Internal Medicine for physicians planning careers in General Internal Medicine practice, careers in Academic Medicine, or further training in a Medical Subspecialty. Our graduates shall possess clinical skills and knowledge, professional attitudes and behaviors, humanistic qualities, and a commitment to lifelong learning that is characteristic of the highest caliber Internist and Medical Specialist.

G OA L S • To train superior Internists for the 21st century. • To assist our trainees in their transition to practice, fellowship, or further education. • To serve as an educational leader – promoting high quality, innovative approaches to training in Internal Medicine. • To serve our patients, the Jefferson community, and the citizens of Philadelphia and the surrounding region with competent, equitable, inclusive, and compassionate healthcare. • To ensure quality care through measurement, advocacy,

advances in systems of care, and excellence. • To educate the students who rotate through the Department providing a sound fundamental experience in Internal Medicine.

R E S I D E N C Y - OV E RV I E W A N D R EC R U I TM E N T The core mission of the Internal Medicine Residency Program at Thomas Jefferson University Hospital is superior training in Internal Medicine. It is our intent that each resident acquires the requisite clinical skills and medical knowledge, professional attitudes and behaviors, approach to problem solving, and concern for their patients that is characteristic of an Internist. We recognize that our graduates will be providing medical care in the local community and across the country for the first half of the 21st Century. As a result, our goals include developing sound approaches to educating future Internists, emphasizing excellence, and dedication to the patients whom we serve. Most of the residents’ experience occurs at Thomas Jefferson University Hospital. It is here that each resident has the opportunity to work with our nationally recognized faculty in the inpatient and outpatient arenas and develop continuity care skills in the Jefferson Hospital Ambulatory Practice (JHAP), Jefferson Women’s

Primary Care, or Jefferson Internal Medicine Associates (JIMA). Selected rotations at affiliated hospitals broaden the residents’ experiences beyond tertiary care. Residents have the opportunity to develop skills in research via outstanding mentorship, elective opportunities, and certificate programs. As an academic program, the interns and residents not only learn via excellent teaching but also learn to become teachers themselves. Through informal discussions and a formal teaching skills seminar, our residents develop proficiency as educators to further enhance their preparation for academic medicine or clinical practice, where education of patients and families is a major goal. Furthermore, we have a dedicated medical education pathway with more robust instruction and opportunity for those interested in becoming clinical educators. We also have pathways within the residency for Hospital Medicine, Health System Science, Women’s Health, and Disability Care, which allow our residents to attain more specific skills, experience, and mentorship, if they wish. The success of our program has been reflected in the remarkable increase in interest in the program that has developed over the last decade.

Program Director, Internal Medicine Residency

Dianna Cheney-Peters, MD Sub-Internship Course Director Christie Crawford, MD Associate Program Director Rebecca Davis, MD Associate Program Director for Primary Care Residency Gretchen Diemer, MD Vice Chair for Education Associate Dean for GME and Affiliations Director, Internal Medicine Residency Education Elective Timothy Kuchera, MD Associate Program Director Course Director, Hospitalist Medicine Elective Albert Lee, MD Associate Program Director Jason Ojeda, MD Associate Program Director Primary Care Track Program Director Barbara Simon, MD Associate Program Director Jennifer Valentine, MD Associate Program Director JeffMD: Phase 3 Medicine Pathway Director Alexis Wickersham, MD Associate Program Director Jillian Zavodnick, MD Associate Program Director Clerkship Director

Department of Medicine 2025 Annual Report

64 APPLICANT STATISTICS Recruitment Season

US Applicants

Total Applicants

Positions/Matched Applicants

Mean USMLE Scores

2001-2002

759

2186*

37

220

2002-2003

833

2480*

37/37

217

2003-2004

908

2894*

35

217

2004-2005

932

2822

37/37

216

2005-2006

957

3521

38/38

220

2006-2007

965

3560

39/39

211

2007-2008

1042

3793

39/39

219

2008-2009

1114

4561

36/36 (3 outside)

214

2009-2010

1156

4607

39/38 (1 outside)

222

2010-2011

1339

4855

39/39

228

2011-2012

1483

4501

36/36 (3 outside)

228

2012-2013

1771

4649 (5114 w/SOAP)

39/38 (1 outside)

234

2013-2014

1787

4937

39/39

235

2014-2015

2039

4902

39/39

235

2015-2016

2514

4602

37/37

235

2016-2017

2660

4577

37/37

241

2017-2018

1760

3097

37/37

238

2018-2019

2283

4409

37/37

241

2019-2020

2268

4409

37/37

239

2020-2021

2102

3284

37/37

239

2021-2022

2323

3332

37/37

244

2022-2023

2371

3586

37/37

239

2023-2024

2472

3669

37/37

256 (Step 2)

2024-2025

2227

3301

37/37

258 (Step 2)

*Includes Combined Categorical/Preliminary Applicants

Department of Medicine 2025 Annual Report

65 MATCH RESULTS: RANKED & MATCHED APPLICANTS Recruitment Year

Available Positions

Total Ranked

Highest/Lowest Matched

1995

36

284

10/181

1996

36

318

1/190

1997

38

264

1/248

1998

38

343

16/264

1999

37

342

43/DNF

2000

37

347

18/237

2001

37

484

15/360

2002

37

315

27/232

2003

37

346

5/318

2004

37

345

7/265

2005

38

382

2/249

2006

39

344

8/316

2007

39

396

25/311

2008

36 (3 taken outside Match)

391

30/318

2009

38 (1 taken outside Match)

400

9/301

2010

39

410

40/377

2011

36 (3 taken outside Match)

403

15/337

2012

38 (1 taken outside Match)

393

20/254

2013

39

394

9/216

2014

39

419

6/229

2015

39

419

16/259

2016

37

466

44/374 (*337 without Primary Care)

2017

33 Categorical; 4 Primary Care

515; 74

34/302 (Categorical); 15/33 (Primary Care)

2018

33 Categorical; 4 Primary Care

522; 67

19/332 (Categorical); 20/37 (Primary Care)

2019

33 Categorical; 4 Primary Care

531; 73

42/301 (Categorical); 1/16 (Primary Care)

2020

33 Categorical; 4 Primary Care

494; 69

44/256 (Categorical); 8/35 (Primary Care)

2021

33 Categorical; 4 Primary Care

498; 66

57-232 (Categorical); 1/26 (Primary Care)

2022

33 Categorical; 4 Primary Care

499; 72

12-252 (Categorical); 35/47 (Primary Care)

2023

33 Categorical; 4 Primary Care

506; 72

8-223 (Categorical); 26/66 (Primary Care)

2024

33 categorical; 4 Primary Care

490; 63

23-252 (Categorical); 22-32 (Primary Care)

2025

33 Categorical; 4 Primary Care

489; 59

4-237 (Categorical); 16-23 (Primary Care)

Department of Medicine 2025 Annual Report

66 WHERE OUR RESIDENTS COME FROM: 1997-2025 MEDICAL SCHOOLS # of Medical Students (1127)

% of Medical Students

State or Province

479

42.50%

Pennsylvania

174

15.43%

New Jersey

124

11.00%

New York

45

4%

Virginia

44

3.9%

International Medical Graduates

43

3.81%

Washington DC

29

2.57%

Florida

25

2.21%

Massachusetts

23

2.04%

Maryland

19

1.68%

Ohio

16

1.41%

Illinois

12

1.06%

Louisiana

10

.88%

Texas

8

.70%

California

7

.62%

North Carolina, Nebraska, Michigan

6

.53%

Connecticut

5

.44%

Tennessee, Souith Carolina

4

35%

Georgia

3

.26%

Kansas, Kentucky, Puerto Rico

2

.17%

Arkansas, Indiana, Missouri, New Mexico, Oklahoma, Rhode Island, Wisconsin, Vermont, Canada

1

.08%

Arizona, Hawaii, Minnesota, New Hampshire, Oregon, Utah, Idaho

Department of Medicine 2025 Annual Report

67 DEPARTMENT SPONSORED FELLOWSHIPS

NonACGME Approved Positions

Hematologic Malignancies CTCL Fellowship

1

GastroenterologyAdvanced Endoscopy / Inflammatory Bowel Disease

2

Heart Failure

1

ID/Pandemic Preparedness

1

POCUS

2

Transplant Nephrology

1

FELLOWSHIP

ACGME Approved Positions

Cardiology

24

Critical Care

1

Heart Failure

1

Interventional Cardiology

2

Electrophysiology (3 approved positions)

2

Endocrinology

4

Gastroenterology

12

Pulmonary/ Critical Care

15

Transplant Hepatology

2

Infectious Diseases

6

Nephrology

8

Oncology and Hematology

24

Rheumatology

2

F E L LOW S H I P S The Department sponsors ACGME approved fellowships in all the subspecialties in Medicine providing for the demand for subspecialists in both academic and community practice environments.

senior-year students, Dr. Jennifer Valentine oversees student elective experience within the department, supporting a variety of faculty members who direct individual courses.

M A J O R I N I T I AT I V E S I N VO LV I N G T H E T E AC H I N G P R O G R A M

STUDENT PROGR AMS Dr. Jillian Zavodnick acts as the Clerkship Director for Internal Medicine. The medicine clerkship lasts 8 weeks and shares a 12-week block with the neurology clerkship. Internal Medicine didactics run throughout the 12-week block and are attended by students on neurology as well as internal medicine. The medicine clerkship consists of two four-week rotations, one at the central Thomas Jefferson University Hospital campus and one at an affiliate site. These rotations are completed on general medicine and subspecialty services. At the end of the rotation, students are assessed by their clinical supervisors using an evaluation of clinical performance; with an Observed Structured Clinical Encounter which emphasizes information-gathering, data synthesis, differential-building and patient communication; and with a shelf exam. With a robust clinical curriculum, students learn to evaluate patients with a broad array of medical problems and develop clinical reasoning skills that will be beneficial to their development as physicians, regardless of their career path. Moreover, students encounter positive role models who reinforce the professional values that internists hold as vital to the practice of medicine. Dr. Dianna Cheney-Peters leads the Sub-Internship program as the Director. As the Director of the Medicine Pathway for

AMBULATORY TRAINING Jefferson continues to distinguish itself through outstanding ambulatory training in continuity and block rotation settings. The majority of residents are assigned to the JHAP or JIMA offices. JHAP is a Level 2 patient centered medical home (PCMH) that cares for mostly an underserved population. JIMA is a Level 3 PCMH which is also home to the Jefferson Internal Medicine Faculty Practice. Both JHAP and JIMA have a strong relationship with the Jefferson School of Pharmacy, ensuring an interprofessional approach to the management of patients with diabetes, anticoagulation, and complex medication regimen management. The Jefferson Women’s Primary Care Clinic is another ambulatory training site for our residents led by Dr. Swati Shroff. In addition to training residents on common primary care topics, this site specifically seeks to highlight sex and gender differences in disease presentation and focus on the unique primary care needs of women across the lifespan, including issues such as breast and cervical cancer screening, family planning, abnormal uterine bleeding, menopause and osteoporosis. Residents participating in the Women’s Health track, under the supervision of Dr. Shailaja Nair and Dr. Elizabeth Boyle, have their primary continuity clinics at this site.

Recognizing that superior Internists also have a strong foundation in medical issues common to subspecialties, we have allocated more time for our residents in the outpatient subspecialty setting apart from their elective time. Over the course of three years, residents will rotate through these same clinics’ multiple times, building a strong outpatient skillset across the medical subspecialties and a rapport working with subspecialist faculty repeatedly and directly and in doing so, also present an opportunity for mentorship. This model not only increases resident access to outpatient experiences, education and mentorship, but it also translates into a more robust outpatient education assuring great competency and success as future internists. PERSONALIZED CAREER PATHWAYS An individualized approach to IM education in the new millennium. Our residents receive excellent training and broad exposure to the many facets of internal medicine during the first two years, becoming well versed in the core of internal medicine. Residents are given elective time in the first and second year to try different specialties and establish career preferences. Instead of dictating the content of the third year, we allow 14 weeks of elective time to target areas that will be most useful to everyone in pursuit of his or her career choice. In addition, we offer unique curricular experiences in medical education, research, and quality care, which prepare the trainee for the challenges that lie ahead. The size of our program gives us the needed flexibility to offer this benefit. The wide variety of electives and our willingness to

Department of Medicine 2025 Annual Report

68 entertain unique ideas are other highlights of this program. There are 7 areas that are recognized as the most common career choices of our residents, but the design of our personalized career pathways allows for additional choices. The recognized areas include:

experience a variety of hospital medicine practice environments,

•

develop clinical competencies needed for excellence as hospitalists,

•

•

build nonclinical skills related to hospital operations, quality, teaching, and leadership, and

Collaborative Contributions

• Hospital Medicine • Subspecialist Pathway Program

•

• Primary Care Program • Medical Education and Leadership • Masters or Certificate in Clinical Investigation • Disability Care • Health Systems Science • Women’s Health Each track has a dedicated track coordinator who is available for mentoring and guidance throughout a resident’s career planning. HOSPITAL MEDICINE CAREER PATHWAY Dr. Timothy Kuchera directs the Hospital Medicine Career Pathway within the Internal Medicine Residency Program. The pathway provides residents with targeted, practical clinical experience aligned with the core principles of the Society of Hospital Medicine and the ACGME Internal Medicine Milestones. Through focused hospital medicine electives and participation in scholarly and multidisciplinary initiatives, residents receive structured preparation for careers in hospital medicine. Participants also receive individualized mentorship and career planning support from Dr. Kuchera. The aims of the pathway are to ensure that graduates:

Academic Medicine and the Journal of Graduate Medical Education.

•

obtain hospital medicine positions that align with their professional goals.

Pathway requirements include 12 weeks of core clinical experiences, 12 weeks of clinical electives that include at least 6 weeks specifically focused on hospital medicine and completion of a multidisciplinary project. Two of the six weeks of hospital medicine-focused electives require participation in an intensive hospital medicine elective designed to foster independent clinical decision making. FY25 Summary •

One resident completed the Hospital Medicine Career Pathway and graduated with Distinction in Hospital Medicine.

•

Two residents participated in the intensive hospitalist elective.

•

Dr. Kuchera provided individualized mentorship and career guidance to six residents pursuing careers in hospital medicine.

Scholarly Output in FY25 Scholarly activity linked to pathway initiatives, the intensive hospitalist elective, and the transition to independent practice included: •

Two peer reviewed manuscripts accepted in

One Letter to the Editor accepted in Academic Medicine

Dr. Kuchera collaborated with Drs. Rebecca Jaffe, Gretchen Diemer, and Jillian Zavodnick to develop and refine the intensive hospitalist elective and to produce the associated scholarly work. SUBSPECIALIST PATHWAY PROGRAM Dr. Christopher Henry and Dr. Barbara Simon work with residents to increase both access and meaningful mentorship for residents interested in pursuing subspecialty fellowship. With a schedule that allocates 50% of resident clinical time in the outpatient setting, residents are being exposed to a greater volume and variety of subspecialties (see section “I. Major Initiatives Involving the Teaching Program, Ambulatory Training). Aside from increasing their participation in both inpatient and outpatient subspecialty patient care, residents are also exposed to a wider breadth of faculty mentors. This includes Core Faculty members of the program, from which we have selected at least one member representing each medical subspecialty. These faculty advise, mentor, and coach residents as well as support and oversee residents in scholarly works and in building their subspecialty fellowship applications. For interested residents, we have established a pathway comprised of suggested goals to achieve within each year of training to

prepare them for a successful match in the fellowship of their choice. This pathway and mentorship includes more robust clinical training, added exposure for more confident career selection, increased opportunities for research and scholarship and easier access to program leadership for guidance and support in fellowship application preparation. Additionally, several meetings are held throughout the year to provide guidance in anticipation of the fellowship application and interview season, including personalized review of applications, CVs, personal statements and interview preparation (including virtual formats). PRIMARY CARE PROGRAM The Jefferson primary care track was established in 2014 to help those with an interest in general internal medicine become better prepared to pursue primary care careers after residency. The mission of the program is to train superb clinicians who are dedicated to advancing the health of the diverse communities we serve and the field of general internal medicine at large through excellence in patient care, education, advocacy, and research. The primary care program is predicated on the principles of community, mentorship, advocacy, research, and curricular innovation. To that end, residents within the program across all three years (Intern-Senior) rotate on ambulatory blocks together and have shared didactic experiences, which consist of lectures, workshops, and training sessions to ensure that each resident is able to deliver high quality, complete care to a diverse population and develop the tools to understand and thrive in a changing healthcare system. Residents in

Department of Medicine 2025 Annual Report

69 the program benefit from early and frequent ambulatory time to build a strong panel of patients in a Level 3 PCMH and develop generalist mentors. To ensure residents are well prepared for a variety of practice settings after graduation, they also have a second longitudinal clinic experience in a federally qualified health center or practice setting of the residents’ choosing. MEDICAL EDUCATION AND PROGRAM LEADERSHIP PATHWAY This pathway includes participation in the medical education elective in addition to 20 observed teaching hours and biannual meetings with education mentors in addition to their required core presentations during residency. The elective operates as a series of structured teaching sessions as well core seminars coordinated by Program Leadership featuring topics such as learning theory, bedside teaching, teaching groups, professionalism and diagnostic clinical reasoning. Residents spend the bulk of their time in the active process of teaching and preparing lessons for medical students and interns. Residents also spend time learning how to prepare and deliver effective feedback and evaluation and then practicing these skills with the use of standardized patients. In FY25, 18 residents graduated with distinction in medical education. MASTERS OR CERTIFICATE IN CLINICAL INVESTIGATION This pathway is available for those residents interested in a career involving clinical or translational research. Thomas Jefferson University offers a Master’s in Clinical Investigation for clinicians who are interested in a career in human investigation or conducting clinical trials. This program requires a multi-

year commitment. Candidates participate in a conference and lecture series concurrent with their residency and fellowship training schedule and are required to finish a clinical research project to receive this degree. Candidates in this program are from the broad spectrum of medical disciplines and have completed projects from basic molecular bench research to exclusively clinical projects. DISABILITY CARE TRAINING PATHWAY Beginning in the FY22 year, Dr. Michael Stillman, in conjunction with Dr. Emily Stewart and Dr. Jason Ojeda fulfilled an educational need by creating this new pathway. The disability care concentration was developed to give select residents’ knowledge of and expertise in the care of individuals with a variety of disabilities. A narrow literature shows that small minorities of medical students and residents receive disability-specific education. In a study conducted by SKMC faculty members in 2019, very few internal medicine and family medicine residents at programs across the Northeast felt comfortable co-managing common secondary conditions associated with disabilities or in identifying their patients' needs for home and communitybased therapies and services. In response to this educational dearth, residents in this first-ofits-kind concentration will rotate through inpatient rehabilitation services, through a variety of outpatient clinics in which individuals with intellectual and development, neurological, and mobility disabilities seek care, and with a Philadelphia-based home care organization, learning about transitions of care and community-based services.

They will also complete an on-line asynchronous certificate program in life care planning, preparing them to anticipate the care needs of individuals with disabilities throughout their entire lives. We expect that residents who complete this concentration will be positioned to lead educational and quality improvement efforts in their future workplaces. As of the 2024-2025 academic year, 7 residents have enrolled in or completed this educational track, only 3 of whom intended to enter a career in primary care. HEALTH SYSTEMS SCIENCE PATHWAY Dr. Evan Nardone is the Director of the Health Systems Science (HSS) Distinction Pathway. This specialized pathway was formed with the goals of preparing a cohort of clinicians to lead innovative change within complex health systems, advancing health outcomes for vulnerable patient populations, and fostering career development within the domains of health systems science (health care delivery, health equity, valuebased care, population/public health, health advocacy, health policy and economics, clinical informatics, quality improvement, and patient safety). Requirements of the pathway include attending scheduled HSS didactics & discussions, completing predidactic modules, integrating HSS concepts in personal clinical teaching conferences, and completing a longitudinal clinical HSS project. Successful participation provides participants with various scholarship opportunities, directed educational experiences, and skills to lead as change agents within health systems.

BEDSIDE TEACHING Bedside teaching continues to be a major focus in the program and is an expectation for faculty on teaching attending rounds. Our emphasis on bedside rounds continues, with particular focus on physical diagnosis and patient communication. CONFERENCES AND CURRICULA We have a comprehensive series of lectures aligned with several curricula to prepare a wellrounded future internist. Our inpatient curriculum is largely comprised of traditional morning reports and noon conferences delivered by Jefferson residents, fellows, and faculty. This is supplemented with our grand rounds series that features more nationally renowned speakers on current or controversial topics in medicine. Additionally, we now offer a majority of these conferences virtually, so we can extend our audience to include learners across all our inpatient and outpatient sites. This has garnered increased attendance and participation. We have separately created an intern lecture series, a session on “Teaching Residents to Teach,” an ICU curriculum, a POCUS curriculum, and an ambulatory curriculum focusing on outpatient-based medicine topics. For the latter series, we have allocated a half day of lectures per week during their ambulatory rotation. This dedicated time away from any service obligations demonstrates to our residents the value we place on their education above all else. We also have started two new initiatives in order to ensure our curriculum is more dimensional than just encompassing core medical knowledge. Recent additions within the past 3 years

Department of Medicine 2025 Annual Report

70 include the recognition and discussion of diversity, equity and inclusion throughout our curriculum. We also incorporated health systems sciences as a mandatory objective in a number of our conference series. In 2023, we initiated a POCUS curriculum which is a comprehensive and multifaceted approach incorporating teaching, simulation, and patient application to teach objectives of image acquisition, image interpretation, and clinical application.

an active curriculum committee comprised of residents with some faculty mentorship and supervision. This is to ensure that residents continue to find our curriculum relevant, appropriate, and engaging. We have personalized boards preparation strategy and troubleshooting for those residents who are struggling or seeking out additional support with the program director. Our rolling three-year board pass rate continues to be at or above 96%, despite a downward trend nationally in program pass rates.

All residents participate in a Quality Improvement and Patient Safety curriculum which is woven in throughout their training. Within the first six months of intern year, all PGY1s participate in a real-time safety event analysis with faculty facilitation and interprofessional collaboration, the findings of which are presented to the Hospital Medicine Peer Review Committee. This learning experience engages residents early in their training and sets a strong foundation for continued safety involvement throughout their career. All residents learn the foundations of quality improvement during their intern year which provides them with improvement strategies and tools which they apply towards a longitudinal quality improvement project during their PGY2 year. Resident groups present their projects at our annual Health Equity and Quality Improvement Summit each spring. Many residents go on to conduct their own quality improvement projects and present safety event cases at our departmental MM&I conference highlighting their ongoing engagement in quality and safety.

PERFORMANCE IMPROVEMENT AND REMEDIATION PROGRAM

To supplement our robust curriculum, we have implemented several adjunctive strategies for improved knowledge and educational support. We have

In our commitment to training superior internists, we recognized the need for a program that could identify residents in need of more personalized attention and early intervention. A more robust performance improvement and formal remediation program for the internal medicine residency was identified in December of 2023. Residents who are struggling academically are brought to our attention. Using the Accreditation Counsel for Graduate Medical Education Milestones 2.0, one of our Associate Program Directors meets with the resident to assess knowledge, skills, and attitudes relevant to the deficiency in an attempt to “diagnose” the root cause of deficiency. Accordingly, we formulate Performance Improvement Plans to help struggling learners achieve competency and improve their clinical performance. Faculty coaches will interface with the remediating residents at regular intervals and provide reports and analyses, both to adjust improvement plans, as well as to inform the Clinical Competency Committee and help determine promotion status. During FY25, 6 residents went through the Performance Improvement and Remediation Program.

DIFFICULT DISCUSSION EDUCATION Beginning in FY23, Dr. Gina Keiffer took over the Direction of this program. The overall goals of this experience are to promote professionalism, enhance communication skills and bedside manner, and teach shared decision making with patients and their loved ones, all with empathy, compassion, and proficiency. The session utilizes the VitalTalk curriculum, which teaches communication skills and utilizes role play to provide direct and timely feedback to learners. This session is taught in small groups of 6-8 Interns and 2-3 faculty members. There is an interactive didactic component where various communication skills are taught and discussed. Following the didactic discussion, the Interns each participate in role play with a standardized patient trained in the VitalTalk method in the presence of the faculty and their peers. Faculty and peers are instructed to take notes during each role play and use that to provide individualized, direct feedback to each learner. RESULTS OF THE INTERNAL MEDICINE BOARD EXAMINATION 2023 We previously reported our success for our residents taking the Internal Medicine Certification Exam in 2024. Test takers included 38 senior residents.Results include: • 2024 exam: 94.9% Pass Rate. (35 of 37) • Our three-year pass rate is 96.6%. (107 out of 111) THE JEFFERSON MEDICAL FORUM Inaugurated in 1999, our resident edited journal of scholarly work

has become part of the tradition of excellence within the Department of Medicine. Each year we recruit new resident editors, but a constant has been the tradition of quality and diversity that has come to characterize the journal. Planning is already underway for the year ahead. The publication has been generously supported by our faculty and graduates. MEDICAL SIMULATION TRAINING For over 16 years, we conducted a program of ACLS skill preparation for our interns and new PGY 2 residents. Initially, utilizing a cardiac monitor and CPR mannequins, the exercises tested resident’s abilities to recognize and respond to cardiac arrhythmias appropriately. In 2000, the Medical College invested in a medical simulator which we have utilized to better prepare interns to advance their rapid response and ACLS skills, as well as to enhance their leadership roles in leading a team during high intensity clinical scenarios. Residents are also led through procedure simulation at the beginning of their PGY1 year as well as a refresher prior to starting PGY2 year. We now utilize the simulation center for additional training and exposure in the clinical application of POCUS. TEACHING RESIDENTS TO TEACH This year we continued our annual Teaching Residents to Teach course. It is a day-long retreat for PGY1 residents focused exclusively on topics related to being an educator and leader. Through this course and our continued emphasis on education, our department has been recognized for its positive impact on student education.

Department of Medicine 2025 Annual Report

71 MEDICAL EDUCATION FACULTY DEVELOPMENT RETREAT Starting in 2024, we received support from the Department of Medicine to host an annual on-campus retreat offering faculty development for key faculty and personnel in our education office. Themes of this retreat have so far included coaching, and most recently, remediation of struggling learners. All retreats include invited speakers and participatory workshops. These full-day events include the Chief Residents, rising Chief Residents, Associate Program Directors, Program Director, Vice Chair of GME, and the core faculty. The intent of this annual program is to continue to support our lead faculty and educational leadership in developing their skills as educators, advocates, and mentors to better support and train our residents. WORK HOURS The program closely monitors work hours, and the workload carried by our residents. We continue to note rotational experiences that are well under duty hour limits, as defined by the ACGME, including during our ICU experiences. We are in a constant process of evolution and use resident feedback and logged hours to identify emerging patterns or pressure points and invoke real time solutions to maintain a healthy work life balance. WELLNESS In our residency program, we have a robust resident-led Wellness Committee focusing on improving resident well-being. This Committee meets regularly with program leadership to discuss initiatives identified by residents as common sources of frustrations in their days, brainstorm actionable ideas for improvement, and engage residents to in meaningful ways to enhance their well-being.

We host programing throughout the year for our residents, including several work-day sessions to best promote work-life integration. In FY25, we hosted several stressrelief events to promote wellbeing and social connection. We continued to ensure the personal well-being for our residents, including a robust sick-call pull system and offering Opt-Out Wellness check-in for all our residents at times throughout perceived with increased stress amongst our residents. Residents can meet with a licensed health professional to discuss the current state of mental health, coping strategies, and be connected with ongoing services as interested. To highlight the culture of wellbeing we strive to emulate, many of our residents have been nominated or selected for our departmental I.M. Thankful Recognition Program and continue to be active nominators of their colleagues. In FY25, we held a resident “Listening Session” to help uncover systems causes of frustration for residents and brainstorm ideas for improvement within the scope of the residency to impact change. We look forward to implementing quick wins in the residency’s scope of influence and advocating for resident well-being as needed at higher levels. CONTRIBUTING TO THE STATE OF THE ART OF EDUCATION IN INTERNAL MEDICINE The program leadership has continued to build its reputation through contributions to the peer reviewed literature (Academic Medicine, Seminars in Medical Practice, Academic Medicine, and the American Journal of Medicine), presentations at national meetings (AAIM), contributions to programs and activities of the American College of Physicians (Resident Research Judging,

participating in promotional brochures and videos), presentations and contributions to national medical subspecialty societies and delivering numerous invited lectures.

HIGHLIGHTS OF THE D E PA R TM E N T ' S E D U C AT I O N A L P E R FO R M A N C E

• An ABIM rolling 3–year Pass Rate of 96% for the core Residency. • Primary Care Track Board Pass Rate 100%. • A 4+2 block schedule and a trickle admission system ensure superior education over service obligations by mitigating work compression, increasing outpatient exposure and adding dedicated time to education and wellness. • We have identified our top teachers and promote their recognition throughout the medical college and hospital. • The professional educational staff (program directors and clerkship directors) regularly present their work at national meetings or in peer-reviewed literature.

CO N C LU S I O N S

In summary, the Residency Training program is achieving its goal of training superior Internists for the 21st Century. Our focus remains upon developing and extending our traditions of excellence. A strong residency program enhances the mission of the entire Department by enhancing the quality of patient care and advancing the education of our students.

Our fellowships offer stateof-the-art clinical training and research opportunities for highly competitive residents from Jefferson and top programs across the country. Benefiting from the foundations described above, our students also gain core competence in the approach to a variety of clinical problems we have noted a growing interest in internal medicine as a result. List of Appendices: • Class list of entering interns 2025–2026. • Career plans for Graduating Residents 2025. • List of Top Teachers

Department of Medicine 2025 Annual Report

73

E D U C AT I O N A P P E N D I X

THOMAS JEFFERSON UNIVERSITY HOSPITAL DEPARTMENT OF MEDICINE HOUSE STAFF: 2025-2026 INTERNS PGY-1'S (CATEGORICAL)

MEDICAL SCHOOL

Taskeen Ahmed, MD

Rutgers Robert Wood Johnson Medical School

Gianna Antinori, MD

Cooper Medical School of Rowan University

Justin Aoyama, MD

Rutgers New Jersey Medical School

Abigail Bent, MD

Eastern Virginia Medical School

Anna Bondonese, MD

Geisinger Commonwealth School of Medicine

Tyler Breslin, MD

University of Rochester School of Medicine and Dentistry

Megan Cecchine, MD

Lewis Katz School of Medicine at Temple University

Hirra Chaudhary, MD

University of Virginia School of Medicine

Ryan D’Souza, MD

Sidney Kimmel Medical College at Thomas Jefferson University

Rebecca Della Croce, MD

Albert Einstein College of Medicine

Jordan Eutsey, MD

Drexel University College of Medicine

Joseph Fabrizio, MD

Sidney Kimmel Medical College at Thomas Jefferson University

Reed Firestone, MD

Cooper Medical School of Rowan University

Nikhil Goyal, MD

Perelman School of Medicine at the University of Pennsylvania

Kenna Hawes, MD

Case Western Reserve University

Celine Jo, MD, MPH

Tufts University School of Medicine

Anisha Jobanputra, DO

NY Institute of Technology College of Osteopathic Medicine

Rhea Kanwar, MD

Pennsylvania State University College of Medicine

Nadia Khusro, MD

Lewis Katz School of Medicine at Temple University

Bojan Lazarevic, MD

Sidney Kimmel Medical College at Thomas Jefferson University

Anna Leone, MD

Ohio State University College of Medicine

Vanessa Lin, MD

Virginia Commonwealth University School of Medicine

Anna Mathew, MD

Rutgers New Jersey Medical School

Alekya Menta, MD

Tufts University School of Medicine

Vibhuti Mishra, MD

Drexel University College of Medicine

Margot Noyelle, MD

Zucker School of Medicine at Hofstra/Northwell

Fiyinfoluwa Olasoko, MD

New York Medical College

Vivek Parikh, MD

University of Virginia School of Medicine

Navya Pendyala, MD

Rutgers New Jersey Medical School

Charlotte Pirquet, MD

Rutgers New Jersey Medical School

Michael Sangobiyi, MD, MPH

Sidney Kimmel Medical College at Thomas Jefferson University

Mohammed Shah, MD

NYU Grossman Long Island School of Medicine

Benjamin Shook, MD

Sidney Kimmel Medical College at Thomas Jefferson University

Trisha Sindhu, MD

Rutgers Robert Wood Johnson Medical School

Lily Steele-Dadzie, MD

Sidney Kimmel Medical College at Thomas Jefferson University

Davis Tran, MD

University of Virginia School of Medicine

David Zhang, MD

Geisinger Commonwealth School of Medicine

*Primary Care

Department of Medicine 2025 Annual Report

74

E D U C AT I O N A P P E N D I X

THOMAS JEFFERSON UNIVERSITY HOSPITAL DEPARTMENT OF MEDICINE: 2025 CAREER PLANS GRADUATING CHIEF RESIDENTS

FUTURE PLANS

Mark Liotta, MD

Cardiology – Medical University of South Carolina

Akash Patel, MD

Gastroenterology – Thomas Jefferson University Hospital

Ashley Traczuk, MD

Hospitalist – Thomas Jefferson University Hospital

Claire Zurlo, MD

Infectious Disease – Thomas Jefferson University Hospital

GRADUATING PRIMARY CARE RESIDENTS

FUTURE PLANS

Eleni Florakis, MD

Primary Care – Summit Health Purchase

Emily Khantses, MD

Rheumatology – NYU Grossman Long Island SOM

Jeffrey White, MD

Primary Care – Penn Medicine – Radnor

GRADUATING CATEGORICAL RESIDENTS

FUTURE PLANS

Amman Bhasin, MD

Hematology/Oncology – Montefiore Medical Center

Matthew Bierowski, MD

Cardiology – Thomas Jefferson University Hospital

Phoebe Chun, MD

General Internal Medicine – Cone Health

Sawan Dutta, MD

Cardiology – Thomas Jefferson University Hospital

Normonique Dyer, DO

Pulmonary/Critical Care – Thomas Jefferson University Hospital

Abdulmojeed Ekiyoyo, MD

Cardiology – Penn Presbyterian Medical Center

Youssef Elfatatry, MD

Hospice & Palliative Care – UC Sand Diego Medical Center

Umma Fatema, MD

Hematology/Oncology – Rutgers Robert Wood Johnson

Illana Goldberg, MD

Hospitalist – Hospital of the University of Pennsylvania

Risa Goldberg, MD

Endocrinology – Weill Cornell Medical Center

Alexandros Grivas, MD

Rheumatology – NYU Grossman Long Island SOM

Liam Heneghan, MD

Hematology/Oncology – Thomas Jefferson University Hospital

Chukwuemezie Kamanu, MBBS

Chief Resident (1yr); Cardiology – Stony Brook University

Sawyer Kiefer, MD

Hospice & Palliative Care – UC San Diego Medical Center

Nicholas MacDonald, MD

Infectious Disease – Thomas Jefferson University Hospital

Amry Majeed, MD

MICU Hospitalist – Penn Presbyterian Medical Center

Kashka Mallari, MD

Cardiology – Cooper University Hospital

Jamie Miller, MD

Hospitalist – Thomas Jefferson University Hospital

Megana Murugesh, MD

Nocturnist – Thomas Jefferson University Hospital

Chioma Nwonu, DO

Gastroenterology – Case Western Reserve University

Suraj Nyalakonda, MD

Hematology/Oncology – Rutgers Robert Wood Johnson

Parker O’Neill, MBBS

Cardiology – University of Maryland Medical Center

Julia Palecki, MD

Chief Resident (1yr); Hematology/Oncology – Weill Cornell

Anjani Patel, MD

Endocrinology - University of Pittsburgh Medical Center

Joshua Riley, MD

Cardiology – Temple University Hospital

Brian Schonewald, MD

Chief Resident (1yr); Pulmonary/Critical Care – UCLA

Beatriz Torre, MD

Chief Resident (1yr); Gastroenterology - University of Miami

Matthew Tucker, MD

Hematology/Oncology – NYU Grossman School of Medicine

Nevin Varghese, MD

Gastroenterology – Rutgers Robert Wood Johnson

Benjamin Young, MD

Gastroenterology – Thomas Jefferson University Hospital

Michael Zimmerman, MD

Hematology/Oncology – Thomas Jefferson University Hospital

Department of Medicine 2025 Annual Report

75

E D U C AT I O N A P P E N D I X

TOP TEACHERS AS R AT E D BY R E S I D E N T S* Lily Ackermann, MD Rene Alvarez, MD Lauren Ammerman, MD Ryan Belecanech, MD Vincent Chan, MD Gretchen Diemer, MD Gautam George, MD Dina Halegoua-De Marzio, MD Christopher Henry, MD Robert Hilton, MD Maura Huffner, MD Chetan Jeurkar, MD Gregory C. Kane, MD David Kastenberg, MD Gina Keiffer, MD Claire Ketchem, MD Timothy Kuchera, MD Patrick Kukulich, MD Rebecca Loh, MD Christopher McGrath, MD Stephanie Moleski, MD Evan Nardone, MD Tatiana Policarpo, MD Jorge Prieto, MD Sanaa Rizk, MD Suneil Seetharam, MD Ross Summer, MD Lim Wong, MD Alyssa Yeager, MD Erika Yoo, MD

*Requires a minimum of 5 evaluations in the electronic rating database

Department of Medicine 2025 Annual Report

76

E D U C AT I O N A P P E N D I X

UNDERGRADUATE MEDICAL EDUCATION MISSION STATEMENT The mission of the Department of Medicine for undergraduate medical education is to provide the students of Sidney Kimmel Medical College with a high quality educational experience. Specific facets of this mission include the enhancement of knowledge and the development of the clinical skills of the medical student, the promotion of outstanding professional behaviors and humanistic attributes and the support of altruistic activities. This mission spans the four years of the Sidney Kimmel Medical College curriculum, is directed by the faculty, and supported by the residents of the Department of Medicine. The Office of Undergraduate Medical Education spearheads this mission by planning and implementing the individual educational experiences, by supporting the faculty and residents who deliver these educational activities, and finally by analyzing the educational outcomes and students’ perceptions of these experiences to ensure continual improvement in these programs.

DEPARTMENT PROGRAMS

at Thomas Jefferson University Hospital, and four weeks at one of our excellent affiliated institutions. In addition to the clinical experiences on the wards, students participate in a curriculum, which consists of small group sessions, brief lectures, and hands-on workshops and which teaches the diagnosis and treatment of common internal medicine diagnoses; the approach to common presentations and abnormal lab values; core skills like electrocardiogram and chest X-ray interpretation; and clinical reasoning. There is also a session in which students practice arterial puncture and venipuncture. An evidence-based medicine project reinforces the essential skills of performing a literature search to answer clinical questions that arise in the context of daily care of patients. Students are assessed by their clinical evaluators as well as for their evidence-based medicine project, via the NBME subject exam, and via an OSCE. The twostation OSCE assesses information gathering, data interpretation, differential building, recognition of emergencies, basic management, and patient communication. For the 2025-2026 academic year Faculty that serve as Clerkship Site Directors are: Abington Hospital: Delani DeLiana, MD

MEDICINE 350: INTERNAL MEDICINE CLERKSHIP

Atlantic Health/Moorestown: Rafael Pajaro, MD

Director: Jillian Zavodnick, MD Coordinator: Hannah Morgan, MAT

Albert Einstein Medical Center: Eduardo Antonio, MD

The Internal Medicine clerkship is structured to allow student exposure to a diverse mix of internal medicine patients on inpatient services. Students spend four weeks of clinical experience

Bayhealth: Zohaib Ghatala, MD Darshan Patel, MD

Methodist Hospital: Jennifer Procopio, MD York Hospital: Daniel Fischman, MD The learning objectives of the clerkship are: • Obtain a history and perform a physical exam that is comprehensive for new patients and appropriately targeted for follow-up patients • Determine appropriate diagnostic testing • Understand the significance of normal and abnormal symptoms, findings, and test results in the context of a patient’s condition • Develop an assessment of a patient’s primary reason for hospitalization using information from the history, physical, and tests • Formulate a prioritized problem list, including a differential diagnosis and plan • Develop oral presentations and written notes that present patient data clearly and concisely while describing clinical reasoning • Maintain professionalism in demeanor, behavior, and dress at all times • Communicate effectively and sensitively with patients, families, hospital staff, and medical team members • Work as an effective and reliable member of a healthcare team

Christiana Hospital: Matthew Burday, DO

• Construct a useful clinical question and use the medical literature to guide clinical practice

Lankenau Hospital: Lia Desposito, DO

• Use feedback and selfreflection to identify next

steps in development; use self-directed study and deliberate practice to progress • Gain exposure to the broad variety of career opportunities in Internal Medicine This academic year, the changes in this course have included: • Continued faculty development around assessment among affiliate site directors MEDICINE 401: THE INPATIENT SUB-INTERNSHIP IN INTERNAL MEDICINE Director: Dianna Cheney-Peters, MD Coordinators Hannah Morgan, MAT This year, 224 senior students chose a Sub-Internship in Internal Medicine to fulfill their requirement for a fourth-year inpatient clerkship. 141 of those students elected to rotate at Thomas Jefferson University Hospital for this experience and 83 at the affiliates. In addition to the experiential learning the students partake in, there are formal didactic sessions dedicated to clinical problem solving, advanced decision-making and practical management considerations. The learning objectives of this sub-internship include: • Recognizing sick vs. non-sick patients – The development of the clinical acumen to distinguish patients requiring urgent or emergent management • Knowing when to ask for assistance – The recognition of one’s limitations and ability to

Department of Medicine 2025 Annual Report

77

E D U C AT I O N A P P E N D I X

effectively request specialty/ subspecialty consultation • Managing time wisely – The application of time management skills to the work required for the care of a medical inpatient and to effectively organize and prioritize a daily patient care task list • Communicating effectively with patients and families – The application of interpersonal and communication skills when interacting with patients and their families This academic year, the changes in this course have included: • No major changes MEDICINE 402: THE OUTPATIENT SUB-INTERNSHIP IN INTERNAL MEDICINE Coordinators: Shannon Aubin, ABA Hannah Morgan, MAT All outpatient experience courses at Sidney Kimmel Medical College are overseen by Amanda Matheson, MD, Outpatient Experience Director for Phase 3. This includes courses outside of the Department of Medicine. The Department of Medicine offers several courses that fulfill SKMC's Outpatient Experience Requirement: MED 402, Rheumatology, Cardiology, Nephrology, Women's Health, and coming soon, Hepatology. This year, 45 students selected this Sub-Internship in Internal Medicine to fulfill their requirement for a fourth-year outpatient subinternship. 18 of those students elected to rotate at Jefferson Hospital for this experience and were accommodated in the Jefferson Internal Medicine Associates Offices. 27 were accommodated at affiliate hospitals and community practices.

The educational goals of this outpatient subinternship include: • The acquisition of advanced knowledge and clinical skills relevant to the care of the ambulatory adult patient. • Introduction to critical appraisal and comparison of national guidelines and their application to clinical practice. • The advanced application of clinical reasoning skills acquired in the core ambulatory clerkships of the third year of the curriculum. • The development of advanced skills in lifelong learning that will allow an educated approach to the medical literature. • The acquisition of special knowledge in the patterns of health care delivery and the general principles of managed care. Planned enhancements for the 2025-2026 academic year include: • Continued recruitment of new clinical sites for this rotation. MEDICINE 403 – 499: ELECTIVES IN INTERNAL MEDICINE Directors: Jennifer Valentine, MD, and Selected Faculty Coordinator: Hannah Morgan, MAT The Department of Medicine sponsored 24 electives in multiple sub-specialty areas. In the 2024-2025 academic year 373 elective spots were taken at Jefferson and 112 spots at the affiliated hospitals. We had 16 students do away rotations at other institutions. We had 49 students participate in research rotations.

The educational goals of these electives include: • The acquisition of advanced knowledge and clinical skills relevant to the care of the patient in a selected discipline in internal medicine. • The advanced application of clinical reasoning skills acquired in the core ambulatory and inpatient clerkships of the third year of the curriculum. • The development of a new skill set relevant to the activity of a consultant physician. • The intensive exposure of the student to a small cadre of faculty with a resultant enhanced ability for faculty role modeling.CAREER COUNSELING AND DEVELOPMENT In the residency match of March 2025, 59 students matched into three-year residencies in Internal Medicine and 1 into Medicine-Pediatrics combined residency. It is critical that the Office of Educational Programs coordinates the career counseling for this sizable portion of the class, 25% — each of these students meets with a faculty advisor (Drs. Dianna Cheney-Peters, Lim Wong, or Jillian Zavodnick), who supports them throughout the application season. Additionally, each of the members of this student group requires a summary “Department Letter” for their residency application. For the 2024-2025 academic year, the Department furnished 69 letters for students applying for residencies in Internal Medicine – this includes students applying for combined residencies in internal medicine and pediatrics, as well as several who applied to medicine in addition to other

specialties (such as orthopedic surgery or surgery), and 53 for those applying for Preliminary Residencies (these letters were written by Dr. Jennifer Valentine). We continue to use the APDIM/ CDIM template for this letter. FACULTY The faculty with administrative roles within the Undergraduate Medical Education activities of the Department of Medicine are listed individually under their respective areas of supervision above.

ACKNOWLEDGEMENTS Department of Medicine 200: Through the Lens Capturing Art, Medicine, & Humanity

TABLE OF CONTENTS

ATTENDINGS Jonathan Foster, MD Gregory Kane, MD

0 3 Division of Cardiology 15

Division of Endocrinology, Diabetes and Metabolic Diseases

19

Division of Gastroenterology and Hepatology

Alyssa Yeager, MD

RESIDENTS Sara Badenhausen, MD Susanna Betti, MD Jessica Cobb, MD Joseph DeSimone, MD

25

Division of Hematology and Cardeza Foundation for Hematologic Research

29

Division of Hospital Medicine

Abdulmojeed Ekiyoyo, MD Umma Fatema, MD Ilana Goldberg, MD Natasha Reddy, MD Brian Schonewald, MD

33

Division of Infectious Diseases and Environmental Medicine STUDENTS

37

Division of Internal Medicine

41

Division of Nephrology

Anna Hamtic Junthe Jonth Emilio Mansilla Rachel Menane Kathleen Spritzer

47

Division of Pulmonary, Allergy and Critical Care Medicine

55

Division of Rheumatology

59

Center for Translational Medicine

63

Graduate Medical Educational Programs in Internal Medicine

Mary Wilkinson

Photographs ©Thomas Jefferson University Photography Services

2025 ANNUAL REPORT DEPARTMENT OF MEDICINE

Department of Medicine College Building, Room 822 1025 Walnut Street Philadelphia, PA 19107